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Abstract 
Background: The global assays assess the interaction of procoagulants and 
anticoagulants on the generation of thrombin. These assays, as functional tests, may 
reflect the bleeding tendency in patients with haemophilia better than the conventional 
assays. 
Design and Method .. : In this study the use of three global assays including rotational 
thromboelastometry (ROTEM Ji), thrombin generation test (TGT), and clot waveform 
analysis were evaluated on a cohort of haemophilia A (HA) and haemophilia B (HB) 
patients. The global assay parameters were compared to the conventional assays and 
the most sensitive parameters correlated with the clinical phenotype of haemophilia 
patients. 
Results and discussion: The modified ROTEM~ analysis initiated by a minute amount 
of tissue factor proved to be useful in assessing haemophilia patients. A strong 
correlation was found between the Maximum Velocity (MaxVel) parameter of 
ROTEM@ and the factor VIII level of haemophilia individuals. The use of com 
trypsin inhibitor (CTI) to inhibit contact pathway improved the sensitivity and 
specificity of the ROTEM:R' analysis. A significant difference between the TGT 
parameters of patients groups and the control was noted. The use of CTI improved the 
sensitivity and specificity of the test, in particular peak height in platelet rich plasma 
(PRP) samples. The results in PRP+CTI group showed that platelets play an important 
role in heterogeneity of thrombin generation amongst severe haemophilia patients 
where the relevant deficient factor is < 1.0 IU/dL compared to conventional clotting 
assays. 
In clot wavefonn analysis, this study showed a better correlation between the velocity 
indices of the APTT test (MinI and Min2) and the FVIII activity of HA individuals 
compared to the correlation between the APTT test itself and the FVIII activity level. 
The Min I and Min2 appear to be more sensitive, simple, fast and cost effective in the 
diagnosis of hypocoagulability, and monitoring of haemophilia patients compared to 
the conventional tests. 
The area under the thrombin generation curve (AUC), peak height (PH), and time to 
peak (TP) parameters of the in-house TGT in PRP+CTI test category showed a strong 
correlation with patient age at first joint bleed (r = 0.693 p = 0.003, r = 0.718 p = 
0.002, and r = -0.703 p = 0.002 respectively). The type of F8 mutation was also 
correlated with the patient's thrombin generation capacity. Based on two subgroups of 
null mutations and non-null mutations, the PH and AUC in PPP+CTI category 
showed a significant increase in the non-null mutation group. The time to the 
maximum velocity of ROTEM~ (tMaxVel) was also shorter in the non-null mutation 
group. 
Conclusion: The use of global assays in diagnosing hypocoagu)ability, and 
monitoring haemophilia patients proved to be useful, especially in areas where 
conventional methods are not responsive. However, the multifactorial dependency of 
global assays make them difficult to interpret on their own, therefore, these assays 
should be used in parallel with the conventional tests in order to be more useful. 
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Chapter 1 Introduction 
Maintenance of blood flow within the vascular system is an important human 
physiological process. The term 'haemostasis' refers to the process of cessation of the 
bleed from the injured vessel by forming a clot that serves to limit haemorrhage. 
Thrombosis, however, is the pathological clot formation that results when haemostasis 
is excessively activated in the absence of bleeding, and/or inadequate response by 
anticoagulant factors to regulate procoagulant activities. 
Under normal physiological conditions there is a delicate equilibrium between the 
pathological states of hypercoagulability and hypocoagulability in the circulating 
blood. 
Haemostasis involves: 
• Vasoconstriction of damaged blood vessels to decrease blood flow within the 
vessel. 
• Platelets and their interaction with the disrupted vessel and other components 
of the coagulation system. 
• The formation of fibrin by the coagulation system. 
• The regulation of the extension of the blood clot by coagulation inhibitors and 
the fibrinolytic system. 
• The remodelling and repair of the injured vessel. 
1.1. Overview of normal haemostasis 
When a blood vessel is damaged, the first physiologic reaction is vasoconstriction that 
helps to slow the blood flow. The disrupted endothelial cell barrier exposes collagen, 
which attracts platelets, anuclear cells that participate in many aspects of clot 
fonnation from the circulating blood and initiate the first adhesion of platelets to the 
exposed collagen, followed by aggregation of platelets, which is mediated by von 
Willebrand factor (VWF). This fonns a primary haemostatic plug, preventing further 
blood flow loss from the injured vessel. The primary plug also provides a surface for 
the blood coagulation process. 
The disrupted vessel wall also exposes tissue factor (TF), a membrane protein located 
in smooth muscle, fibroblasts, and macrophages that combines with circulating 
coagulation factor VIla (FVIIa) to trigger the coagulation system leading to a stepwise 
activation of a series of proenzyrnes to produce thrombin. In tum, thrombin converts 
fibrinogen to insoluble fibrin that is then cross-linked by the action of factor XIIJa 
(FXIIIa), and anchored into place by the process of clot retraction. The complexity of 
coagulation results from numerous feedback loops and inhibitory mechanisms that 
balance coagulation and fibrinolysis. 
1.1.1. Blood vessels 
Blood vessels are lined with a continuous layer of endothelial cells that protect the 
underlying basal membrane, subendothelium and smooth muscle, and their highly 
reactive elements from contacting blood cells, platelets, and coagulation proteins. 
These elements include adhesive proteins such as collagen, fibronectin, laminin, 
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vitronectin, and VWF, which promote platelet adhesion, and TF that triggers blood 
coagulation. 
The degree of platelet adherence to an injured vessel wall is dependent upon the 
relative reactivity of the components of the vessel wall that have become exposed. 
Slight trauma or irritation to the endothelium will result in reversible activation of 
platelets and limited activation of the clotting system. Injury to, or dctachment of the 
endothelium, will expose the basal membrane and/or subendothelium to blood. This 
interaction and simultaneous expression of TF (by exposure) will fully and 
irreversibly activate platelets and the coagulation system. 
Vasoconstriction of the damaged vessel occurs in response to the localised release of 
vasoactive amines from activated platelets. Damaged vessel walls also mediate the 
activation of fibrinolysis, kinin formation and the complement system (Hoffbrand et 
at., 1999). There are several coagulation inhibitors that are produced by endothelial 
cells. Endothelial cells express heparan sulphate, a glycosaminoglycan, which 
catalyses anticoagulant activity of antithrombin (AT). Plasma AT binds to heparan 
sulphate located on the luminal surface, and in the basement membrane of the 
endothelium. Thrombomodulin IS another endothelium-bound protein with 
anticoagulant function, facilitating activation of protein C (PC) and thrombin 
activatable fibrinolysis inhibitor (T AFI). In response to systemic procoagulant stimuli, 
tissue-type plasminogen activator (tP A) is transiently released from endothelial cells 
to promote fibrinolysis. Endothelium activated by inflammation modulates 
procoagulant responses by synthesising TF, VWF, and plasminogen activator 
inhibitor (P AI-I) (Tanaka et al., 2009). 
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1.1.2. Platelets 
Blood platelets are fragments of the cytoplasm of the megakaryocyte, and hence are 
anuclear and formed in the bone marrow. The megakaryocytes are derived from 
pluripotential stem cells and their precursors are megakaryoblasts. Thrombopoietin, a 
glycoprotein hormone which is produced by liver and kidney, is the major regulator of 
platelet production (Kato et at., 1998). It stimulates the production and differentiation 
of megakaryocytes. Each megakaryocyte may give rise to as many as four thousand 
platelets (Hoffbrand et at., 2006). 
Primary haemostasis is triggered in response to vessel wall damage by the exposure of 
blood to subendothelial tissue. Platelet membrane is vital to the process because of the 
specific glycoprotein (GP) receptors, through which platelets interact with other 
components of haemostasis (Kaushansky, 1995). Before the first interaction of a 
platelet with the injured vessel wall, VWF binds to exposed collagens in the vessel 
wall. The initial contact of platelets can then take place via the interaction of the 
platelet receptor complex GPIbN/IX with the immobilised VWF. This interaction 
initiates the tethering of circulating platelets to the vessel wall. Platelets roll over 
VWF in the direction of flow driven by the shear forces. The adhesion of platelets to 
subendothelium involves the functioning of at least four other receptors: the collagen 
receptors (l2PI(GPla-IIa) and GPVI, the fibronectin receptor (lSPI and the fibrinogen 
receptor (llIbP3 (GPIIb-I1Ia). Spreading of the platelet will follow the firm adhesion 
and is essential to withstand the shear forces exerted by the flowing blood (Gresele, 
2002). Once platelets are bound to the vessel wall they can be activated by a variety of 
ligands, such as interaction of GPVI with collagen, and activation by thrombin. 
Thrombin activates platelets through protease-activated receptors (PAR). There are 
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four PARs (designated PARl-4), of which, only PARI and PAR4 are found on 
human platelets. It is thought that PAR 1 is necessary for platelet response at low 
thrombin concentration (Kahn et al., 1999). Platelets next undergo a shape change by 
becoming more spherical with extended pseudopods thus spreading over the exposed 
subendothelium (80uaziz et al., 2007). The contents of the platelet granules are 
released: a- granules release fibrinogen, VWF, thrombospondin, factor V (FV), 
vitronectin and other proteins; the dense bodies release adenosine diphosphate (ADP), 
adenosine triphosphate (ATP), serotonin, and calcium. Cytoplasmic events include 
activation of the eicosanoid pathway (8egonja et aI., 2007), decreased cAMP and 
increased mobilisation ofCa2+ (Calvete, 1999). 
As platelets become activated, they become adhesive for other platelets interacting via 
fibrinogen bound to their GPIIb-II1a receptors. The activation of other platelets occurs 
by release and secretion ofthromboxane A2, ADP, Ca2+, and serotonin from activated 
platelet's granules. Thromboxane A2 is the major product of membrane arachidonic 
acid (AA) metabolism. During activation, under control of a transport mediating 
protein called "scramblase", negatively charged phospholipid CPL), 
phosphatidylserine (PL:PS) are translocated to the outer surface of the plasma 
membrane. In addition, microvesiculation of the membrane occurs. The microvesicles 
further enhance surface expression of PL:PS, which acts as a binding surface for 
activated forms of factor V (FVa), factor IX (FIXa), and factor X (FXa), which in the 
presence of Ca2+ form the prothrombinase complex (see below) (Calvete, 1999). The 
formation of the primary platelet plug temporarily occludes the site of damage to 
prevent blood loss. 
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1.1.3. Coagulation 
The activated platelets stimulate local activation of plasma coagulation factors by the 
presentation of negatively charged phospholipids on their surface. Activation of 
coagulation factor receptors and release of a granules content (i.e. FV, VWF and 
fibrinogen) set the scene for activation of coagulation factors. The small quantities of 
thrombin (0.05 to 1.00 nM), resulting from the activation of the TF pathway are 
sufficient to activate platelet protease-activated receptors (PAR) and FXI on the 
platelet surface in the presence of calcium ions. 
Coagulation factors are glycosylated proteins that circulate in the blood as inert 
proenzymes. Once stimulated, the proenzymes become active, triggering a process of 
serial cascade activation. There are two main groups of coagulation factors that can be 
categorised by their modes of action. The first, zymogens (inactive precursor of an 
enzyme) factors II, VII, IX, X, XI, XII and prekallikrein, become serine protease 
enzymes upon activation (factors IIa, VIla, IXa, Xa, Xla, XIIa and kallikrein). Their 
active site is a serine residue with nearby histidyl groups and they can work in two 
different ways. Firstly, there is limited proteolysis and this enzymatic reaction reveals 
the active site of the target protein through partial cleavage. Secondly, there is a 
conformational change revealing the active site without any disintegration of the 
target molecule. Of the serine proteases, factors IIa, VIla, IXa and Xa form have a 
common feature, which is the presence of carboxylated glutamyl acid residues that 
enable binding to phospholipids. The last stage of their production, y-carboxylation, is 
a post-translational vitamin K-dependent step (Davie et af., 1991). 
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The second group of factors are co-factors (factors Va and VIlla), which circulate as 
pre-co factors factor V (FV) and factor VIII (FVIII), and do not take part directly in 
any proteolytic event but are necessary for acceleration of the pathway. They enhance 
the activity of target proteins by increasing local concentrations of coagulation factors 
on phospholipid surfaces, creating a condition favourable for proteolysis. 
In 1964, two independent groups of scientists introduced a model of coagulation as a 
series of reactions in which one clotting factor activates the next one leading to fibrin 
clot formation. One group proposed the "cascade" model (Macfarlane, 1964), and this 
was shortly followed by the second group suggesting the "waterfall" model (Davie & 
Ratnoff, 1964). The cascade or waterfall models described each clotting factor as a 
proenzyme that could be converted to an active enzyme. These models also suggested 
that the clotting sequences were divided by two pathways: the intrinsic pathway and 
the extrinsic pathway. The initiation of either pathway resulted in activation of a 
common pathway and the eventual generation of fibrin clot (Luchtman-lones & Broze, 
1995). (Figure 1.1) 
The limitations of the coagulation cascade as a model of the haemostatic process are 
highlighted by certain clinical observations. Patients deficient in the initial 
components of the intrinsic pathway (FXII, high-molecular weight kininogen, or 
prekallikrein) have a prolonged activated partial thromboplastin time but no bleeding 
tendency. In spite of this fact, components of the intrinsic pathway must have an 
important role in haemostasis, because patients deficient in FVIII or factor IX (FIX) 
have a serious bleeding tendency, although the extrinsic pathway is intact. 
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Similarly, patients deficient in FVII also have a senous bleeding tendency, even 
though the intrinsic pathway is intact. Thus, the intrinsic and extrinsic pathways 
cannot operate as independent pathways in vivo as they do in the cascade model. 
Other observations showed that patients with FXI deficiency, although not usualJy 
subject to spontaneous haemorrhage, were prone to excessive bleeding after surgery 
or trauma (Hu et aI., 1998). These observations pointed to the pivotal roles of FVIIIa 
and FIXa in the activation of FX, and made particularly interesting the observation 
that FIX activation could be catalysed not only by FXla, but also by FVIIa-TF, 
suggesting that the TF pathway could initiate the intrinsic pathway directly and 
independently of the contact factor pathway. However, this did not explain the 
haemostatic defect observed in FXI deficiency, which therefore suggested that the 
activation of FXI physiologically might proceed by a pathway independent of contact 
activation pathway (Walsh, 2004). An alternative mechanism for proteolytic 
activation of FXI by thrombin, demonstrated in 1991, was subsequently shown to 
proceed at 5000- to 1O,000-fold accelerated rates on the activated platelet surface 
(Naito & Fujikawa, 1991). 
The cascade model of coagulation also does not explain the amplification of thrombin 
by its own positive feedback process by activating FV, FVIII, and platelets (Butenas 
et af. 1997) (see 1.1.4.2). 
1.1.4. Cell-based model of coagulation 
A major development over the recent years was the discovery that exposure of blood 
to cells that express TF on their surface, such as epithelial cells, is both necessary and 
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sufficient to initiate blood coagulation in vivo. This finding led to the belief that the 
intrinsic pathway (the contact system) does not have a true physiological role in 
haemostasis (Hoffman & Monroe, 200 I). Mounting evidence suggests that TF is 
present in blood on cellular microparticles. These membrane fragments derive from 
various cell types: white blood cells, endothelium, and platelets, which may playa 
more important role in pathological haemostasis (thrombosis) as opposed to normal 
clotting (Osterud & Bjorklid, 2006). In the cell-based model of coagulation, 
coagulation occurs in three overlapping phases: initiation, priming (amplification), 
and propagation (Figure 1.2) (Monroe et al., 2002b). 
1.1.4.1. Initiation phase 
The blood coagulation reactions are initiated when sub-endothelial TF is exposed to 
the blood flow following damage or injury. The initiation of coagulation may also 
occur as a consequence of activation of endothelium by chemicals, cytokines, or 
inflammatory processes (Butenas & Mann, 2007). The initiation phase of coagulation 
occurs when exposed TF (expressed on fibroblasts, monocytes and macrophages) 
binds to circulating FVIIa that exists in very small quantities (approximately I % of 
FVII) (Mann et al., 1998). TF is the high-affinity cellular receptor for coagulation 
FVIIa (Butenas et aI., 2005) and in the absence of TF, FVIIa has very low catalytic 
activity, therefore, binding to TF is necessary to render FVIIa functional by an 
allosteric mechanism. The TF-FVIIa complex activates FIX and factor X (FX) to the 
activated forms FIXa and FXa, of which the latter, initially, is the more efficient 
substrate. Therefore, the formation of TF-FVIIa-FXa is termed the extrinsic Xase 
complex (Nemerson, 1988). The amount of FXa is limited as its generation is rapidly 
down-regulated by tissue factor pathway inhibitor (TFPI). This small amount of FXa 
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acti ate FV to F a on the urface of TF bearing cell, and together they generate a 
mall amount (picomolar concentrations) of thrombin (Monroe el aI. , 2002). 
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1.1.4.2. Amplification (priming) phase 
In the amplification (priming) phase, the small amount of thrombin produced on TF-
bearing cells activates cofactors FV and FVIII, and platelets. Although platelets have 
already adhered at the site of injury and become partially activated, the addition of 
thrombin can induce a higher level of procoagulant activity than adhesive interactions 
alone (Monroe & Hoffman, 2006). On the surface of platelets membrane, (I) 
thrombin binds to PAR I, which plays a key role in platelet activation (Smyth et aI., 
2007); (2) activating cofactor FVIII to FVIIIa and releasing it from VWF; (3) 
activating FV to FVa as a cofactor to FXa; and (4) activating FXI bound to the 
platelet surface (Monroe et af., 2002b). The FlXa, which is generated during initiation 
phase, migrates to the surface of platelet to facilitate the propagation phase of 
coagulation (Moore el aI., 2010). 
1.1.4.3. Propagation phase 
The propagation phase occurs on activated platelets. The enzyme FIXa, the cofactor 
FVIIIa, activated during the initiation and amplification phases, respectively, together 
with FX as the substrate form the intrinsic Xase complex on a membrane surface 
provided by platelets and endothelial cells. Additional FlXa is also activated by 
platelet-bound FXIa (Monroe & Hoffman, 2006). The intrinsic Xase activates FX at a 
50-100 fold higher rate than the extrinsic Xase (Mann et aI., 1998). FXa, together 
with FVa, Ca2+, PL, and prothrombin (FII) as the substrate form the prothrombinase 
complex to produce thrombin (FIla). The thrombin produced amplifies its own 
generation by activating FXI and further activation of platelets, FV and FVIII 
(Butenas et aI., 1997). In addition, large numbers of platelets can be recruited to the 
site of injury to provide enough surfaces for large-scale thrombin generation. 
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Thrombin cleaves fibrinopeptides A and B from fibrinogen, to expose recognition 
sites that polymerise the fibrinogen into fibrin strands. Fibrin acts as a template to 
accelerate thrombin activation of thrombin activatable fibrinolysis inhibitor (T AFI) to 
protect the clot against proteolysis. Also, thrombin cleaves factor XIII (FXIII) to form 
the insoluble cross-linked fibrin clot (Monroe & Hoffman, 2006). Factor XIII also 
binds to u2-antiplasmin, the main inhibitor of plasmin, which is responsible for 
dissolution of the clot (Moore et aI., 2010). 
In most models of coagulation, the formation of the fibrin clot occurs at the start of 
the propagation phase when the burst of platelet surface thrombin generation is just 
beginning. Consequently, more than 95% of total thrombin production takes place 
after initial clot formation. It has been proposed that the excess thrombin is produced 
to activate the TAFI, thereby protecting the clot against proteolysis (Mann et aI., 
2003a). TAFI is a carboxypeptidase that removes terminal lysine residues from fibrin, 
thereby, removing potential binding sites for fibrinolytic enzymes and enhancing clot 
resistance to fibrinolysis. Failure of T AFI activation is thought to contribute 
significantly to the bleeding tendency in haemophilia (Mosnier et al., 2001). 
1.1.5. Regulation of coagulation 
Three major groups of inhibitors control and regulate coagulation activity. These are 
serine protease inhibitors, the activated co-factor inhibitors, and the extrinsic pathway 
inhibitor. They are all produced principally in the liver and their action is triggered 
before the process of fibrin deposition has commenced (Hoffbrand et al., 2006). 
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1.1.5.1. Serine protease inhibitors (serpins) 
The serine protease inhibitors are glycoproteins that inhibit the activated procoagulants. 
The best known serine protease inhibitor is Antithrombin (AT) (Hoffman & Monroe, 
2007). AT is a single chain glycoprotein, which is synthesised principally in the liver 
and inhibits the activity of thrombin and FXa, and to a lesser degree other serine 
proteases, such as FIXa, FXla, and FVIIa in the FVIIa-TF complex , but not free 
FVIIa (Moore et aI., 20 I 0). 
A T inactivates its substrate by binding irreversibly through an arginine residue to the 
active serine site of the protease by fonning a I: I complex with the enzyme at their 
active site, which prevents the procoagulant from participation in the coagulation process. 
The rate of inactivation is relatively slow, but activity of AT is greatly enhanced by the 
anticoagulant heparin, or in-vivo, by heparan sulphate, a proteoglycan located on the 
surface of endothelial cells. They produce a confonnational change in AT as a result of 
which the reactive arginine residue becomes more readily able to combine with and 
inhibit the serine active centre of thrombin and other serine protease clotting factors. 
Heparin induces a 2300-fold increase in the rate of thrombin inactivation by AT such 
that its action becomes almost instantaneous. Congenital deficiencies of AT often lead to 
recurrent thrombosis in adult life (Rezaie, 2002). 
Other serpins include heparin co-factor II (which is a selective thrombin inhibitor), C, 
inhibitor (which neutralises kallikrein, factors XIIa and XIa) and u2_macroglobulin 
(which inhibits thrombin and kallikrein) (Hoffman & Monroe, 2007). 
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1.1.5.2. Activated cofactors inhibitors 
The main activated co-factor (FVa and FVIIIa) inhibitor is activated protein C (APC) 
(Hepner et af., 2002). Protein C is a vitamin K -dependent glycoprotein, synthesised in 
the liver. It circulates as an inactive zymogen, which is converted to an active serine 
protease, APC, by the proteolytic action of thrombin. Activation is accelerated by an 
endothelial surface protein, thrombomodulin (TM), through attachment of PC to 
endothelial protein C receptor (EPCR), which [onns a complex with thrombin 
simultaneously inhibiting the procoagulant activity of thrombin on fibrinogen, FV, FVIII 
and platelets. APC cleaves and inactivates FVa and VIIIa so that they can no longer 
interact with FXa and FIXa respectively. The inhibitory action of APC occurs on 
phospholipid surfaces. 
Protein S (PS), a non-enzymatic APC co-factor, specifically enhances the inhibitory 
activity of APC, by promoting its binding to the platelet membrane phospholipid and 
orienting it above the surface of activated platelet (Moore et aI., 2010). PS is also a 
vitamin K-dependent glycoprotein synthesised in the liver and endothelial cells. About 
40% of the PS in plasma is in the free fonn, whilst the remaining 60% is associated in a 
1: 1 complex with the C4b-binding protein (C4BP) and does not enhance PC function. 
1.1.5.3. Tissue factor pathway inhibitor (TFPI) 
The inhibitors mentioned above cause little or no inhibition of FVIIa. Instead the action 
of FVIIa is modulated by a specific extrinsic pathway inhibitor known as tissue factor 
pathway inhibitor (TFPI). TFPI has no effect on FVIIa alone but acts on FVIIa-TF 
complex, in the presence of factor Xa, in which the two proteases are inactivated 
sequentially. Most of the TFPI is associated with, and thought to be synthesised by, 
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endothelial cells, with a smaller amount being found in platelets and plasma (Monroe & 
Key, 2007). 
1.1.6. Fibrinolysis 
The fibrinolytic system (see Figure 1.3) exists to restore nonnal blood flow by restricting 
the extent of clot fonnation and dissolving the fonned fibrin clot. The main protein 
involved in this process is plasminogen. It is present in plasma mainly adsorbed onto 
fibrinogen and fibrin molecules. Plasminogen can be activated to fonn plasmin, directly 
by tissue plasminogen activator (tPA) or urokinase or by proteolytic enzymes such as 
trypsin, factor XIIa, thrombin and kallikrein (Mosnier et al., 2001). 
Fibrinogen lysis begins with plasmin cleavage of polypeptides from the carboxyl-
tenninal (C-tenninal) part of lysine on the Au chains, followed by the removal of the 
first 42 amino acids from N-tenninal end of B~ chains of fibrinogen. This large residual 
portion is tenned fragment X, which is asymmetrically degraded further to release one 
fragment D, in which the chains remain linked by disulphide bonds. The reminder of the 
parent molecule is tenned fragment y, which is again cleaved by plasmin, removing a 
second fragment 0 and leaving the disulphide-linked N-tenninal ends of all six chains, 
which are referred as fragment E (Hoflbrand et al., 1999). Cross-linked fibrin is cleaved 
by plasmin in a similar way to fibrinogen; however, because of the presence of cross 
links, the resultant products are D-dimer, D-dimer-E fragments, and oligomers of 
fragment X and y, in addition to X, Y, 0, and E. Plasmin promotes its own generation in 
two ways. On one hand, continuous cleavage of fibrin by plasmin generates new C-
terminal lysine residues that act as binding sites for plasminogen and tP A. 
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On the other hand, plasmin promotes its own formation by proteolytically removing Glu-
plasminogen to generate Lys-plasminogen. Lys-plasminogen is a better substrate for tPA 
(Mosnier et al., 200 I). 
1.1.6.1. Inhibitors of fibrinolysis 
The fibrinolytic system is also controlled by two main types of inhibitors. Firstly, those 
that inhibit plasmin, the main one being u2_antiplasmin, a glycoprotein that binds to the 
active site of plasmin, effectively inactivating it. The other group inhibit the activation of 
plasminogen and include plasminogen activator inhibitor (PAl types I, 2, and 3) (Lee et 
al.. 2000). PAI-I and PAI-2 are fast acting inhibitors of tP A. PAI-I is secreted into the 
circulation from endothelial cells, whereas PAI-2 is mainly synthesised in the placenta 
and is only present in blood in high concentrations in mid-late pregnancy. PAI-3 is an 
inhibitor of tPA, urokinase, thrombin and APe. It is present in blood and its action can 
be stimulated by heparin. 
1.1.6.2. Inhibition of fibrinolysis by T AFI 
During the initiation phase of fibrinolysis, limited amounts of plasmin are generated. 
These small amounts of plasmin are not sufficient to degrade the fibrin clot but enable 
fibrinolysis to progress into its propagation phase. Plasmin promotes transition of 
fibrinolysis into the propagation phase by truncating Glu-plasminogen into Lys-
plasminogen and by limited proteolysis of fibrin, thereby creating fibrin with C-terminal 
lysine residues. T AFI inhibits fibrinolysis by inactivating plasmin-mediated auto-
feedback loops that are designed to generate a burst of plasmin formation. The C-
terminal lysine residues of fibrin are removed by TAFI (Mosnier & Bouma, 2006). 
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1.2. Haemophilia 
Haemophilia is a bleeding disorder resulting from a congenital deficiency of FVIII 
(Haemophilia A), FIX (Haemophilia B) or FXI (Haemophilia C). It was first 
described in the Talmud, a collection of Jewish Rabbinical writings from the 2nd 
century AD, which stated that circumcision should not occur if two siblings had died 
from bleeding (Rosner, 1969). In the 12th century, the Arab physician, Albucasis, 
wrote of a family whose males died of bleeding after minor injuries. Dr. John Conrad 
Otto has been credited with writing the first recent account of hemophilia in his 1803 
dissertation, An Account of a Hemorrhagic Disposition Existing in Certain Families. 
However, the word "Haemophilia" did not appear until 1823 when a student at the 
University of Zurich in Germany used the term (Giangrande, 2004). 
Haemophilia first achieved extensive attention when it became known as "the royal 
disease." Queen Victoria was a carrier of haemophilia, probably as a result of a 
spontaneous mutation. Two of her daughters were carriers of haemophilia, and one of 
her sons, Leopold, had haemophilia and died at the age of thirty-one. Alexandra, a 
carrier of the disease and a granddaughter of Queen Victoria, married Czar Nicholas 
II of Russia and had a haemophilic son, Alexis, in 1904. Alexandra sought the help of 
Rasputin for her son, which enabled Rasputin to gain power in the government and 
indirectly cause the overthrow of the Romanov Dynasty (Stevens, 1999). Recently 
their type haemophilia was identified by applying genomic methodologies (multiplex 
target amplification and massively parallel sequencing) to historical specimens from 
the Romanov branch of the royal family. A mutation was found in FIX gene on the X 
chromosome, which caused severe haemophilia B (Rogaev et aI., 2009). 
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In 1944 researchers found in one case that when the blood from two different 
individuals with haemophiIia was mixed, both were able to clot. Nobody could 
explain this finding until 1952, when researchers in England realized there were two 
types of haemophilia. They had been studying a 10-year-old boy with haemophilia 
named Stephen Christmas who did not seem to have the "typical" disease. They called 
his version haemophilia B, also called "Christmas disease," and the more prevalent 
kind haemophilia A (HA), also called "classic haemophilia"(Aggeler et aI., 1952). 
Factor XI deficiency (Haemophi1ia C) was first described in 1953 in a Jewish family 
in the United States by Rosenthal el al. Two sisters had abnormal bleeding after a 
tooth extraction and surgery to remove tonsils. Four more of the thirteen members of 
the family over four generations were identified as factor XI deficient. (It was not in 
the scope of this thesis to study haemophilia C patients) 
1.2.1. Haemophilia A 
Haemophilia A (HA), the most common hereditary coagulation disorder, affects I in 
5000 male births worldwide (Mannucci, 2002). HA is an X-linked recessive disorder 
which is caused by a qualitative or quantitative abnormality of plasma FVIII protein. 
However, about 30 percent of cases arise from a spontaneous mutation, where there is 
no family history of haemophilia (Mannucci & Tuddenham, 2001). Females can be 
affected if both X chromosomes inherit the defective gene. Another mechanism for 
HA in females has been described: the presence of two de novo factor VIII mutations, 
an X chromosome deletion, and a paternal FVIII inversion mutation (Windsor et al., 
1995). In some haemophilia carriers, as a result of extreme "Iyonisation", the X 
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chromosome carrying the nonnal genes (FVIlI/FIX) is inactivated randomly. This 
may result in low FVIII/FIX level and bleeding phenotype (Ingerslev et aI., 1989). 
1.2.1.1. Molecular genetics of haemophilia A 
The human FVIII gene (F8) was cloned between 1982 and 1984 by Gitschier and 
collaborators and, at the same time, by Toole et al. (Lee et aI., 2005; Toole el aI., 
1992). The F8 is located at the most distal band, Xq28, of the long arm of the X 
chromosome. The gene contains 26 exons, nearly 186 kilobases (kb). The 25 
intervening regions (introns) that separate the exons range in size from 207 to 32400 
base pairs (bp). The FVIII messenger RNA (mRNA) encodes a 2351-aminoacid 
polypeptide and is synthesised in the liver, spleen, and lymph nodes. Upon secretion, 
a 19-aminoacid N-tenninal leader sequence is cleaved (Hoyer, 1994). The mature 
FVIII plasma protein of 2332-amino acids contains a domain structure of A 1-a1-A2-
a2-B-a3-A3-C l-C2 (Figure 1.4). The secreted FVIII is consists of a heavy chain (A 1-
A2-B) linked non-covalently to a light chain (A3-C1-C2). FVIII circulates in plasma 
complexed non-covalently with VWF that acts as a plasma carrier, and protects it 
from proteolysis and rapid clearance (Bhopale & Nanda, 2003). 
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Figure 1.4 Factor VIII peptide. 
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Factor VIII protein depicted with its domain structure with specific cleavage sites for thrombin, FXa and APC and 
binding sites for interaction with FIXa. 
a = activated factor; APC = activated protein C; F = factor. Adapted from (Pruthi, 2005; Pruthi & Nichols, 1999). 
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HA is classified as mild, moderate or severe, based on the factor level in plasma and 
the severity of clinical disease. Approximately 40-50% of patients with a mutant F8 
have severe haemophilia (the level of FVIII activity is < 1 % of nonnal) whereas the 
remainder have moderate or mild haemophilia (FVIII activity, 1- 5% ofnonnal or> 
5-40% ofnonnal respectively) (Lozier & Kessler, 2000). 
HA is caused by a broad spectrum of mutations that can occur along the entire length 
of the F8. The mutations lead to defects at the level of transcription, translation, or to 
change of individual amino acids in the FVIII protein. The online HA mutation 
database (http://europium.csc.mrc.ac.uk) lists over 2000 individual reports of FVIII 
variations from all over the world. 
F8 defects can be divided into several categories: 
l. Gross gene rearrangements of DNA sequence (inversions); 
ll. Deletions of genetic sequence of a size varying from one base-pair up to the 
entire gene; 
iii. Single DNA base substitutions, resulting in either amino acid replacement 
(missense), premature peptide chain tennination (non-sense or stop mutation), 
or mRNA splicing defects; 
IV. Insertion of DNA of varying size. 
Inversion gene defects usually involve intron 22 of the F8, which causes severe HA 
and is found in 400/0-50% of patients with severe disease. The F8 is completely 
disrupted: introns 1 to 22 are moved away from their nonnal context and their 
orientation is inverted. The intron 22 inversion is principally an error of DNA 
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replication during spennatogenesis in males. The distal inversion is more common 
than the proximal inversion (Tuddenham et af., 1991). 
The second most common mutation in severe HA is the intron I inversion mutation. 
This mutation is present in approximately 1.8% of severe HA patients in the UK 
(Keeney et al., 2005). 
Point mutations are the most prevalent type of defect, probably underlying the disease 
in 90-95% of patients. Point mutations are comprised of missense mutations. 
nonsense point mutations, and mRNA splice-site point mutations (Bowen, 2002). 
Point mutations leading to new stop codons are essentially all associated with a 
severe phenotype, as are most frame-shift mutations. An exception IS 
the insertion or deletion of adenosine bases resulting in a sequence of eight to ten 
adenosines, which may result in moderately severe HA (Nakaya et aI., 2001). Splice 
site mutations are often severe but may be mild, depending on the specific change and 
location. Missense mutations occur in fewer than 20% of individuals with severe HA 
but nearly all of those with mild or moderately severe bleeding tendencies (Keeney et 
aI., 2005). Deletions, the second most common gene defects (5-10% of patients), and 
insertions are extremely rare. 
HA patients are distinguished by the presence or absence of circulating FVIII protein 
and are divided into two main groups, tenned cross-reacting material-negative 
(CRM-) and -positive (CRM+), with different molecular pathogenesis. CRM-
haemophilia is characterized by a gross reduction or absence of circulating FVIII 
antigen (FVIII:Ag) as a result of altered folding, secretion or stability in plasma: 
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FVIII activity (FVIII coagulant (FVIII:C» is reduced in parallel with FVIII:Ag. 
CRM+ haemophilia is characterized by dysfunctional protein circulating at essentially 
normal FVIII:Ag levels (but with lower/absent FVIII:C) in which the mutation affects 
FVIII function but not secretion or stability. A subgroup of CRM+, CRM-reduced 
(CRM f ), is defined by mildly reduced circulating FVIII:Ag, together with further 
reduced FVIII:C, the mutation affecting both function and secretion or stability 
(David el aI., 2001). 
Amino acid substitutions cause the majority of moderate and mild forms of HA. The 
mechanisms, by which missense mutations lead to decreased FVIII activity in plasma, 
depend on the localization and nature of substituted amino-acid residues. Such 
mutations have been described in domains AI, A2, A3 and C2. They are usually 
associated with the moderate or mild CRM- HA (Gale et al., 2000). 
Certain amino acid substitutions in the region a3 and domains C 1 and C2 may become 
an obstacle to the normal binding of FVIII to VWF. The result is shortening of the 
mutant FVIII plasma half-life and mild or moderate CRM- HA. This can be 
exemplified by a substitution His2155Asp, which is associated with a change of 
surface charge of the C 1 domain and marked reduction of FVIII binding to VWF. 
Another example is a substitution of sulphated Tyr 1680 in the region a3, which points 
to the importance of post-translation modification for functional interactions of FVlII. 
The 3D model revealed that in the C2 domain mutations are localized in the region 
involved in binding both VWF and the phospholipid membrane (Gilbert et al., 2002). 
Two types of mutations lead to insufficient thrombin activation of FVIII. The 
consequence is usually moderate or mild, CRM+ haemophilia with dysfunctional 
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FVIII in plasma. One type of mutation alters ammo acids within the thrombin 
cleavage sites. In addition, substitutions outside the cleavage sites have been 
described, e. g. substitution of sulphated Tyr349 in domain Al (Michnick et al., 1994). 
A group of missense mutations involves amino acids forming the interfaces between 
domains A 1 and A2 and domains A2 and A3. Substitutions of these residues cause 
destabilization of the non-covalent interaction of the A2 domain within heterotrimer 
of the activated FVIII and thus lead to premature termination of its activity. In such 
patients with mild or moderate haemophilia, lower plasma FVIII activity is detected 
when determined using the two-stage assay as compared to the one stage assay (Pipe 
et aI., 2001). 
Interaction between FVIIIa and FIXa on the surface of the phospholipid membrane 
can be disturbed by missense mutations in the A3 domain that serves as the receptor 
site for FIXa. Amino acid substitutions within the A2 domain may affect, on the one 
hand residues that are in direct contact with the catalytic domain of FIXa and, on the 
other hand, the more distant residues, where an effect on the conformation of the 
contact surface can be presumed. The consequence of these mutations is a decrease of 
FVIIIa cofactor activity resulting in CRM+ haemophilia of severity ranging from 
severe to mild (Jenkins et al., 2002). 
1.2.1.2. The role of FVIII in coagulation 
Upon secretion into plasma, FVIII is bound to VWF in non-covalent form. FVIII 
cannot be activated until released from VWF. The role of VWF is to localise FVIII at 
the site of vascular injury through binding to subendothelial matrix protein and 
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adherent platelets. On exposure to thrombin or FXa, a proteolytic cleavage at Arg 740 
transiently converts the heterogeneous heavy chains into 92-kd fragments (Bhopale & 
Nanda, 2003). At the same time, a small fragment is cleaved from the light chain to 
separate FVIII from VWF. Cleavage at Argl689 appears to be the mechanism by 
which VWF disassociates from FVIII. These cleavages produce the activated FVIII 
heterotrimer factor VIlla (FVIIIa), thereby relieving the inhibitory activity ofVWF on 
FVIII, permitting the FVIIla to interact with negatively charged PL. Concurrently, the 
B domain of FVIII is also removed (Hoyer, 1994). 
The cofactor activity of FVlIIa in the assembled Xase complex is provided by three 
essential interactions: binding to the PL membrane, the enzyme FIXa, and the 
substrate FX. FVIIIa increases the catalytic activity of FIXa by several orders of 
magnitude on a PL surface. This results in approximately 50-fold more efficient 
conversion of FX into FXa. Thus, the role of FVlIIa is to generate large amounts of 
FXa and in this way to provide efficient propagation of the clotting process, and 
consequently, a burst of thrombin generation (Fay, 2004). 
1.2.2. Haemophilia B 
Haemophilia B is caused by defects in, or absence of, coagulation FIX. Haemophilia 
B is a recessively inherited X-linked bleeding disorder, which is less common than 
HA with prevalence of 1 in 25000 male births worldwide (Mitchell et aI., 2005). 
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1.2.2.1. Molecular genetics of haemophiIia B 
The FIX gene (F9) was cloned in 1982 by three independent groups (Green et aI., 
1993). It is smaller and structurally simpler than the F8, and located near the tcnninus 
of the long arm of the X chromosome (Xq27.1). It is approximately 34 kb in length 
and contains only eight exons and seven introns (Figure 1.5). The number of exons 
and splice junction types are highly conserved in homologous vitamin K-dependent 
proteins, e. g. FX, FYI I, and protein C (Green et af., 1993). 
The first exon encodes the prepeptide (also called signal or leader sequence). The 
prepeptide is cleaved off, following secretion, by a prepeptidase (Lee et al., 2005). 
The prepeptide is followed by another signalling peptide, the propeptide, which is 
encoded in ex on b. This I8-residue sequence is the signal for modification, post-
translationally, at 12 glutamic acid residues by a vitamin K-dependent gamma-
carboxylase to produce y-carboxyglutamic acid. This is called glutamic acid-rich 
(GLA) domain region (Handford et aI., 1991). The GLA is followed by 2 epidennal 
growth factor (EGF) domains, an activation peptide, and a cata]ytic domain (Figure 
1.5) (Pruthi, 2005) . 
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Figure 1.5 Factor IX peptide. . 
FIX is activated by FXla or FYlIa-TF complex in a sequential cleavage at Arg 145 and 180 r.esld~es. . . 
act=activation peptide; C=carboxyl terminus; EGF=epidermal growth factor; GLA=glutamlc aCId nch; N=amlOo 
terminus; Pre=prepeptide; pro=propeptide.(Pruthi, 2005) 
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Haemophilia B is a mutationally heterogeneous disorder. Most mutations are single 
base pair changes that result in missense, frame-shift, or nonsense mutations. Short 
deletions (less than 30 nucleotides) account for approximately 7%, larger deletions 
approximately 3%, and insertions approximately 2% of mutations. Many of the single 
base pair changes occur at CpG doublets that are "hot spots" for mutation (Green et 
al., 1993). "Coldspots" also exist in the gene, where missense mutations are rare or 
absent. These correlate with parts of the protein that are not required for catalytic 
activity and are cleaved off during activation (Giannelli et al., 1993). 
Missense mutations account for most mutations that typically result in mild disease 
unless the mutations occur in residues critical for normal FIX function. Some 
mutations in the promoter region of the F9 result in a unique phenotype, termed 
haemophilia B Leyden, which is characterised by severe disease at birth with 
progressive amelioration of severity throughout adolescence and puberty. The post-
pubertal increase in FIX activity in haemophilia B Leyden patients has been suggested 
to be caused by androgens. This idea was supported by the observation that danazol, 
an androgen derivative, stimulates FIX activity in pre-pubescent haemophilia B 
Leyden patients (Boland et al., 1995). 
However, some promoter mutations (e.g. Brandenburg mutation at bp 26) in the FIX 
promoter result in a severe lifelong disease state (Morgan et aI., 1997). Nonsense 
mutations in the signal peptide and propeptide regions lead to severe haemophiIia B. 
Mutations In the GLA domain disrupt y-carboxylation (post-translational 
modification) and calcium binding, the latter is important for normal FIXa binding to 
collagen, activated platelets, and endothelial cells. Mutations in the EGF domains 
28 
disrupt protein-protein interaction (FVlIIa and FVIIa-tissue factor), resulting in 
reduced activation of FIX. Also, EGF mutations affect binding to Ca2+ (Giannelli el 
aI., 1993). 
An unusual FIX variant due to mutation at Ala-lOis characterised by normal baseline 
FIX activity. However, Warfarin therapy results in a severe and disproportionate 
reduction in FIX activity (typically < 1 %), which causes bleeding in patients being 
treated with Warfarin. An indication of such a situation is a disproportionate 
prolongation of the activated partial thromboplastin time (APTT), which should 
prompt clotting factor assays (Pruthi, 2005). 
1.2.2.2. The role of FIX in coagulation 
Factor IX participates in two physiologically important reactions: cleavage of specific 
peptide bonds to generate the activated fonn, FIXa, and cleavage of a specific 
substrate, FX, by the FIXa. In the first reaction, either FVIIa-TF or FXla can cleave 
FIX to generate FIXa. In the second reaction, FIXa in the presence of cofactor FVIIIa, 
Ca2+, and PL cleaves FX to generate FXa (High & Roberts, 1995). 
1.2.3. Clinical phenotype of haemophilia 
Haemophilias A and B are clinically indistinguishable from each other. Diagnosis 
must be confinned by specific factor assay. Patients with haemophilia display a 
spectrum of bleeding manifestations (deep muscle and joint haemorrhage, 
haematomas, easy bruising, post traumatic bleeding, bleeding post-oral injury and 
tooth extraction, etc). The propensity to musculoskeletal haemorrhage can lead to 
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recurrent haemarthroses (target joints) and chronic muscle Injury and fibrosis 
(Goodnight et aI., 2001). 
The bleeding tendency is related to the measured concentration of the factor and is 
classified as mild, moderate, or severe (Table 1.1). This classification generally 
predicts bleeding risk, guides the optimum management strategy, and predicts 
outcome (White et al., 2001). The number of bleeding episodes, the amount of factor 
used and the presence of arthropathies reflect the course of the disease in each patient 
(Tizzano el aI., 2002a). AlthO'ugh most patients with severe haemophilia need regular 
replacement therapy, a small proportion of individuals with severe haemophilia 
exhibit a milder clinical presentation and rarely bleed and need only occasional 
treatment. 
Table 1.1 Classification of haemophilia 
Concentration Classification Clinical manifestations 
of FVIIIIFIX 
<I IU/dL Severe Spontaneous joint and muscle bleeding; bleeding 
after injuries, accidents, and surgery 
1-5 IU/dL Moderate Bleeding into joints and muscles after minor 
injuries; excessive bleeding after surgery and dental 
extractions 
>5-40 IU/dL Mild Bleeding after surgery, dental extractions and 
accidents 
Where nonnal IS 100 lU/dL of FVIlI/FIX (100%). as defined by the current World Health Orgamsahon InternatIOnal Standard 
(White el al., 200 I ). 
1.2.3.1. Variability in clinical phenotype 
The clinical phenotype in part is related to the baseline factor VIII or IX level, but 
variability in clinical phenotype is also seen among severe haemophilia patients. 
About 10-15% of patients with FVIII levels of < 1.0 IU/dL have clinically mild 
disease in tenns of frequency of bleeds and extent of arthropathy. In addition, in some 
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patients from the same family, carrying the same gene defect, the bleeding tendency 
may not be identical. The mechanism of this phenotypic heterogeneity is not clearly 
understood (Dargaud et aI., 2004). 
Recent studies have suggested that the presence of prothrombotic factors e.g. FV 
Leiden G 1691 A and prothrombin G20210A polymorphisms, can modify the clinical 
phenotype in haemophilia (van Dijk et aI., 2004). Increased levels of other 
procoagulant factors shown to confer an increased risk of thrombosis can also be 
potential modifiers of the haemophilia phenotype. Several studies have confirmed 
that higher levels of factors II, V (Mary, 2007), VIII (Koster et al., 1995), IX (Vlieg et 
aI., 2000), and XI (Meijers et al., 2000) are associated with venous thromboembolism 
(VTE) risk. Other reports suggest that FXII deficiency is related to risk of thrombosis 
(Gallimore et al., 2004). 
Platelets occupy a central role in the maintenance of haemostasis by adhering to sites 
of vascular injury and facilitating thrombin generation, leading to the formation of a 
fibrin clot. Individuals differ greatly with respect to platelet function, and platelets 
from different individuals differ inherently in their ability to support thrombin 
generation. There is evidence supporting the role of platelets and platelet-related 
factors in modifying bleeding tendency in patients with haemophilia (Dargaud, et al. 
2006; Yee, 2006). Procoagulant microparticles are increasingly recognised as 
important mediators of haemostasis and thrombosis (Mackman, 2006). Platelet-
derived microparticles demonstrate at least a fourfold variation in healthy individuals 
(n = IS) (Berckmans et al., 2001) and even greater heterogeneity among haemophilia 
patients (n = 79) (Proulle et al., 2005). 
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1.2.4. Diagnosis of haemophilia 
Haemophilia is diagnosed either because of a known family history or after 
presentation with bleeding. The hallmark of severe haemophilia is spontaneous 
bleeding into joints and muscles that can be painful and destructive if inadequately 
treated. Most children with severe haemophilia experience their first bleed into a joint 
by the age of four, but many bleed from other sites before this age. Moderate 
haemophilia is diagnosed in most cases by the age of five, but mild haemophilia may 
be diagnosed much later in life after trauma or surgery. Therefore an accurate 
personal and family history is a crucial first step in the diagnosis of any bleeding 
disorder. 
The activated partial thromboplastin time (APTT) has been used as a screening test 
for coagulation factor deficiencies since the early 1950s (Langdell et a/. , 1953). The 
modern APTT test is a recalcification clotting time of citrated plasma with added 
surface contact activation (by either kaolin, celite, silica or ellagic acid) and a source 
of phospholipid. This is especially sensitive to coagulation abnormalities of the 
"intrinsic" pathway (factors VIII, IX, XI, and XII). Isolated prolongation of the APTT 
indicates a deficiency of one or more coagulation factors or inhibition of the 
coagulation process by heparin, lupus anticoagulant or specific factor inhibitors 
(Tripodi & Mannucci, 2006). 
32 
1.2.4.1. One-stage APTT factor assay 
The basis of this bioassay is that of an APTT is performed on various dilutions of a 
standard and the sample, which are made in buffer and added to the specific factor 
deficient plasma (e.g. FVIIIIFIX deficient plasma), to investigate the reduced or 
missing clotting factor. By plotting on a graph the time taken to clot for a known 
amount of the factor (e.g. FVIIIIFIX), a standard curve is produced. The clotting time 
of at least three dilutions of the test plasma can be measured from the standard curve. 
An important prerequisite for this assay is parallelism between the standard curve and 
dilutions of patient plasma. Non-parallelism indicates presence of an inhibitor or very 
low level of the investigating factor. This assay is the most commonly used in the 
clinical laboratory due to the relatively low cost and automation of the assay 
(Goodnight & Hathaway, 2001). 
1.2.4.2. Two-stage assay 
The two-stage assay was developed by Biggs and colleagues in 1955. In the first stage, 
FVa and FXa are generated in an amount which is related to the sample's FVIII 
activity. In the second stage, prothrombin and fibrinogen are added, usually in the 
fonn of nonnal plasma, and the clotting time is recorded (Biggs et of., 1955). This 
method makes no use of FVIII deficient plasma. It is claimed to show a better 
precision in general and also to be more sensitive than the one-stage method. 
However, it is more cumbersome to perform; hence it is not commonly used today 
(Barrow cliffe, 2004). 
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1.2.4.3. Chromogenic assay 
The availability of a chromogenic substrate for FXa triggered the development of 
chromogenic methods for factor VIII activity and a specific method was published in 
1985 (Rosen et al., 1985). The assay principle is similar to the two-stage assay in 
being based upon an incubation step for generation of factor Xa and with no need of 
FVIII deficient plasma but rather utilizing purified bovine factors IXa and X. 
However, instead of using a fibrin clotting time as the end-point, the amount of factor 
Xa is determined from the hydrolysis of chromogenic substrate. The amount of 
generated factor Xa is directly proportional to the FVIII activity. This method has a 
greater precision and lower inter-laboratory variability than the one-stage assay with 
2-7% coefficient of variation (CV) (van Dieijen et aI., 1987), as compared to one-
stage assays which have CV of 7-10% (Raut et al., 2001). The chromogenic assay is 
not widely used in the clinical setting due to the high cost of chromogenic substrates 
(Girolami & Vettore, 2009). 
1.2.4.4. Discrepancies between methods 
There are a number of reports on discrepancy between methods for measuring FVIII 
activity level, particularly in mild HA patients. In a comprehensive survey by Duncan 
et al. (1994), where the one-stage and the two-stage clotting methods were used in 
parallel, there were a number of index patients and also their affected family members 
who showed significantly higher results with the one-stage method than with the two-
stage method, the latter method correlating much better with the clinical severity. 
Later, several single point mutations causing alterations of amino acids in the AI, A2 
and A3 domains were identified in a number of those families, and those mutations 
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were not found in patients who showed similar results in the two methods (Pipe et aI., 
2001; Rudzki et al., 1996). 
More recently, a discrepant result was also reported between the one-stage method 
and the chromogenic method, where the one-stage method showed a lower result and 
in this case correlated better with the clinical picture (Rodgers et aI., 2007). In the 
one-stage FVIII assay, where the physiological concentrations of thrombin activate 
the physiological concentrations of FVIII, the time between the first appearance of 
catalytic amounts of thrombin and a measurable clot may be as little as 15-20 s. 
Under these conditions, the assay will be extremely sensitive to altered thrombin 
binding or cleavage of FVIII. In contrast, in the chromogenic assay, an excess amount 
of thrombin activates diluted FVIII in a much longer time compared to the one-stage 
assay. Thus any altered affinity of thrombin towards FVIII will be overcome by this 
high thrombin concentration and activate FVIII (Oldenburg & Pavlova, 2010). 
1.2.5. Treatment of haemophilia 
Severe haemophilia patients may bleed spontaneously into joints and therefore require 
treatment, to replace the missing or dysfunctional factor. Bleeds can be treated as they 
occur (on demand) or treatment can be given regularly to prevent bleeds occurring 
(prophylaxis). By maintaining FVIIVFlX at a low level, spontaneous bleeding into the 
joints can be avoided. Treatment, when started at a young age, can prevent the 
development of arthropathy (van den Berg et af., 2001). In patients with mild or 
moderate haemophilia treatment would be usually needed after injury or before a 
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surgical procedure. There are essentially two types of factor concentrates, plasma 
derived and recombinant. 
A major challenge to the treatment of haemophilia is the development of inhibitors to 
the replacing factor. An inhibitor is a polyclonal inhibitory immunoglobulin G 
antibody directed against FVIII or FIX. It is estimated that the incidence of antibody 
development in persons with severe or moderate HA is between 20% and 33% (Lee et 
al., 2005). 
Among persons with haemophilia B, inhibitors are much less frequent, affecting only 
1 to 6 %. However, the development of factor IX inhibitors can be associated with a 
mild or severe allergic reaction during factor IX administration. There is a high-risk 
period for the development of inhibitors during the first 50-100 days of exposure to 
infused factor. Historically, the majority of inhibitors have been reported to develop 
during childhood, at an average age of 10 years. A number of prognostic factors have 
been proposed such as genetic, environmental, and the type of factor concentrates 
(Hoffbrand et at. 2006). 
1.3. Thrombin generation test 
Thrombin generation is the central event in blood coagulation: Insufficient thrombin 
leads to an increased risk of bleeding, while unregulated thrombin generation 
predisposes to thrombosis. Whilst the PT and APTT are useful tests in identifying 
bleeding risk, they are of little value in predicting thrombotic risk, as they do not 
reflect overall thrombin generation. Figure 1.6 illustrates two haemostasis reaction 
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curves; a clot fonnation curve (e.g. PT or APTT), and a thrombin generation curve. 
For blood to clot, in vivo, it is only necessary for a small proportion of the available 
prothrombin to be converted to thrombin, with > 95% of thrombin fonnation 
occurring after this point (Baglin, 2005; Mann et al., 2003b). 
The thrombin generation test (TOT) has been used for more than 50 years since its 
development by Macfarlane and Biggs (1953) for use in whole blood and 
simultaneously by Pitney and Dacie (1953). Both methods were similar in that blood 
or plasma was placed in glass tubes with saline, subsamples were removed into a 
fibrinogen solution and the time taken for the fibrinogen to clot was measured. 
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Figure 1.6 Comparison of clot formation and thrombin generation curves 
TGT (doted red line) can be described in phases: Lag (TI), maximum rate (T2), peak (T3) and total free thrombin 
produced (area under the curve, T4). Fibrin clot formation (blue) occurs concurrent with thrombin generation. In 
contrast to thrombin generation, the lag phase in the clot formation curve (el) is a complex function reflecting 
initial thrombin generation, initial fibrin formation in an in vitro reaction tube. All clotting based coagulation 
assays detect this point as the end point of clot formation; (e2) occurs during thrombin's burst phase when the 
thrombin concentration is increasing, which is not detected in fibrin clot end point tests (Wolberg, 2007). 
In the 1980s Hemker and colleagues developed this assay further by introducing some 
modification into the TGT (Hemker et al., 1986). Initially Hemker et al. used the 
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chromogenic substrate and the plasma sample was defibrinated. However, the method 
was still a two-stage assay and therefore cumbersome. Sub sampling onto a 
chromogenic substrate was the first method in which thrombin was measured directly. 
Thrombin is neutralised predominantly by AT and a2-macroglobulin (a2-M). The 
technical problem was that the thrombin-a2-macroglobulin complex could cleave 
chromogenic substrates; therefore, the thrombin generation curve was the result of 
combined activities of free thrombin and thrombin-a2-macroglobulin complex on the 
chromogenic substrate (Figure 1.7). In order to calculate the area under the free 
thrombin curve (the physiological enzymatic work potential) a mathematical 
computer program was used to calculate the free thrombin activity from the thrombin 
generation curve (Hemker et aI., 1993). This was later designated the endogenous 
thrombin potential (ETP) (Hemker & Beguin, 1995). 
The method still required defibrination of the plasma sample and it was realised that 
removal of fibrinogen has an adverse effect on the thrombin generation curve with a 
lower thrombin peak and a higher end-signal from the thrombin-az-M complex 
(Hemker et at. 2000). 
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Figure 1.7 Thrombin generation curve with o2-macroglobulin 
TGT curve measured by cleavage of a chromogenic substrate (curve C) is combined activity of the thrombin-a2-
macroglobulin complex and free thrombin. Curve B is the thrombin-a2-macroglobulin complex activity only. 
Curve A is the area under the free-thrombin activity designated the Endogenous Thrombin Potential (ETP, 
nmol/min). 00, optical density for chromogenic substrate; t, time. (Baglin, 2005). 
A further development of measurement of the thrombin generation was the use of a 
slow reacting substrate, which permitted continuous registration of thrombin activity 
in the primary reaction tube (Hemker et al., 2000a). This converted the TGT method 
to a much simpler one-stage assay. The replacement of the chromogenic substrate 
with a slow reacting fluorogenic substrate enabled continuous measurement of 
thrombin generation without the need for defibrination. The calibrated automated 
thrombogram (CAT) was later introduced (Hemker et al., 2003). In the CAT method 
the splitting of a fluorogenic substrate is monitored by comparing it to a constant 
known thrombin activity in a parallel, non-clotting sample. 
Because of the use of fluorescence as a detection mechanism turbid media can be 
studied. Therefore the role of the platelets, fibrin, fibrin-platelet interaction and 
diffusion-controlled mechanisms are reflected as well. Thrombin generation can now 
39 
be perfonned on platelet poor plasma (PPP) as well as platelet rich plasma (PRP), as 
the signal from the fluorophore is not quenched by turbidity (Hemker et al., 2000b). 
1.4. Thromboelastometry 
Thromboelastometry was first described by Hartert in 1948. In the original 
thromboelastogram a whole blood sample was placed into a cuvette, which rotated 
gently back and forth with a cycle time of 6/min. The viscoelastic changes that occur 
during coagulation were recorded (Luddington, 2005). Results obtained by classical 
thrombelastography (TEG) are dependent on the activity of the plasma coagulation 
system, platelet function, and fibrinolysis. Therefore, application of TEG could have 
several advantages compared with standard coagulation analysis that reflect only a 
part of the haemostatic process and additionally include partially unphysiologic 
activators. 
With the advent of computer-assisted equipment, this technology is gaining more and 
more relevance in the clinical assessment of bleeding and thrombotic conditions 
(Rivard et al., 2005). Recently, a modified rotational thromboelastometry analyzer 
(ROTEM~, Pentaphann, Munich, Gennany), has been marketed that overcomes some 
of the limitations of classical TEG. For example, by using an electronic pipette, 
reproducibility and perfonnance has increased. 
During ROTEM® measurements, the axis holding the pin, which serves as the sensor, 
is rotated alternately to the right and left at 4.750 by means of a spring mechanism. 
The rotations are optically monitored by means of a mirror, a light source, and a light 
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beam detector, and are eventually converted into a real time mea urement by an 
integrated computer y tern (Figure 1.8). Upon mea urement, initially, the rotation of 
the pin is unhindered, which i repre ented at this tage by a traight line in function 
of time. In ROTEMJl. thi time it i defined a coagulation time (CT). 
Rotating axis 
Spring 
Ball bearrng 
Plastic pin 
Heated 
cuvette holder 
Figure 1.8 ROT M 
Reproduced from http:// \' w\\p~ntapharm.de with permi ion. 
light source 
Mirror 
Data Processing 
Detector 
Cuvette With 
blood 
Fibrin strands 
and platelet 
aggregates 
With the initiation (by contact activation) of the coagulation proce s, the rotational 
movements are influenced by adhesion of fibrin threads developing between the cup 
and pin. The period of time to reach a width of 20 mm i the clot formation time 
(CFT). CT and CFT are u ually expre ed in seconds. The maximum width of the 
thromboela togram corre pond to the maximum clot firmness (MCF). The maximum 
width of the thrombocla togram i mea ured in millimetres (Figure. 1.9a) 
On reaching the M F, the econdary coagulation phase i completed. Subsequently, 
the amplitude i reduced by fibrinolytic proce scs. 
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Figure 1.9 ROT M ' tracing 
Principal characteristic ofthromboelastometry oftware parameter and first derivative parameters ofwholc blood 
clot formation. (a) tandard thromboelastometry tracking. CT i the clotting time, CFT is the clot formation time, 
and the MCF is the maximum amplitude of clot formation . (b) ROTEM1t tracking imported into the ROTEM~ 
oftware (CalcuRo). (c) Velocity profile, the fir t derivative of the thromboelastometry course. Maximum velocity 
(MaxVel , marked with a horizontal arrow) is the maximum rate of whole blood clot formation. Time to maximum 
velociry (tMaxVel, marked with a perpendicular arrow) i the timc until maximum velocity occurs. The area under 
the velocity curve (A , marked with gray colour) indicate the maximum clot formation , an indirect 
mea urement of clot trength. Taken from ( aren en ef 01., 2003) with permis ion . 
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In addition, a angle (aO) may be used, which demonstrates the kinetics of clot 
formation. The a angle represents the speed at which a solid clot forms and IS 
primarily influenced by platelet function, but coagulation factors contribute to a 
certain extent, especially fibrinogen. Apart from the parameters CT, CFT, aO, and 
MCF, there are several further parameters such as the maximum lysis (ML) and the 
fibrinolysis index (LI), which may be measured after 30, 45 and 60 min, respectively, 
describing the fibrinolytic process (Serensen et ai., 2003). 
Thromboelastometry curves can be analysed using a software program provided with 
the ROTE Mil! analyzer, which was first described by Smensen et al. (2003). The raw 
data is imported into ROTEM ili software CalcuRo (Pentapharm GmbH, Munchen, 
Germany) for analysis of maximum velocity (Max Vel), time to maximum velocity 
(tMaxVel), and area under the curve (AUC) (Landskroner et al., 2005) (Figure 1.9.c). 
1.5. Clot waveform 
The MDA ® analyser (Organon Teknika, Cambridge, UK) is a fully automated 
coagulometer, which performs coagulation assays by using a variable wavelength 
photo-optical detection system. During the performance of routine clotting assays 
such as APTT and PT, it is possible to obtain a continuous measurement of the 
changes in light transmittance that occur as the fibrinogen in the test citrated plasma 
sample undergoes polymerisation to form a clot. The resultant photo-optical data 
profiles obtained by continuous monitoring are called waveforms caused by their 
sigmoid patterns, which can be used to define specific events that occur prior to, 
during and following initiation of the clotting reaction (Downey et al., 1997). 
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The waveform is mathematically processed by a software algorithm to derive a set of 
10 parameters (Table 1.2) such as coagulation velocity (Mini) by measuring the 
percentage difference in light transmittance divided by time difference in second 
(%T/s), and acceleration (Min2), calculated based on difference in percentage of 
change in light transmittance over time in squared second (% T/s2) (Figure 1.10) 
(Shima et al., 2002). 
Using this approach, the waveform of an APTT assay can be divided into three 
segments or phases: pro-coagulant phase, coagulation phase, and post-coagulation 
phase. These phases are characterised by a set of parameters that define: 
• The timing of individual events during the reaction. 
• The rate at which these events occur. 
• The magnitude of the change. 
Table 1.2 Clot waveform parameters 
Phase Parameter Description 
Pro-coagulation (a-b) Slope I Initial slope of line fit to data from a (point of addition of 
Delta 1 activating reagent) to b (initiation of coagulation) 
Amplitude of signal change from point a to b 
Coagulation (b-d) Index min2 Time at point b (onset of coagulation) 
Min2 Minimum value of second derivative (acceleration at point b) 
Index minI Time at point c (coagulation midpoint) 
MinI Minimum value of first derivative (coagulation velocity) 
Index max2 Time at point d (end of coagulation phase) 
Max2 Maximum value of the second derivative (deceleration point) 
Post-coagulation (d-e) SIope3 Slope ofline fit from d to e (end of acquisition time) 
Delta Amplitude of total sismal change between point a and e 
44 
E 
Q) 
u 
c: 
m 
a __ ..... b 
-- ~_d ________________________ ~e~ 
= E 
en 
c 
m 
~ 
.... 
~tI~~nll 
! , 
~-.!~-.. ~-2-1-----------"-----
Time (5) 
Figure 1.10 Clot waveform. 
In the nonnal wavefonn. the upper trace shows the changes in transmittance (T) observed over time (t) during the 
performance of an APTT. The middle trace shows the first derivative (dT/dt) from the transmittance data and is 
denoted Min I. The lower trace shows the second derivative (d2T/dt2) and is denoted Min2. Point a is the start of 
transmittance by addition of activating reagent. Point b indicates the initiation of coagulation. Point c is the 
coagulation midpoint. Point d is the end of coagulation phase. Point e is the end of acquisition time. The absolute 
value of Min 1 shows the maximum coagulation velocity and the absolute value of Min2 shows the maximum 
coagulation acceleration (adapted from Shima (2008». 
The data provided by clot wavefonn analysis reflect fibrinogen to fibrin conversion. 
Fibrinogen is the ultimate substrate for thrombin in the coagulation cascade, and it is 
likely, therefore that clot waveforms also reflect thrombin generation (Shima et al.. 
2008). Thus clot waveform analysis may be useful for the investigation of the clinical 
phenotype of individual patients. 
A comparison of clot wavefonn analysis and TGT In haemophilia A and 8 
demonstrated a significant correlation between the clot waveform and TGT 
parameters (Shima et al., 2008). 
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1.6. Aims 
1.6.1. Rationale for current study 
Traditional coagulation assays, such as APTT, are usually performed in platelet poor 
plasma (PPP). They provide information only on the initial stage of clot formation. 
The end point of APTT -based assays is the formation of a fibrin clot by the initial 
generation of thrombin. However, more than 95% of thrombin, which is produced 
during the propagation phase of coagulation, remains undetected in these assays 
(Bates & Weitz, 2005). In patients with documented haemorrhagic disorders, only 
modest alterations of thrombin production occur during the initiation phase, while 
depression of thrombin production during the propagation phase is the hallmark of 
these congenital bleeding diseases as assessed by the laborious sub-sampling 
chromogenic method of thrombin generation (Hemker & Beguin, 1995). 
The sensitivity of APTT based coagulation factor assays is limited to 1.0 JU/dL 
activity of the relevant coagulation factor level (Scharrer & Schramm, 2007); 
therefore, the phenotype of patients with a factor level of < 1.0 IU/dL and mild 
bleeding frequency remains inconclusive by the current assays. Further clot waveform 
analysis is sensitive to changes of factor VIII concentration < 1.0 IU/dL (Shima et aI., 
2002). It is conceivable that global assays incorporating platelets and other cellular 
components might amplify the effects of factor VIII < 1.0 lUI dL on thrombin 
generation. 
There has also been growing interest as to whether global tests, including the TGT, 
thromboelastometry, clot waveform analysis, that assess the interaction of the 
procoagulants and anticoagulants on generation of thrombin, and the ability of 
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platelets to support this thrombin generation may better define the bleeding tendency 
in patients with haemophilia. This would have an impact on the immediate 
management of patients, and potentially contribute to individualising treatment based 
on the patient's coagulation phenotype. 
It has been reported that thrombin generation in mild and moderate haemophilia is 
less impaired than in patients with severe haemophilia (Beltran-Miranda et aI., 2005; 
Dargaud et aI., 2005). Accordingly, differences in thrombin generation between 
patients with severe haemophilia may explain the observed differences in clinical 
presentation. 
Preliminary data, (Chantarangkul et aI., 2003; Dargaud et aI., 2005; Dargaud et al., 
2007; Lewis et aI., 2007; Luddington & Baglin, 2004) show that the analysis of 
parameters in thrombin generation is a useful tool to detect bleeding tendency in 
haemophiliacs. However, these studies have been performed on PPP; therefore the 
effect of platelets on thrombin generation has not been taken into account. 
Furthermore, none of the studies published when the project was conceived correlated 
global assays to the type of mutation or the clinical phenotype. 
1.6.2. Aims 
The aim of this study was to critically evaluate the role of global assays in the 
investigation of haemophilia disorder, including the influence of preanalytical 
variables. 
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1.6.3. Objectives 
The global assays chosen for this study, included modified rotating 
thromboelastometry (ROTEME ) as described by Serensen et al. (2003), performed on 
whole blood, with the whole blood being activated either by the contact pathway or 
through the use of tissue factor. 
In house thrombin generation in platelet poor and platelet rich plasma was also 
performed with appropriate concentration of tissue factor, to assess the heterogeneity 
of thrombin generation. A commercial thrombin generation assay as described by 
Hemker et at. (2003), the calibrated automated thrombogram (CAT) was also used to 
compare with the in-house method. 
Clot waveform analysis, based on light transmission on the MDA analyser, was also 
incorporated to provide a sophisticated analysis of the fibrin clot formation beyond 
clot detection as a surrogate marker of thrombin generation (Shima et aI., 2002). 
The prevalence of thrombophilic defects, such as FV Leiden and prothrombin gene 
mutation (G2021OA) that can potentially influence global coagulation assays was also 
evaluated. The global assays were compared with each other, and to conventional 
factor assays to identify the most sensitive parameters of disease severity. 
Furthermore, these sensitive parameters of global assays were correlated to the type of 
mutation and the clinical phenotype as described by the clinicians in the Haemophilia 
Centre, to evaluate their utility in predicting the bleeding tendency. 
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1.6.4. Hypothesis 
Global assays including TGT, ROTEM®, and clot wavefonn analysis may reflect the 
clinical phenotype of individuals with haemophilia A and B better than current 
conventional methods such as clotting factor assays. 
The existence of other defects in haemostasis system may modulate the coagulation 
potential of individuals toward hypolhypercoagulability. In haemophilia this may 
influence the bleeding phenotype of patients. 
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Chapter 2 Materials and Methods 
2.1. Patient Material 
Patients studied were registered at the Katharine Donnandy Haemophilia Centre and 
Thrombosis Unit, Royal Free Hospital, London, UK. All patients had been previously 
identified as having haemophilia A or B. All patient material was collected with 
informed consent and the study conducted in accordance with the International 
Conference on Harmonisation (lCH) and World Health Organisation (WHO) Good 
Clinical Practice standards, after local ethical committee (the Royal Free hospital 
ethics committee; reference number: 04/Q0501120) approval. 
2.1.1. Inclusion criteria 
• Patients with Haemophilia A or B 
• Willingness to participate in the study by infonned written consent 
• Age 2 16 years old 
• Most recent concentrate treatment 72 h before sample collection for 
haemophilia A patients and 5 days for haemophilia B patients (the median 
half-life for FVIII and FIX are 12 (van Dijk et a/., 2005b) and 19 h 
respectively (Poon et a/., 1995); the washout period is considered 3 to 5 
half lives (Lee et a/., 2004). 
2.1.2. Exclusion criteria 
• 
• 
Patients with an inhibitor towards Factor VIII or IX 
Severe HA or HB patients with > 1 IU/dL FVIIIIFIX activity level 
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(which could be the treatment factor concentrate) 
• Patients with liver disease (liver function tests included alanine 
transaminase (AL T), aspartate transaminase (AST) and y-glutamyl 
transpeptidase (yGT), which were performed at the time of enrolment by 
taking an extra blood sample and analysed in the Biochemistry laboratory 
ofRFH) 
• Patients with high lipid level (elevation of lipids and/or cholesterol levels 
may increase the total amount of thrombin generation (Aoki et aI., 1997; 
Takayuki et 01., 2001; Vincenzo et al., 1997); lipid profile was analysed at 
the same time with liver function test) 
• Inability or unwillingness to comply with protocol (including patients that 
have difficulty understanding written or verbal English). 
There were 97 patients who were enrolled into the study and who were previously 
diagnosed with severe HA (n = 49), moderate HA (n = 11), mild HA (n = 16), severe 
HB (n = 14), moderate HB (n = 3), and mild HB (n = 4). The diagnosis in these 
patients was based on the clinical presentation, the baseline factor level (Appendix I), 
which was performed by one-stage factor assay, and relevant factor mutational 
analysis. The individuals were diagnosed at the Katharine Dormandy Haemophilia 
Centre and Thrombosis unit (KDHCTU) of the Royal Free Hospital, London, UK. In 
order to obtain the baseline factor level of individuals, patients were asked to omit 
treatment for 72 h for Haemophilia A, and 5 days for Haemophilia B. 
A number of individuals were excluded due to slow clearance of treatment material 
(13 severe HA, seven severe HB) or abnormal liver function tests. Also as result of a 
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technical problem with the ROTEMS: analyser, six severe HA and one severe H B 
patients were not included in the ROTEM:!l: study. A brief description of study 
subjects has been given in each chapter. 
2.2. Control Subjects 
A group of healthy subjects from the Royal Free Hospital staff were used as controls 
and bled after informed consent to allow calculation of reference ranges for TGT, 
ROTEMoc, and clot waveform analysis. All samples were collected with informed 
consent. 
2.3. Sample Collection 
Collection tubes, Monovettel', were purchased from Sarstedt, Leicester, UK. Whole 
blood samples were collected by venepuncture into Monovette® tubes containing 
0.106 M (3.8%) trisodium citrate in a ratio of 1 part anticoagulant to 9 parts blood for 
analysis. Monovette1t1 tubes were spiked with 20 /lglmL com trypsin inhibitor (CTI) 
(see section 2.4.8). Whole blood was also collected into Monovette:!lJ tubes containing 
ethylene diamine tetra acetic acid (EDTA) for full blood count (FBC), and 
Monovette® gel tubes to investigate liver function and lipid profile of each patient. 
FBC was performed by the Haematology Laboratory, and liver function tests and lipid 
profiles were analysed by the Clinical Biochemistry Laboratory, at the Royal Free 
Hospital. 
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2.3.1. Sample processing and storage 
Citrated whole blood (CWB) for investigation by ROTEM® was rested for 30 min (as 
required by manufacturer for testing on citrated whole blood) before performing the 
test, according to manufacturer's instructions. CWB samples were centrifuged at ISO 
g for IS min to obtain platelet rich plasma (PRP). A platelet count was performed in 
the Haematology Laboratory, using an ADVIA ®120 (Bayer, Newbury, UK), and 
adjusted by autologous platelet poor plasma (PPP) to obtain a platelet count of 150 x 
109/L. The remainder of citrate samples collected by Monovette® were double spun at 
2000 g for 15 min to obtain PPP, which were then ali quoted into microtubes and 
stored at -70°C for remainder of the coagulation investigations. 
For TGT, PPP was centrifuged at 6000 g for a further 2 min to obtain ultra spun PPP, 
free from platelets and micro-particles. The preliminary experimental result of TGT 
showed that double spinning of samples would not remove platelets or platelet debris. 
This was proven when the double spun plasma samples were indirectly tested for the 
presence of phospholipids by kaolin clotting time (KCT) test. The KCT is essentially 
an APTT test without added phospholipids. The double spun plasma samples had 
significantly shorter KCT than the triple spun plasma samples, therefore, the third 
spin, which was at 6000 g for 2 min, was added to the study protocol. 
2.4. Coagulation Investigations 
Prothrombin time (PT-Fibrinogen HS Plus, Haemostasis Instrumentation Laboratory 
(ILTM) Ltd, Warrington, UK), APTT (SynthASil, IL™), thrombin time (TT) (Thrombin 
™ d Time, IL TM), and Clauss fibrinogen (Fibrinogen-C, IL ), assays were performe on an 
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ACLTM TOP (lLTM) analyser as routine for each patient on the day of testing. The 
remainder of the investigations were done after being batched. 
2.4.1. Intrinsic and extrinsic factor assays 
One stage APTT and PT based factor assays were analysed, using an ACC" 300R 
(ILT"). All factor assays were perfonned in an identical fashion using appropriate 
factor deficient plasma. One stage factor assays were perfonned for the intrinsic 
factors VIII, IX, XI, XII; and extrinsic factors and common pathway II, V, VII, and X 
on the ACLTM 300R. Patient's PPP was diluted 1: 10, 1 :20, and I :40 on Owren's 
Buffered Saline (OBS) and compared to a three-point standard curve. 
For intrinsic factor assays, 100 JlL of APTT reagent (APTT Iyophilised reagent ILT"), 
1 00 JlL of factor deficient plasma (Technoclone, Dorking, UK) and 100 JlL of diluted 
test or standard (CRYOcheckT" pooled nonnal plasma (Alpha Laboratories Ltd, 
Eastleigh, UK) were wanned at 37°C for 5 min, then 100 ilL 0.25 M CaCh (lLT") was 
added and the time taken for the mixture to clot was recorded. For the extrinsic factor 
assays, 100 JlL of diluted test or standard was warmed at 37°C for 2 min then 200 JlL 
of PT reagent was added. The time taken for the mixture to clot was measured in 
seconds by ACC" 300R analyser. All sample results (three point dilution) were 
plotted on graph paper (log-linear graph paper for factors VIII, IX, and XI, and log-
log graph paper for factors II, V, VII, X, and XII) against a 3 point standard curve. 
The CRYOcheckT" is a normal reference plasma collected from a minimum of 20 
carefully screened donors and calibrated against international reference standards, and 
values for haemostatic parameters are assigned. At the KDHCTU laboratory, 
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C ™ RYOcheck values for haemostatic parameters is further evaluated, and calibrated 
against British or international standards for the use on ACL™ analysers. 
2.4.2. Chromogenic FVIII Assay 
FVIII was measured using Coatest Cf4 kit Chromogenix (Quadratech, Epsom, Surrey). 
The kit provided Iyophilised FXlFIXa reagent, and chromogenic substrate (S-2765 
Benzoyl-Ile-Glu(y-OR)-Gly-Arg-pN), for reconstitution with distilled water. Liquid 
phospholipid (PL) reagent is also provided. The dilution buffer was made by diluting 
stock buffer I in 10 with distilled water. 
Test, quality control and standard sample dilutions were made in replicate with buffer 
to 1 in 50, I in 100, and 1 in 200. Samples were then loaded onto an ACL™ 300R 
analyser and kit reagents added. The ACL™ 300R was set up in the following manner: 
25 ilL of sample was incubated with 75 ilL of combined reagent for 300 s, 
subsequently 50 ilL of chromogenic substrate was added, and optical density (00) at 
405 nm was measured following a further 220 s incubation period. 
2.4.3. Physiological inhibitors of coagulation 
2.4.3.1. Antithrombin (AT) Activity Assay 
The assay was performed on the ACLTM 300R OeM) by an in-house chromogenic 
assay (Harper et al., 1991). 
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Method: 
Lyophilised bovine thrombin (Diagnostic Reagent Ltd, Thame, UK) reconstituted 
with one mL distilled water, then 40 ilL of reconstituted Bovine thrombin (1000 
IV/mL), and 60 ilL sodium heparin (1000 IV/mL) were added to to mL working 
buffer to make a working enzyme reagent. Chromogenic substrate, S2238 (H-D-CHT-
Abut-Arg-pNA), was reconstituted with 25 mL distilled water. The standard curve 
was prepared using four dilutions of I :50, I :75, I: 100, and I :200 of the reference 
plasma (CRYOcheck™) in working buffer. Quality controls and test plasma were 
diluted I: 100 and 1: 200 in working buffer. Using AT chromogenic programme on the 
ACe" 300R the test was performed. AT, in the presence of heparin and excess 
amount of thrombin formed an antithrombin-thrombin-heparin complex. The residual 
thrombin catalysed the release of para-nitroaniline (pNA) from the chromogenic 
substrate. The rate at which pNA is released is measured photometrically at 405 nm 
and the AT levels in the plasma were inversely proportional to the change in optical 
density. 
2.4.3.2. Protein C Activity Assay 
Protein C (Hepner et al.) was measured using HemosILn.t PC activity kit (ILT").The 
ILT" PC activity kit uses a protein fraction derived from the venom of the southern 
copperhead snake Agkistrodon contortrix contortrix, which activates Pc. The 
activated PC, in tum, hydrolyses a synthetic chromogenic substrate (S-2366 pyroGlu-
Pro-Arg-pNA). The release of pNA is proportional to the activity of Pc. 
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Method: 
The kit consisted of a PC activator (lyophilised fraction of aforementioned snake 
venom), a chromogenic substrate (lyophilised S-2399), and a diluent (concentrated 
solution containing 0.9% sodium chloride). 
The lyophilised PC activator and chromogenic substrate were each reconstituted with 
2.5 mL distilled water and kept at room temperature for 30 min according to the 
manufacturer's instruction. The diluent was diluted I in 10 with distilled water. Using 
the ACLT'" TOP PC activity test protocol, 56 ilL of quality control/test plasma was 
mixed with 56 ilL of PC activator and incubated for 4 min, before the addition of 56 
ilL of substrate reagent. The pNA released was monitored kinetically at OD of 405 
nm. 
2.4.3.3. Free Protein S Assay 
Free PS was measured using a commercial latex free protein kits (Free PS, ILT"'), on 
an ACLT'" TOP (lLT"') according to the manufacturer's instructions, by measuring an 
increase in turbidity produced by the agglutination of two latex reagents. Purified 
C4BP is adsorbed on the C4BP latex in the presence of Ca
2
+. Free PS, in the test 
plasma, will move from the solution to the latex surface, and the amount of PS 
covering the latex will be proportional to the free PS concentration in the sample. The 
free PS-C4BP latex triggers the agglutination reaction with the second latex reagent 
which is sensitised with a monoclonal antibody directed against human PS. The 
degree of agglutination will be directly proportional to the free PS concentration in the 
test sample. 
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Method: 
The kit consisted of two reagents and one buffer: reagent R I (latex polystyrene beads 
coated with purified human C4BP), reagent R2 (latex polystyrene beads coated with a 
monoclonal antibody against human PS), and C4BP buffer (Borax buffer containing 
bovine serum albumin). 
The content of R I reagent was dissolved with the whole content of C4BP buffer (4 
mL) and kept at room temperature for 30 min before being placed on the ACCM TOP 
analyser. Using the ACCM TOP PS activity test protocol, 12 ~L of quality control/test 
plasma was incubated with 150 ~L of reagent R I for 130 s. Changes of 00 at 405 nm 
were recorded for 300 s after adding 80 ~L of reagent R2. 
2.4.4. von Willebrand Factor Antigen (VWF:Ag) 
The Enzyme Linked Immunosorbent Assay (ELISA) principle was adopted for two 
assays. 
The following buffers were used for both ELISA methods: 
Bicarbonate Buffer (0.05M) 
1.59 g Na2C03, 2.93 g NaHC03 in 1.0 L distilled water, pH 9.6 
High Salt Wash Buffer with Tween (HSBT) (O.155M) 
1.95 g NaH2P04.2H20, 141.1 g NaCI, 13.4 g Na2HP04.12H20, 10.0 mL Tween 20 in 
5.0 L of distilled water, pH 7.4 
Tag and Sample Dilution Buffer 
15.0 g polyethylene glycol (PEG) 8000 in 500 mL HSBT 
Substrate buffer (0.1 M) 
7.3 g citric acid, 23.87 g Na2HP04.12H20 in 1.0 L of distilled water, pH 5.0 
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NUNC maxisorb microtitre plates (Life Technologies Ltd, Paisley, Scotland) were 
used for VWF:Ag ELISA and Covalik microtitre plates (Life Technologies Ltd, 
Paisley, Scotland) were used for VWF collagen binding assay (VWF:CB). The optical 
density readings were determined by a Titertek plate reader (ICN, Flow Biomedicals 
LTD, Bucks). 
Method: 
Polyclonal anti VWF:Ag (Dako Ltd, Bucks, UK) was diluted 1 in 1000 in bicarbonate 
buffer. 100 JlL of diluted coat antibody was added to each well of microtitre plate. 
The plate was sealed and left at 4°C overnight. A seven point standard curve (125.00 
to 6.25 IU/dL) was prepared using CRYOcheck™ pooled normal plasma, initially 
diluted 1:80 (125 IU/dL). Test plasma and quality control samples (CRYOcheck™ 
was used as a normal quality control, and control plasma P (Sysmex UK Ltd, Milton 
Keynes, UK), was used as an abnormal quality control) were diluted I: 100 and 1:200. 
The coated plate was washed 5 times with HSBT. Test, quality control or standard 
dilutions were added in 100 JlL volumes, in duplicate, to the plate and incubated for 
one hour at room temperature. At the end of incubation the plate was washed a further 
five times with HSBT, after which, 100 JlL of diluted (l :8000) (in sample dilution 
buffer) horseradish peroxidise conjugated anti-VWF antibody (Dako) was added to 
each well of the plate. The plate was again incubated for one hour on a plate shaker at 
room temperature (18-25°C). Just before the end of incubation the substrate solution 
was prepared by dissolving one 10.0 mg orthophenyline-diamine (OPD) tablet in 15.0 
mL substrate buffer. The plate was then washed for a final five times. Immediately 
before the next step, 7.0 JlL of 30% hydrogen peroxide was added to the substrate 
solution, 100 JlL of substrate solution was then added to each well at timed intervals 
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(one second). After 10 min the reaction was stopped by the addition of 100 ~L of 1.5 
M sulphuric acid to each well at the same time interval. The absorbance of each welI 
of the plate was read within 30 min at 492 nm. The plate reader software calibrated a 
VWF:Ag standard curve (optical density against IU/dL on a semi-log scale) and then 
calculated the mean of duplicate tests and the quality control results from the curve. 
2.4.5. Collagen Binding Assay (VWF:CB) 
Human placental type III collagen was diluted I in 200 in bicarbonate buffer. I 00 ~L 
of the dilution was added to each well of the microtitre plate. The plate was sealed and 
left at room temperature overnight. A seven point standard curve (125.00 to 6.25 
IU/dL) was prepared using CRYOcheck™ pooled normal plasma. Test plasma, normal 
quality control (CRYOcheck™) and abnormal quality control (control plasma P) 
samples were diluted 1 :200 and 1 :400. 
The coated plate was washed 5 times with HSBT. Test, quality control or standard 
dilutions were added in 100 ~L volumes in duplicate to the plate and incubated for I h 
at room temperature. At the end of incubation the plate was washed a further five 
times with HSBT, after which, 100 ~L of diluted (1 :4000) (in sample buffer) 
horseradish peroxidise conjugated anti-VWF antibody (Dako) was added to each well 
of the plate. The plate was again incubated for I h on a plate shaker at room 
temperature (18-25°C). Just before the end of incubation the substrate solution was 
prepared by dissolving one 10.0 mg orthophenyline-diamine (OPD) tablet in 15.0 mL 
substrate buffer. The plate was then washed for a final five times. Immediately before 
the next step, 7.0 ~L of 30% hydrogen peroxide was added to the substrate solution, 
1 00 ~L of substrate solution was then added to each well at timed intervals (one 
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second). After 10 min the reaction was stopped by the addition of 100 JlL 1.5 M 
sulphuric acid to each well at the same time interval. The absorbance of each well of 
the plate was read within 30 min at 492 nm. The plate reader software calibrated a 
VWF:CB standard curve (optical density against IU/dL on a semi-log scale) and then 
calculated the mean test and the quality control results from the curve. 
2.4.6. Factor VIII Antigen (FVIII:Ag) Assay 
The FVIII: Ag was measured by an ELISA method, usmg a commercial assay 
Asserachrom:B VIII:Ag kit (Diagnostica STAGO UK Ltd, Reading, UK). 
Kit reagents: 
Reagent 1: 16-well strip coated with mouse monoclonal anti-human FVIII F( ab h 
fragment to capture FVIII. 
Reagent 2: Mouse monoclonal anti-human FVIII antibody coupled with peroxidase to 
bind to the remaining free antigenic detenninants of the bound FVIII. 
Reagent 3: Tetramethylbenzidine < I % substrate solution. The bound enzyme 
peroxidase is revealed by its action on the tetramethylbenzidine substrate. 
Reagent 4: phosphate buffer as dilution buffer for calibrator, quality controls, and 
plasma samples. 
Reagent 5: 20-fold concentration washing solution. 
Reagent 6: freeze-dried human plasma containing a known amount of FVIII, to be 
used as a calibrator. 
Reagent 7: freeze-dried human plasma containing a known amount of FVIII, to be 
used as a quality control. 
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Method: 
The assay was calibrated with Reagent 6 diluted I: 10 with Reagent 4 (dilution buffer). 
Serial 1:2 dilutions were made from the starting solution by Reagent 4. Plasma 
samples and quality controls were diluted at two dilutions, of I: 10 and 1 :20, with 
Reagent 4. 
200 ~L of diluted calibrator (diluted in Reagent 4), quality controls, and test plasma 
were added in duplicate to the strip wells and incubated at room temperature for 2 h. 
All wells were washed with 1 :20 diluted Reagent 5 (diluted with distilled water). 
After completely emptying the plate, 200 ~L Reagent 3 for exactly 5 min, then 50 ~L 
1.0 M sulphuric acid were added to each well. After 15 min, the absorbance of each 
well was read at 450 nm. Log-log graph paper was used to draw the calibration curve 
(the calibrator values (%) on the X-axis and their corresponding absorbance values on 
the Y -axis). The absorbance values of the quality control and test plasma dilutions 
were interpolated and the value of FVIII:Ag level of each sample were derived from 
the calibration curve. Results from I: 10 dilutions were read directly from the curve; 
and those for I :20 dilutions were multiplied by 2. 
2.4.7. Factor V Leiden and Prothrombin gene mutation analysis 
For both assay methods the DNA was extracted by the QIAamp Blood Mini Kit 
(QIAGEN, Hilden, Germany) using citrated whole blood. Using a standard 
polymerase chain reaction (PCR) method the factor VLeiden mutation (GI69IA) was 
detected by PCR amplification of genomic DNA followed by Mnl I restriction 
enzyme digestion, as described previously (Bertina et al., 1994). 
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The prothrombin mutation (G202IOA) was detennined by PCR amplification of 
genomic DNA followed by Hind III restriction enzyme digestion, as described 
previously (Poort et at., 1996). 
2.4.8. Thrombin Generation Test 
Reagents: 
HEPES Working Buffer (HWB): 0.476 g of 1.0 M 4-(2-hydroxyethyl)-1 
piperazineethanesulfonic (HEPES) (Autogen BioclearTM, Caine, Wiltshire, UK), 
0.812 g 1.0 M NaCl, and 0.5 g Bovine Serum Albumin (BSA) (Sigma, Poole, UK) 
dissolved in 100 mL distilled water to make 20 mmollL HEPES, 140 mmollL NaCI, 
5.0 mIlL, pH 7.35. 
HEPES Substrate Buffer (HSB): 0.476 g of 1.0 M HEPES, and 6.0 g of BSA were 
dissolved in 100 mL distilled water to make 20 mmollL HEPES, 60 gil BSA, pH 
7.35. 
Com Trypsin Inhibitor: 
CTI (Cambridge Bioscience Ltd, Cambridge, UK) is a specific inhibitor of human 
FXIIa. In order to eliminate activation of the coagulation cascade through contact 
activation it is necessary to inactivate/inhibit FXIIa prior to initiation of coagulation 
with a low concentration of TF. Contact pathway activation readily occurs in vitro 
when blood is exposed to artificial surfaces (i.e. blood collection tubes). The 
activation of contact pathway may also occur at the time of venepuncture, sample 
processing and centrifugation. Even when all precautionary measures to be taken to 
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illuminate pre-analytical variables, several studies have shown the necessity of 
inhibition of contact pathway at low TF concentration (Dargaud ef al., 2006b; 
Luddington & 8aglin, 2004; van Veen et aI., 2009). 
This study was conducted before the use of cn in TGT was recommended as the 
standard of testing for patients with inherited bleeding disorders (8emtorp & 
Salvagno, 2008), and therefore samples were analysed with and without CTI to show 
the effect of cn in TGT and ROTEM(R; studies. CTI was added to the sodium citrate 
Monovette® tubes just before collecting blood samples. The final concentration of 
cn in the Monovette1!- was 20 IlgimL. 
Phospholipid Vesicles Preparation 
The PLs used were a mixture of 60% phosphatidyl choline (PL:PC), 20% 
phosphatidyl serine (PL:PS) and 20% phosphatidyl ethanolamine (PL:PE). The stocks 
reagents were purchased from A vanti Polar Lipids (Delfzyl, The Netherland). 
For preparation of 1 mL mixture of 1 mM PL:PS-PL:PE-PL:PC (20-20-60): 
Stocks: PL:PS (10.0 mg/mL; 2.5 mL; MW: 810.03; CHCh) = 12.34 mM 
PL:PE (25.0 mg/mL; 4.0 mL; MW: 744.04; CHCh) = 33.60 mM 
PL:PC (25.0 mglmL; 4.0 mL; MW: 786.15; CHCh) = 31.80 mM 
16.0 ilL PL:PS + 6.0 ilL PL:PE + 19.0 ilL PL:PC was pipetted into a glass tube. 
Nitrogen-gas (80C, Stratford, UK) was blown in the tube until all chlorofonn 
(CHCh) disappeared, after which, 1.0 mL buffer (140 mM NaCl, 20 mM HEPES, pH 
7.35) was added. The resulting solution was a turbid suspension and had to be 
extruded by a mini-extruder (Avanti Polar Lipids, Delfzyl, The Netherlands), through 
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a 100 nm and 300 nm filter until the solution was clear and to make unilamcllar 
phospholipid vesicles. The final concentration was 600 JlM. 
Trigger: 
Lyophilised recombinant human tissue factor (rTF), InnovinlR (Sysmex UK Ltd, 
Milton Keynes, UK) (not containing polybrene or Ca +2) reagent was used as a trigger 
for initiation of thrombin generation and was reconstituted with 10 mL distilled water. 
The concentration of Innovin~' was determined using the Actichrome(j{, TF activity 
assay (American Diagnostica Inc., Greenwich, CT, USA) for measuring TF activity. 
Manufacturer's instructions were followed and several dilutions of standard and 
Innovin® were made as test samples. The standard dilutions were made from stock 
solution of 500 pM (available in the kit) in serial dilutions to make 30 pM, 15 pM, 7.5 
pM, 3.75 pM, and 1.88 pM, and 100 JlL of assay buffer as a blank. Innovin(j{) sample 
was first diluted 1 in 10 as a stock, and then serially diluted 1 :20, 1 :40, and 1 :80 in 
assay buffer. Standard dilutions and Innovin® sample dilutions were mixed with 
FVlIa and FX provided in the kit. The reagents were incubated at 37°C, aIlowing for 
the fonnation of TF/FVIIa complex to act on FX for conversion to FXa. The amount 
of FXa generated was measured by its ability to cleave Spectrozyme® Xa, a highly 
specific chromogenic substrate for factor Xa, added to the reaction solution. The 
cleaved substrate releases a pNA chromophore into the reaction solution and the 
absorbance at 405 nm was compared to those values obtained from a standard curve 
generated using known amounts of active human tissue factor. Reading from standard 
curve, the concentration of Innovin ® was calculated as 6 JlM. 
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The trigger for PPP TGT was prepared as follows: 10 J.lL of diluted Innovin K (150 
pM) was added to 230 ilL HWB. To this, 10 J.lL of 600 J.lM PL was added. The 
concentration of rTF and PL in this trigger were 6 pM and 24 J.lM respectively. The 
trigger for PRP TGT was Innovincg diluted in HWB to give a concentration of 3 pM. 
Although these concentrations were recommended by Hemker et al. (2002) for 
investigation of a hypocoagulable state, a titration of TF was performed to optimise 
the concentration ofTF. 
Optimisation of trigger: 
The optimal TF and PL concentration for clinical studies is still being evaluated; 
higher tissue factor concentrations produced less variability in the AUC and less 
sensitivity to contact activation, whereas lower concentrations were more sensitive to 
.,changes in thrombin generation (Dargaud et al., 2010). At present, tissue factor 
preparations are highly variable in source material and specific activity. International 
standards are needed for tissue factor activators. Calibration with thrombin-u2-
macroglobulin has the advantage that it can be used as an internal standard for 
samples with absorbance interference problems. As an alternative, the fluorescence 
signals in each experiment were normalised with a normal control throughout the 
study, and the results were expressed as percentage of the same normal control. 
It was found that thrombin generation in the presence of corn trypsin inhibitor (CTI) 
and lower dose tissue factor activator seemed to be more sensitive to differences 
between plasma samples. Tissue factor and phospholipid concentrations were adjusted 
to suit specific clinical questions. In order to include the effect of FXI, it has been 
recommended to use a low TF concentration (Hemker, et al. 2002). A series of TF 
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(lnnovin) dilution were made for optirni ation of low do e TF thrombin generation. 
For platelet poor pIa rna (PPP) thrombin generation a erie of 0.5 pM 1.0 pM, 2.0 
pM, 3.0 pM, 4.0 pM and 5 pM (final concentration) wa made and in-house TGT 
perfonned on a nonnal indi idual PPP ample (with eTr) (Figure 2.1) and a severe 
haernophilia A PPP ample (with en) (Figure 2.2). For platelet rich pIa rna (PRP) 
TGT, fir t platelet count wa adju ted by the individual's own PPP to obtain a platelet 
count of 150 x l09/L, then a erie of TF dilution were made to obtain a final 
concentration of 0.032 pM, 0.063 pM, 0.125 pM, 0.500 pM, and 1.000 pM. In-house 
TGT wa performed with above trigger on a ample of a nonnal individual (Figure 
2.3) and a evere haemophilia A (Figure 2.4). 
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Figure 2.1 Titration of TF in a normal control (PPP) 
TGT was performed on a normal control PPP sample (with CTl) to optimi e the amount ofTF as a I?w 
dose trigger for in e tigation of thrombin generation potential for a . hypocoagulable tate I.e. 
haemophilia. A erie of TF dilution were made to obtain a final concentratIOn of 0.5 pM, 1.0 pM, 2.0 
pM, 3.0 pM, 4.0 pM and 5 pM, and then u ed a a trigger for titration ofTF. 
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Figure 2.2 Titration of TF in a severe HA individual (PPP) 
TGT was performed on a severe haemophilia A PPP sample (with eTl) to optimi e the amount ofTF 
as a low do e trigger for inve tigation of thrombin generation potential for a hypocoagulable state i.e. 
haemophiJia . A erie of TF dilution were made to obtain a final concentration of 0.5 pM, 1.0 pM, 2.0 
pM, 3.0 pM, 4 .0 pM and 5 pM, and then u ed a a trigger for titration ofTF. 
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Figure 2.3 Titration of TF in a normal control (PRP) 
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TGT wa performed on a normal control PRP sample (with TJ) to optimi e the amount ofTF as a low 
do e trigger for inve ti gation of thrombin generation potential for a hypocoagulable tate i.e. 
haemophilia . A erie ofTF dilution were made to obtain a final concentration of 0.032 pM, 0.063 pM , 
0 . 125 pM, 0.250 pM, 0.500 pM and 1.000 pM, and then used as a trigger for titration ofTF. 
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Figure 2.4 Titration of TF in a evere baemophilia individual (PRP) 
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TGT wa performed on a evere haemophilia A PRP ample (with CTI) to optimise the amount of TF 
as a low do e trigger for inve tigation of thrombin generation potential for a hypocoagulable state i.e. 
haemophilia . A serie ofTF dilution were made to obtain a fina l concentration of 0.032 pM, 0.063 pM, 
0.125 pM , 0.250 pM, 0.500 pM and 1.000 pM, and then u ed as a trigger for titration ofTF. 
TGT Starting Reagent (FluCa): 
A ] 00 mM fluorogenic ub trate Z-Gly-Gly-Arg-AMC (Bachem, St Helen , UK) was 
prepared by adding 0.25 g of fluorogenic ubstrate to 5.0 mL dimethyl ulfoxide 
(DMSO), aliquoted and tored at - DoC. Twenty five ilL of 100 mM DM 0 
flu orogenic sub trate, and 100 ilL of 1.0 M CaCh were added to 875 ilL HSB to make 
the FluCa reagent ju t before tarting the as ay. The concentrations of fluorogenic 
substrate and CaCh were 2.5 mM and 0.1 M re pectively. 
Method: 
Eighty ilL of te t or quality control pIa rna (PPPIPRP) in duplicate, were added to an 
Immulon 2HB, round-bottom 96 well microplate (Dynex technologie , Southampton, 
UK). Twenty ilL of trigger (PPPIPRP) wa added to each well of the plate. The final 
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concentration in the reaction mixture was 4.0 f.lM PL and 1.0 pM rTF in PPP, and 0.5 
pM rTF in PRP. The plate was then placed on a Spectramax™ Gemini XS (Molecular 
Devices Ltd, Wokingham, UK) spectrofluorometer, and shaken for a few seconds, 
then incubated for 2 min at 37°C. Twenty JlL of FluCa was added immediately to 
each wells and shaken promptly, before starting the spectrofluorometer. The plate was 
read at 30 s intervals for one hour, the fluorochrome of the fluorogenic substrate 
excited at 390 nm wavelength, and then emitted light at 460 nm wavelength. The 
emitted light was detected and plotted using SOFTmax PRO software (Molecular 
Devices Ltd, Wokingham, UK) provided by manufacturer. 
Data Analysis: 
The data were exported into an EXCEL 1\ .. file and the amount of thrombin generated 
was calculated according to the method by Hemker (Hemker, 2005), and modified 
(see below) by the National Institute for Biological Standards and Control (NIBSC). 
The spreadsheet was kindly donated by Dr. Sanj Raut (NIBSC). 
This software was used to detennine the amount of free thrombin in a continuous 
TGT with a fluorogenic substrate, by subtracting thrombin-u2-M complex. u2-M is a 
large plasma protein, which inhibits the coagulation system by binding to thrombin, 
and the fibrinolysis system by inactivating plasmin. The thrombin in the u2-M-lla 
complex has no known biological activity but in vitro retains its ability to cleave 
fluorogenic substrate in test experiments. Therefore it is necessary to subtract from the 
total thrombin generated in the experiment. The EXCEL ® spreadsheet with enabled 
MACRO fonnulas enabled us to calculate free thrombin from relative fluorogenic unit 
(RFU) produced by cleavage of substrate (Table 2.1). From free-thrombin data the 
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peak-height (PH) and time to peak-height (TP) were calculated (Table 2.2). In 
addition the area under the thrombin generation curve (AVe) was calculated by the 
trapezium rule. The amount of thrombin generated was calculated according to the 
method by Hemker (Hemker & Beguin, 1999) (Table 2.1, Figure 2.1). This method 
was used by Hemker et af. to determine the amount of free thrombin in a continuous 
TGT with a fluorogenic substrate (Hemker et ai, 2000). 
Table 2.1 Calculation offree thrombin 
A B C D E F 
Time Data (total Product from 
Product from arM k I (min) thrombin) free thrombin 
2 0.5 =C3-E2 =E2+($F$1 *D3) =sum(FI12:FI22) 
3 I =C4-E3 =E3+($F$1 *D4) =(D4-03)/0.5 
4 1.5 =C5-E4 =E4+($F$1 *D5) =(D5-D4 )/0.5 
.® Free thrombm was calculated on an excel spreadsheet by transferrmg the raw data (fluorogemc 
relative unit (RFU», which was the total thrombin generated, into the column C. The total thrombin 
RFU was measured every 30 s (0.5 min) in column B. In column E the amount of thrombin-arM 
complex was calculated by using of a k which was derived from the last 10 measurement of the 
reaction. 
A macro was established to calculate peak height and time to peak (Table 2.2) 
according to the method by Hemker et al. (2000). 
Table 2.2 Calculation of peak height and time to peak thrombin generation 
A B C D 
I I 2 3 
2 TP =INDEX($A$6:$A$125.B3, I) =INDEX($A$6:$A$125,C3, I) =INDEX($A$6:$A$125,D3, I) 
3 =MATCH(B4.B6:B 125.0) =MA TCH( C4,C6:C 125,0) =MATCH(D4,D6:DI25,0) 
4 PH =MAX(B6:BI25) =MAX(C6:CI25) =MAX(D6:DI25) 
5 I 2 3 
6 I Data Data Data 
7 1.5 Data Data Data 
EquatIOns for the calculatIOn of peak heIght and tIme to peak from free thrombm values. Usmg a macro enabled 
formula on EXCEL1< spreadsheet peak height (PH) and time to peak (TP) thrombin generation were calculated. 
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RFU.min 
The fluorogenic ub trate wa titrated to inve tigate if the rate and total amount of 
thrombin generation i optimal at the concentration 2.5 mM which was recommended 
by Hemker el al. (2002) (Figure 2.5) 
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Figure 2.S Titration of fluorogenic ub trate in a normal control 
Fluorogenic ubstrate wa titrated in a normal control (PPP with eTJ). An increase in peak height 
thrombin generation wa noticed up to concentration of 2.5 mM (final concentration). The increase 
above this level did not change the rate or the total amount of thrombin generation. 
In thi method a normal control wa u ed throughout of the study, and in each 
experiment, to enable u to tran form the raw data to the percentage of the normal. 
However, the concentration of free thrombin could not be calculated in this method. 
In order to calculate the concentration of free thrombin, an appropriate calibration 
should have been u ed to correct for inner-filter effects, i.e. the quenching of the 
fluorescence ignal by ub trate molecul that have already been converted, and the 
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effect of substrate consumption. This was realised by Hemker et al. and they 
introduced the a2-M-lla complex as a calibrator in the CAT system (Hemker et al.. 
2003). This study was commenced before the CAT was commercialised, and once the 
KDHCTU purchased the analyser, thrombin generation was performed on frozen 
aliquots of PPP samples which were saved at the time of processing, and the results 
were compared with the in-house TGT method as it is reported in chapter 4. 
2.4.9. Calibrated Automated Thrombogram® (CAT) 
The calibrated automated thrombography:.ll' (CAT) (Hemker et aI., 2003) instrument 
(Diagnostica Stago Ltd, Reading, UK), was used to analyse the quality controls and 
test samples along with the in-house TGT. The CAT package included: 
• Thrombin calibrator: Thrombin calibrator was reconstituted in 1.0 mL distilled 
water. 
• PPP-Reagent Low: Used as a trigger and was added to PPP to initiate 
thrombin generation. PPP-Reagent Low contains a mixture of 4.0 11M PL and 
1.0 pM rTF (the concentration is the final concentration after adding plasma 
and FluCa). 
• FluCa Kit: Fluo-buffer which contains HEPES buffer and CaCh, and Fluo-
substrate contains the fluorogenic substrate solubilised in dimethyl sulfoxide 
(DMSO). 
Method 
Using Immulon 2HB, round-bottom 96-well plates (Dynex technologies), each 
experiment needed two sets of readings, one from a well in which thrombin 
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generation was taking place (TG well) and a second one from a well to which thc 
calibrator was added (CAL well). The experiments were carried out in duplicate, i.c. a 
set of two TG wells were compared to a set of two CAL wells. To each well, 80 ilL of 
plasma was added. The TG wells receive 20 ilL of the trigger, and the CAL wells 20 
ilL of the u2-M-T solution. At the start of the experiment, the instrument dispenses 20 
ilL of FluCa to all the wells to be measured, registers this as zero time, shakes them 
for 10 s and starts reading with a 390/460 filter set (excitation/emission). During the 
measurement, the thromhinoscopeF software uses a default calibrator to calculate 
tentative (before excluding the arM-T) thrombin concentrations and displays the 
course of thrombin concentration in time for each group. After the measurement, the 
program calculates all parameters of the CAT including: endogenous thrombin 
potential (ETP), peak height, lag time, time to peak and expresses the results in 
nanomolar thrombin over time. 
Standardisation of results: 
In order to compare the results produced by two methods, a normal control was used 
throughout study and in each experiment; the results were calculated as percentage of 
the nonnal control in each run. 
2.4.10. Rotational Thromboelastometry (ROTEM@) 
Using the non-activated thromboelastometry (NA TEM) protocol as a guide ROTEMCR 
(Pentapharm Gmbh, Munich, Gennany), ROTEMi&1 was performed on citrated whole 
blood (CWB) samples with or without cn and rTF. rTF stock was diluted I in 1000 
(20 mM Hepes, 140 mM NaCl, pH 7.35 dilution buffer) to make a solution of 6.0 pM 
rTF. Where the test was performed with rTF, 20 III of diluted rTF was added to the 
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ROTEM iE cup, immediately followed by 300 ).1L test or quality control samples 
(with/without CTI) followed by 20 ).1L of 200 mM CaCh, mixed and immediately 
~ 
returned to the ROTEM instrument, to perform the test. The tests were haIted after 
two hours and the following parameters CT, CFT, aO, and MCF were extracted from 
the analyser. The curves were subsequently analysed using the software program 
provided with the ROTEMl< analyser and raw data was imported into an EXCELJ< 
worksheet for analysis of MaxVel, tMaxVel, and AVC parameters. 
2.4.11. Clot waveform analysis 
The APTT test was performed on the MDA~) coagulometer (Organon Teknika, 
Cambridge, UK) using MDA)l reagents Platelin LS and Platelin LS CaCb (Organon 
Teknika), in the Haemostasis laboratory, Addenbrooke's Hospital, Cambridge, UK 
with kind permission of Dr Roger Luddington. A frozen aliquot (stored at -80°C 
immediately after processing) of patients and normal control group were taken on dry 
ice to Addenbrooke's Hospital for testing. 
The MDA;)l measured continuous changes in light transmittance that occur as the 
test/quality control plasma sample clotted. The waveform was mathematically 
processed by a software algorithm, provided with the MDA ®, to derive several 
parameters such as coagulation velocity (Min 1) by measuring the percentage 
difference in light transmittance divided by time difference in seconds (%T/s), and 
acceleration (Min2) was calculated based on difference in percentage of change in 
light transmittance over time in squared seconds (% T Is2) (Shima et al., 2002). 
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Chapter 3 ROTEM® analysis 
3.1. Introduction 
The majority of coagulation tests only detect the initiation phase of clotting in vitro in 
plasma following addition of excessive amounts of activating reagent and 
unphysiological phospholipids to substitute the missing cell surfaces and platelets. 
However, ninety five percent of the thrombin generation during the coagulation 
process, in vivo. takes place after the initiation phase of the clot formation (Abrahams 
et aI., 2002; Baglin, 2005; Mann, 2003). Also several studies have demonstrated the 
importance of the functions of platelets (Yee, 2006) and leukocytes during 
coagulation (Bouchard & Tracy, 200 I; McEver, 200 I). Thus whole blood coagulation 
analysis, to assess global haemostasis, theoretically appears more informative 
compared to plasma based assays such as the most common laboratory screening 
tests- PT and APTT, although the contribution of vessel endothelium is necessarily 
excluded. 
Rotational thromboelastometry (ROTEM~') has been used for many years to assess 
the overall haemostatic function in whole blood, by evaluating the changes in the 
viscoelastic properties of blood during coagulation, and captures the information on 
the interaction of platelets and blood cells with the proteins of the coagulation process 
from the time of the initial platelet-fibrin interaction, through platelet aggregation, 
fibrin cross linkage, to eventual clot lysis. With the advent of computer-assisted 
equipment, and a modification, originally described by Sorensen et al. (2003), interest 
i)I,) 
has res urged in this technique. Sorensen et al. modified the ROTEM analysis by 
initiating whole blood clot formation with a small amount of TF in order to mimic the 
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in vivo coagulation process in the ROTEM illl cup. They mathematically extracted thc 
first derivative ofROTEM~ tracing by CalcuRoTM software and introduced three new 
parameters, maximum velocity (MaxVel), time to maximum velocity (tMaxVel), and 
area under the velocity curve (AUC) which may add more information in assessing 
the haemostasis status of individuals. 
However, to exclusively investigate TF-dependent coagulation and clot formation, 
and mimic the in vivo haemostasis scenario, the contact pathway must be eliminated 
in order to diminish possible artificial activation which could be triggered by 
venepuncture, sample handling or other pre-analytical variables. Corn trypsin 
inhibitor (CTI) has been used to quench the contact pathway by inhibiting FXIIa 
(Rand et aI., 1996); (Dargaud et al., 2006b) in thrombin generation based on 
Hemker's (2005) method. The use of CTI in a thrombin generation assay has been 
studied by different groups, and it has been shown, when low dose of TF is used to 
trigger coagulation, CTI reduces the variability of thrombin generation within- and 
between-individuals (Dargaud et aI., 2006b; Luddington & Baglin, 2004). In another 
study utilising ROTEMJ< to monitor the effect of FVIII replacement therapy, (Lewis 
et aI., 2007), CTI was used to quench contact activation, however, but to this date 
there has been no systematic study looking into the effects of CTI on low dose tissue 
factor triggered whole blood coagulation as assessed by ROTEM@. 
3.2. Aims 
The aim of this study was to evaluate the usefulness of ROTEM1!) in diagnosing 
haemophilia, when perfonned by three different techniques. The techniques include 
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1. Activation of blood coagulation through the contact pathway 
11. Activation of blood coagulation through the extrinsic pathway with the usc of 
TF 
Ill. Activation of blood coagulation through the extrinsic pathway with the usc of 
TF, where contact activation has been inhibited by CTI. 
3.3. Study subjects 
Ninety seven patients were consented for the study, and ROTEMi!<' data for further 
analysis was available for 70 patients. This included 30 severe HA, 11 moderate HA, 
16 mild HA, seven severe HB, three moderate HB, and three mild HB. The age range 
was between 18 and 90 years (mean 43, median 41 years). The control group 
comprised 22 healthy male individuals aged between 22 and 62 (mean 40, median 39 
years). All severe haemophilia samples included in the statistical analysis had FVIIl 
or FIX activity levels of < 1.0 IU/dL, as measured by the one stage clotting assay. 
3.4. ROTEM@ analysis 
Citrated whole blood (CWB) was analysed by ROTEM®, as was described in section 
2.4.10, to assess the global haemostasis profile in three test categories: 
1. CWB samples in which coagulation was started by addition of CaCh 
(activated by the surface of the measurement cup} 
lI. CWB samples in which TF (0.35 pM final concentration) was added before 
the start of the final reaction by CaCh, denoted CWB+TF. 
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Ill. CWB samples in which CTI was added to the sample tube prior to blood 
collection, then initiated with TF (0.35 pM final concentration) just before the 
final reaction started by CaCho Denoted CWB+CTI+TF. 
3.4.1. Conventional ROTEM@ parameters 
The following conventional parameters were analysed in this study 
• Clotting time (CT) 
• Clot formation time (CFT) 
• Alpha angle (aO). 
3.4.2. Derived ROTEM@ parameters 
The velocity profile of thromboelastometry was processed using CalcuRo ™ software, 
for calculation of dynamic coagulation parameters (Figure I. 9c). 
• Maximum velocity (MaxVel): describes the maximum rate of clot formation 
and is calculated from the 151 derivative of the ROTEMI!\) tracing curve. This is 
dependent on the activity of intrinsic clotting factors including FVIIIa, FIXa, 
FXIa, FXlIa, prothrombinase complex, and fibrinogen level. Where CTI was 
used and the coagulation was initiated by small amount of TF, the MaxVel 
would be depended upon the activities of FVIIa, FVIIIa, FIXa, FXla, 
prothrombinase complex, and fibrinogen level. 
• Time to maximum velocity (tMaxVel): measures the time from the start of the 
reaction until the maximum velocity. This is related to clotting factors, 
fibrinogen and the platelet count. 
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• Area under the curve (AUC): this is the area under the velocity curve, i.c. the 
area under the first derivative curve, and it quantifies the maximum clot 
firmness. 
3.5. Data and statistical analysis 
Conventional and derived parameters were analysed for controls and all patient 
groups (severe, moderate, and mild HA; severe, moderate, and mild HB) in three test 
categories (CWB, CWB+TF, and CWB+CTI+TF). 
Statistical analysis was performed using GraphPad Prism version 5.00 for Windows, 
(GraphPad Software, San Diego California USA). Mann-Whitney U test was 
performed to compare the parameters between the di fferent patient groups and the 
controls. Wilcoxon rank test was performed to compare paired parameters across the 
test categories, and Kruskal-Wallis nonparametric ANOV A test was performed to 
analyse the variance between the three test categories. The correlation coefficient was 
determined using the Spearman rank method. Receiver operating characteristic curve 
(ROC) was performed to evaluate the sensitivity and specificity of the ROTEMQ<) 
analysis. In all statistical analysis, a p value of < 0.05 was considered significant 
(Zweig & Campbell, 1993) 
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3.6. Results 
3.6.1. ROTEM® conventional parameters 
The results showed a nonparametric distribution for the majority of ROTEM'J\ 
conventional parameters (CT, CFT, and aD), therefore median and the range (based on 
5 th 95th . 
- percentiles) was calculated for each parameter (Table 3.1). Intra assay 
variation (based on four simultaneous measurements of two nonnal male subjects) 
was CT = 6.8%, CFT = 9.0%, aO = 4.9%, AUC = 9.3%, MaxVel = 5.9% and tMaxVel 
= 8.3%. Inter-assay variation (based on four simultaneous measurements of two 
nonnal male subjects) was CT = 9.8%, CFT = 13.8%, aO = 15.4%, AUe = 9.8%, 
MaxVel = 11.7% and tMaxVel = 11.1 %. 
Table 3.1 ROTEM@ conventional parameters 
ROTEMl! 
Normal Severe Moderate Mild Severe Moderate Mild 
Test HA HA HA HB HB HB 
Parameters Category n = 1., n =30 n = /I n = 16 n=7 n = 3* n = 3' 
MedLan Mahan Median Moolan Mahan Ml'llmn Medwll ~5"'· Y'i'~ J~Tenlllt .. 1 (~" - Q5'" oerceTlllle) (5"'- liS'· oen:enille) (5"'- Y5~" petcl."Illllt!'l 15'1.. Q5'"VC'::(,l'ntlie) (Ii"_ IJ5'" perct"nillc) ('i'" 1/"" 1X"l,'l'lIl1it'i 
eWB 597 1783 1262 1019 2020.5 1202 890 ~354-93-a (1132-5524) 1772-1580) (641-1328) 11156-320~ {l052-1~~ J!5!3"7-!Q9~ __ CT CWB+TF 311 754 486 483 771.5 567 575 
s (186-437) (372-1779) I (348-757) (288-1398) (489-1333) J374-762}_ . _(345 ___ ~Ofil .. 
CWB+CT 412.5 I 1018 768.5 727 859 677 583 
+TF (201-6122 I (464-2832) (374-1652) (409-1554) (497-3678) (311-1043) (431-764) 
CWB 242.5 536.5 378.5 355 819 477 400 (150-4731 . {288-1434) (284-522) (177-445) (302-1255) (270-660) (278-521 ) 
eFT CW8+ TF 122 291 211 211 391 258 278 
s (95-226) (180-587) (173-326) (102-323) (165-470) 1194-3741 (200-365) 
CW8+CTI 177.5 544 413 366 594 339 263 
+TF (112-280) (256-1773) (211-524) (183-738) (261-922) (244-568) (244-286) 
49.5 28.5 36.5 37 20 32.7 36 CWB (30.4-61.92. J14.4-44.6) (28-44) (26-57) (10-44) (23-46) (28-44) 
0° 64 45 53 
53 35 48.3 45.5 CWB+TF (51.0-71.01 . (26.5-57) (40-58) (42-69) (31-59) (36-56) (37-54) 
CWB+CTI 57.5 27.5 35 39 25 44.5 50.7 
+TF (47.0-67.7) (10.9-50.6) (28-52) (26-58) (17-47) ~26-5~ (44-56) 
.IR! The median and the range (5 th_ 95 th percentIles) ROTEM conventIOnal parameters were calculated III control group 
and six patient groups in three test categories. CT = clotting time, CFT = clot formation time, HA ~ haemophilia A, 
HB = haemophilia B, CWB = citrated whole blood, TF = tissue factor, cn = com trypsin inhibitor, a = alpha angle. 
·where the number of samples was not statistically significant. minimum and maximum values were reported 
81 
3.6.1.1. Clotting time 
CT was analysed for controls, patient groups, and the test categories. The reference 
ranges were established using the control group (Table 3.1). A significant difference 
(p = 0.007) was found between the median of control and patient groups in all test 
categories (Figures 3.1, 3.2, and 3.3). 
No significant difference was found in the CT between moderate and mild HA in any 
of the test categories. A significant difference was noted when the severe and 
moderate HA groups were compared only in the CWB test category (p = 0.0019) 
showing that CT in CWB test category may differentiate between a severe and a 
moderate haemophilic patient. In HB groups, a significant difference was found 
between mild HB and the control group (p = 0.007), and between severe and moderate 
HB (p = 0.033), but no significant difference was found between mild and moderate 
HB (p = 0.998). 
The coefficient of variation (CV) was also calculated for all the groups and three test 
categories, which revealed a wide variation. The CV was highest for the 
CWB+CTI+ TF test category, (severe HA (61 %), moderate HA (51 %), and mi Id HA 
(62%» when compared to the CWB+TF (47, 30, and 50% respectively), and the 
CWB (53, 24, and 16% respectively). These results show that the use of CTI might 
potentially identify the heterogeneity amongst the patients in the same group. 
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Figure 3.1 ROTEM CT parameter in WB 
evere, moderate, mild HA and HB compared to control group in W8 category. "rror bar h w the 
median and inter-quartile range. (the p value are for the indicated paired population) 
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Figure 3.2 ROTEM T parameter in CWB+TF 
evere, moderate, mi ld HA and HB compared to control group in W8+TF category. Error bar h w 
the median and inter-quartile range. (the p value are for the indicated paired p pulation ) 
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Figure 3.3 ROTEM ' T parameter in WB+ TI+Tf 
evere, moderate, mild HA and HB compared to control group in WB+CTJ+ TF category. Error bar 
show the median and inter-quarti le range. (the p values are for the indicated pai red population) 
CT in the evere HA group wa compared between all te t categorie by u ing the 
Wilcoxon rank te t; and howed ignificant difference between the three te t 
categorie (CWB, CWB+TF and CWB+CTI+TF) (p < 0.0001). 
3.6.1.2. Clot formation time 
The median and 5th_95th P rcentile range for CFT were calculated (Table 3.1) and 
compared to the control group (Figure 3.4, 3.5, and 3.6). A significant difference in 
prolongation of the FT wa hown by the Mann Whitney U test between the control 
group and ix patient group in the three test categories (the highe t p = 0.031 
between mild HA and th control group in CWB te t category). There wa a 
significant difference between severe HA and moderate HA in CWB+ TI+ TF (p = 
0.021) and CWB (p = 0.022) te t categorie but not in CWB+TF (p = 0.130) category. 
4 
The difference between moderate and mild HA, however, wa not ignificant in any 
te t category. Thi may indicate the te t is not en itive enough to di tinguish between 
the two group , or the current cia ification of everitie ba ed on the coagulation 
factor level , may not reflect the overall clot formation potential of an individual. 
The CV ofCFT was highe tin CWB+CTl+TF te tin evere HA (63%), moderate HA 
(29%), and mild HA (3 %) when compared to CWB+TF (36, 27, and 28% 
respectively) and CWB (50, 21, and 27% respectively). In HB group a wide 
variation wa noticed among e ere HB, which wa similar to the evere HA group. 
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Figure 3.4 ROT EM eFT parameter in WB 
Severe, moderate, mild HA and HB compared to the control group in CWB category. Error bars show 
the median and inter-quartile range. (the p value are for the indicated paired populations) 
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Figure 3.5 ROTEM FT parameter in C\ B+TF 
evere, moderate, mild HA and HB compared to the control group in CWB+TF category. Error bar 
show the median and inter-quartile range. (the p value are for the indicated paired populations) 
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Figure 3.6. ROTEM FT parameter in CWB+CTJ+TF 
Severe, moderate, mild HA and HB compared to the control group in CWB+CTJ+TF category. Error 
bar show the median and inter-quartile range. (the p va lue are for the indicated paired population) 
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3.6.1.3. Alpha angle 
Th d · d 5th 95 th . . e me Ian an - percentIle range for aD were calculated (Table 3.1) and 
compared to the control group (Figure 3.7, 3.8, and 3.9). A ignificant decrea e in a O 
wa hown by the Mann-Whitney U test between the control group and the six patient 
groups in the three test categories (p < 0.05). There was no significant difference 
found between evere and moderate HA in CWB+CTI+TF (p = 0.057) and CWB+TF 
(p = 0.116) test categorie , however, there was a significant difference in CWB test 
category (p = 0.0401). There wa no ignificant difference in aD between moderate 
and mild HA (p = 0.446 in CWB+CTI+TF, p = 0.258 in CWB+TF, and p = 0.629 in 
CWB). In HB groups, a ignificant difference was found between the mild HB and the 
control group (p = 0.028) but no ignificant difference between mild and moderate (p 
= 1.0), or moderate and severe (p = 0.183) HB was found . 
eWB 
80 p= 0.028 
( , 
p= 0.629 p= 1.000 
TT 60 p= 0.040 p= 0.183 ( 
, 
~ ( ( aO • + • TT 40 • •• TT ~ .,. • T •• •• • 20 .+ 
•• 
0 
Moderate Mild Severe Moderate Mild Normal Severe 
HA HA HA HB HB HB 
Figure 3.7 ROTEM alpha angle para meter in CWB 
evere moderate, mjld HA and HB compared to the control group in eWB category. Error bars show 
the median and inter-quartile range. (the p value are for the indicated paired population) 
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Figure 3.8 ROTE ,,' a lpha a ngle parameter in W8 +TF 
Severe, moderate. mild HA and HB compared to the control group in CWB+TF category. Error bars 
show the median and inter-quartile range. (the p value are for the indicated paired population) 
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Figure 3.9. ROTEM alpha angle parameter in WB+CTJ+TF 
Severe, moderate, mild HA and HB compared to the control group in CWB+CTl+TF category. Error 
bar show the median and inter-quartile range. (the p values are for the indicated paired populations) 
3.6.2. ROTEM® derived parameters 
:g 
The ROTEM derived parameters (MaxVel, tMaxVel, and AVe) for the control 
group and the all patient groups in three test categories were analysed (Table 3.2). The 
results showed a nonparametric distribution for the majority of the parameters, 
therefore median and the range (based on 5th_ 95th percentiles) was calculated for each 
parameter. Intra assay variation (based on four simultaneous measurements of two 
normal male subjects) was AUe = 10.2%, MaxVel = 7.1 % and tMaxVel = 8.3%. 
Inter-assay variation (based on measurements of two nonnaI male subjects over four 
different days) was Aue = 12.8%, MaxVel = 10.5% and tMaxVel = 10.3%. 
Table 3.2 ROTEM® derived parameters 
ROTEM® 
Normal Severe Moderate Mild Severe Moderate Mild 
Test HA HA HA HB HB HB 
Parameters Category n = " 11 = 30 11 = IJ 11 = /6 11 = 7 11 = 3· 11 ~ 3· 
Mt"lilan Ml.,than Metllan MI!(han Median M\.'l.hun Mt'lll.1n 
(:'i" - 4~" petct!'nldd (~". 'I:'''' per~'cnulC'1 j5"'-1,I5"'~n:l!ntll('1 (5'1'- 1,15'" neu:ellll1e) (5'1.· 'i:-."p\:n;cnllll'l (5"'- 4:'iLlJ~'!yt'l\tJlc) (~"'. 95,j, flt'rrl'llllkt 
eWB 7.4 3 3.3 4 2 3.3 4 (5.1-12.51 {1.2-5.2) (2.0-4.0) (3.0-8.0) (2.0-5.0) (2.0-4.8) (3.0-5.0) 
MaxVel 
eWB+ TF 10 5 5 7 3.5 5.7 6.5 
·1 (7.0-15.2) . (2.6-8.3) (3.4-8.3) (5.0-12.0) (3.0-9.0) (4.0-7.0) /6.0-7.0) 
mm.min 
eWB+CTI 8.95 3. 0 3.5 5 3 5.2 7 
+TF 
_(6.5-13·71 Jt9-6.3) (2.90-4.9) (3.0-8.0) (2.0-6.0) .12.5-7.8) (5.0-7.0) 
9 i 38.7 25.9 19.7 46.3 23.9 15.9 CWB I .15.5-13&1 (21.9-92.0) (18.3-33.0) (13.3-26.8) (24.3-68.6) .(20.6-26·~L i!.1J-2.oliL 
tMaxVel CWB+ TF 7.7 I 16.9 12.4 10.5 17.6 11.5 11.2 (3. 5-12-1L+_.@·8-35.4) /10.8-18.9) (6.6-13.9) (11.1-29.6) ~8...:...4:.14.3L __ 17-.~-14.6.L 
min CWB+CTI 8.4 22.6 19.2 15.8 23.3 16.1 11.6 
+TF (4.7-14.9) {9.3-52.2) (12.5-32.2 (10.1-26.9) (11.3-48.0) (10.8-22.3) (7.7-15.4) 
55 47.6 44.2 48.1 46.9 40.5 43.5 
eWB (43.6-60.Ql (27.8-61.0) (39.7-58.7) (35.4-60.0) (36.1-55.1 ) (34.2-48.7) (39.9-46.5) 
AVe 58.8 51.6 49.1 53.6 52.3 51.2 50.1 CWB+TF (44.1-82.0) (39.2-69.5) (43.0-63.4 ) (46.8-62.6) (43.0-57.0) (44.0-56.1 ) (47.2-53.0) 
mm CWB+CTI 55.5 48 51.6 52.5 47.1 55.4 52.5 
+TF ..1.48.4-62.3) (40.5-68.3) (44.6-65.0) (42.8-62.0) (40.4-53·11 142.9-67.8) (49.7-54.4) 
.(j!; 
The median and the range (5 th_ 95 th percentIles) ROTEM denved parameters were calculated 10 control group and 
Haemophilia patients in three categories. MaxVel = maximum velocity, tMaxVel = time to maximum velocity, AUe = 
area under the first derivative curve, HA = haemophilia A, HB = haemophilia B, CWB = citrated whole blood, TF = 
tissue factor, eTI = com trypsin inhibitor. 
·where the number of samples was not statistically significant. minimum and maximum values were reported 
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3.6.2.1. Maximum velocity 
Maximum velocity (MaxVel) parameter of ROTEM(!t! was analysed in all the patient 
groups and the median and range calculated (Table 3.2). The Mann-Whitney U test 
showed the Max Vel in severe, moderate, mild HA and HB was significantly lower in 
all test categories when compared to the control group (the highest p = 0.0405 
between moderate HB and the control group (Figure 3.12). However, the Mann-
Whitney U test was not significant when Max Vel was compared between the severe 
and the moderate HA groups (p = 0.148) in CWB+CTI+TF, CWB+TF (p = 0.249), 
and CWB (p = 0.981) test categories, although a significant difference was found 
between the MaxVeI of moderate and mild HA in CWB+CTI+TF (p = 0.019) and 
CWB (p = 0.008) test categories, but not in CWB+TF test category (p = 0.097). 
Wilcoxon rank test was performed to investigate if MaxVel is different between test 
categories. The results showed a significant difference between CWB+ TF and 
CWB+CTI+TF (p = 0.0004) where median MaxVel was higher in CWB+TF. This 
indicates that the addition of TF, without exclusion of contact activation by CTI, may 
cause overestimation of the results. There was no significant difference between 
MaxVel in CWB and CWB+CTI+TF (p = 0.529). Comparing the difference between 
the MaxVel in CWB and CWB+TF, a significant was found (p = 0.0005). This may 
suggest that the initiation, whether through contact or TF, may return the same results. 
In HB groups, no significant difference was found between severe, moderate, and 
mild patient groups. This may be due to the small numbers in each group. The 
difference between groups in different categories has been illustrated in Figures 3.10, 
3.11, and 3.12. 
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The CV for the MaxVel parameter in the evere, moderate and mild HA in 
CWB+CTI+TF wa 41 %, 27%, and 26% respectively. The e finding are consi tent 
with other tudie which reported a large heterogeneity of ROTEM parameters 
(Inger lev et 01. 2003; 0ren en & Inger lev, 2004). In the total HB group (n = 13) 
MaxVel wa ignificantly different betw n the HB group and the control group (p < 
0.0001). 
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Figure 3. 10 ROTEM Max cl compa ri on in WB . 
The graph depict MaxVel parameter in evere, moderate, mild HA and HB patIent and the control 
group. Median (middle line) with inter-quartile range (error bars) illu trated in each group. (the p 
value are for the indicated paired population) 
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Figure 3. 1 I ROTEM MaxVel comparison in WB+TF 
The graph depicts MaxVel parameter in evere, moderate, mild HA and HB patients and the control 
group. Median (middle line) with inter-quartile range (error bars) illu trated in each group. (the p 
value are for the indicated paired population) 
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Figure 3. 12 ROTEM Max el compar ison in CWB+TF+CTJ 
The graph depict MaxVel parameter in evere, moderate, mild HA and HB patient and the control 
group. Median (middle line) with inter-quartile range (error bar) illu trated in each group. (the p 
value are for the indicated paired population) 
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3.6.2.2. Time to maximum velocity 
The tMaxVel parameter was analysed and compared to the control group (Table 3.2). 
tMaxVel was significantly prolonged in all HA and HB groups compared to the 
control group (the highest p = 0.048) (Figures 3.13, 3.14, and 3.15). To determine any 
difference between the severe and moderate HA groups in the different test categories, 
the Mann-Whitney U test was performed and a significant difference was found 
between the severe and the moderate HA in CWB test category only (p = 0.002). The 
comparison between the moderate and mild HA patient group showed a significant 
difference in the CWB and CWB+TF test categories (p = 0.010 and 0.007 
respectively) but not in CWB+CTI+ TF test category (p = 0.538). In HB groups, no 
significant difference was found between severe and moderate or moderate and mild 
HB groups. This could be explained by small number of participants in these groups 
and also the fact that the median FIX activity levels in these group were very close to 
each other (median FIX = 2.0 IU/dL in moderate HB, and 5.0 JU/dL in mild HB). 
Wilcoxon rank test compared the difference between test categories, and showed 
significant difference in tMax Vel of severe HA in all test categories. In moderate HA, 
the difference between tMax Vel in CWB and CWB+ TF test categories was 
significant (p = 0.008), but not between CWB and CWB+CTI+TF test categories (p = 
0.109). There was also significant difference between tMaxVel ofCWB+CTI+TF and 
CWB+TF test categories (p = 0.007). 
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Figure3.13 ROTEM tMax el parameter in WB 
tMaxVel in e ere, moderate, mild HA and HB compared to the control group. Median (middle line) 
with inter-quartile range (error bar) illu trated in ea h group. (the p values are for the indicated paired 
population ) 
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Figure3.14 ROT M tMax el parameter in CWB+TF 
tMaxVel in evere, moderate, mild HA and HB compared to the control group. Median (middle line) 
with inter-quartile range (error bar) illu trated in each group. (the p value are for the indicated paired 
population ) 
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Figure 3.15 ROT M ' L'\1a Vel parameter in WB+TF+CTJ 
tMaxVel in evere, moderate, mild HA and HB compared to the control group. Median (midd le line) 
with inter-quartile range (error bar) illu trated in each group. (the p value are for thc indicated paired 
population) 
3.6.2.3. rea under the curve 
The AUe of ROTEM R velocity curve wa mea ured and the median and 5th_ 95 th 
percentile were calculated (Table 3.2). The Mann-Whitney U test showed ignificant 
difference between control group and HA or HB group in eWB (the highe t p 
=0.023) and CWB+TF (the highe tp =0.028) but not in CWB+CTI+TF (the lowe tp 
=0.079) te t category. There wa no ignificant difference between evere, moderate, 
mild HA or HB group in any test category (Figures 3.16, 3.17, and 3.18). The result 
howed that A C parameter wa not ensitive enough to distingui h between control 
group and any of patient group in any tc t category. 
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AU parameter in e ere, moderate, mild Hand HB compared to the control group in CWB+ TF test 
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CWB+CTJ+TF te t category. Median (middle line) with inter-quartile range (error bars) illustrated in 
each group. (the p value are for the indicated paired populations) 
The variability within group howed a high degree of heterogeneity particularly in 
severe HA and HB. Thi wa more pronounced in CWB+ TF te t category in which 
the tandard deviation ( D = 1.6) wa higher than CWB and CWB+CTI+TF te t 
categorie ( D = 1.0 and 1.3 re pectively). However, four evere, four moderate and 
eight mild HA were within the reference range in CWB+TF te t category as were one 
severe, one moderate, and two mild HA in CWB, and one evere, no moderate and 
two mild HA in WB+CTI+TF te t category. 
3.6.2.4. Correlation of ROTEM parameter with FVIIJ levels 
The Speannan correlation coefficient wa perfonned between ROTEM parameter 
and the corre ponding FYIII level of mild and moderate HA (Appendix 1) (median = 
10 IU/dL, 5th_ 95 th percentile range 1.4-39.6 IU/dL) how d that the MaxYel 
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correlated significantly with the level of FVIII in CWB+CTI+TF (r = 0.805, P 
<0.0001), and CWB (r = 0.61O,p = 0.004) test categories only. The linear regression 
analysis showed a significant coefficient of determination (r2 = 0.648, p < 0.0001) 
(Figure 3.19). Correlation of the tMaxVel with the FVIII level was only found in 
eWB test category (r = -0.625, p = 0.003) and to a lesser degree in CWB+TF (r = -
0.487, P = 0.025). This correlation was performed on combined moderate and mild 
HA groups to increase the number of individuals and to produce a statistically valid 
outcome. 
The correlation between tMaxVel and APTT (Appendix I) was also significant (r = 
0.726 P < 0.000 I). Spearman correlation between FVIII levels of mild and moderate 
HA and APTT were less significant than the MaxVel in CWB+CTI+TF (r = -0.710,p 
< 0.000 I). The linear regression analysis showed a significant coefficient of 
determination (r2 = 0.648, p < 0.0001) (Figure 3.20). There was no correlation 
® between one-stage FIX clotting assay and any of the ROTEM parameters. 
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Figure 3.19 Linear regression FVIII vs MaxVel in CWB+CTI+TF 
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Linear regression analysis was performed to compare FYIII activity levels and MaxYel in moderate 
and mild HA (n = 27) in CWB+CTI+ TF test category (r2 = 0.648, p < 0.000 I). 
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Figure 3.20 Linear regression APTT vs MaxVel in CWB+CTI+TF 
Linear regression analysis was performed to compare APTT and MaxYel in moderate and mild HA (n 
= 27) in CWB+CTI+TF test category (r2 = 0.504, p < 0.0001). 
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3.6.2.5. The sensitivity and specificity of ROTEM® parameters 
The sensitivity, specificity and likelihood ratio were calculated for the conventional 
and derived parameters by receiver operating characteristic (ROC) analysis to 
establish which parameter and in what test category was sensitive and specific to 
distinguish between normal and abnormal result. The sensitivity and specificity in this 
test is not for diagnosis of a particular disorder e.g. haemophilia. The aim of using 
ROC statistical analysis was to investigate the sensitivity (proportion of individuals 
who had abnormal clot formation which was measured by ROTEMi)l; i.e. haemophilia 
patients) and specificity (proportion of normal individuals who had normal clot 
formation which was measured by ROTEM':il) of ROTEMi!!! parameters as a screening 
test for hypocoagulable states, and to establish whether the use of CTI would improve 
the sensitivity of the test. The ROC analysis was performed on all HA and HB 
patients (n = 70) in each test category and compared to 22 normal individuals. 
The ROC was calculated for Max Vel in all three test categories, comparing the patient 
groups with the normal group (Table 3.3). The sensitivity was higher in 
CWB+CTI+TF (92%) than CWB+TF (85%), and slightly higher than CWB (90.41). 
The specificity for CWB+CTI+TF, CWB+TF, and CWB were 95% in all three 
categories. The likelihood ratio, therefore, was higher in CWB+CTI+ TF (20.31), than 
CWB+ TF (16.19), and CWB (18.08). These results indicate that only 8% of 70 
patients had normal MaxVel in CWB+CTI+TF test category, and only 5% of normal 
individuals had abnormal MaxVel in the same category. 
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T bl 3 3 ROTEM~ M V a e • : ax el sensitivity an d specificity 
Test Category Sensitivity Specificity Likelihood ratio 
0, 
/0 % 
CWB+CTI+TF 92 95 20.31 
CWB+TF 85 95 16.19 
CWB 90 95 18.08 
... The sensItIVIty, specIficIty and Itkelthood ratIO of MaxVel In all HA and HB (n = 70) in three 
categories was calculated by comparing with normal individuals (n = 22). CWB = citrated whole blood, 
CTI = com trypsin inhibitor, TF = tissue factor 
To avoid skewed results, the ROC analysis repeated for mild HA (n = 16) only, by 
comparing to the normal individual group (n = 22) in all three test categories and for 
all parameters (Table 3.4). The results showed CFT in CWB+CTI+TF was the most 
sensitive conventional parameter for distinguishing normal from abnormal across the 
three test categories with the sensitivity of 85%, the specificity of 95% and likelihood 
ratio of 18.62. The sensitivity, the specificity of the a
O 
was similar to the CFT (85%) in 
CBW +CTI+ TF but less specific (91 %) than the CFT (95%). The sensitivity and 
likelihood ratio of MaxVel parameter in CWB+CTI+TF category was higher in 
comparison to the other test categories. The sensitivity, the specificity, and likelihood 
ratios in HB group were 81 %,95%, and 17.88 respectively. 
The tMaxVel was the most sensitive parameter of ROTEM® in mild HA CWB 
category with sensitivity of 100% and specificity of 95%. In the HB group, the ROC 
showed similar results with HA with 100% sensitivity, 95% specificity and 20.0 
likelihood ratio. In contrast, AUC was the least sensitive and specific parameter 
among ROTEM k parameters in all test categories. 
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Table3.4. Sensithity and specificity of ROTEM@ MaxVel 
ROTEMJ<: 
ROC 
(Mild HA patients) 
Parameters Sensitivity Specificity Likelihood Ratio 
Category % 0/0 
i CWB 62 95 12.31 CT I CWB+ TF 67 95 12.6i-----i 
S r--- -----------. 
62 95 
"- .----- - -- ... -
CWB~CTI~TF I 13.54 , 
CWB 69 90 6.92 
CFT CWB+ TF 60 95 11.40 
s 
CWB+CTI+TF 85 95 18.62 
CWB 46 95 9.23 
aO CWB+ TF 53 95 10.13 
CWB+CTI+TF 85 91 9.31 
CWB 77 95 15.38 
MaxVel CWB+ TF 57 95 10.86 
mm.min- I 
CWB+CTI+TF 85 95 18.62 
CWB 100 95 20.0 
tMaxVel 71 89 
~-------
, CWB+ TF 6.79 
min r-- --
i CWB+CTI+TF 54 95 11.85 
CWB 38 95 8.46 
AUC CWB+TF 74 79 3.44 
mm 
CWB-t-CHtTF 46 95 9.23 
,1\ . .. The ROC was analysed In all three categorIes for all parameters of ROTEM In mIld HA haemophlha patIents (n 
= 16) and nonnal group (n = 22). CT = clotting time. CFT = clot fonnation time. MaxVel = maximum velocity. tMaxVel = 
time to maximum velocity. AUC = area under the first derivative curve. CWB = citrated whole blood. CTI = com trypsin 
inhibitor. TF = tissue factor 
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3.7. Discussion 
The ROTEM1!- whole blood analyser was used in this study to examine changes in 
viscoelastic properties of whole blood clot formation in haemophilia patients. 
Thrombelastography/thromboelastometry has been used for several decades 
(Luddington et al .. 2005). In recent years, however, they have become a more useful 
tool for the assessment of whole blood haemostasis in laboratories. ROTEM iII' is not 
routinely used to monitor patients with haemophilia as the ROTEMi&l tracing in this 
group of patients takes a long time to produce a result, and not all the parameters can 
be extracted as a result of the prolonged clotting time. However, the use of a small 
amount of TF for initiation of coagulation has made this technique useful as it more 
clearly mimics the in vivo situation, particularly in haemophilia patients with 
inhibitors (Ingerslev et aI., 2003; Sorensen & Ingerslev, 2004b). 
The aim of this study in this chapter was to investigate the effect of leukocytes, red 
blood cells and platelets, on the changes to the viscoelastic properties of clot 
fonnation in patients with haemophilia, and to establish the most sensitive and 
specific parameters to distinguish between normal and abnormal results. Once the 
most sensitive and specific parameter was identified, its correlation with the clinical 
phenotype was analysed (see Chapter 6). 
Although other groups have performed similar studies, the number of participants in 
those studies was less than our study i.e. Lewis et al. (2007) investigated 12 severe 
HA, and ven Veen et al. (2009) assessed 29 HA patients. 
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Furthennore, the effect of preanalytical variables, especially, the effect of eTI on 
whole blood clotting assay were also not thoroughly investigated. Contact activation 
during sampling and sample processing can have a significant influence on the results. 
The results showed significant differences between MaxVel in CWB+TF and 
CWB+CTI+TF, and also between tMaxVel in CWB and CWB+CTI+TF test 
categories. This may indicate that the influence of contact activation, in addition to the 
effect of TF, may cause overestimation of results in MaxVel and shortening the 
tMaxVel in CWB+TF. 
Consistent with other studies, this study showed that severe HA and HB patients had a 
very prolonged CT and CFT when compared to a control group under all test 
conditions. The MaxVel was markedly depressed in severe haemophilia but increased 
proportionally in patients with moderate and mild haemophilia. This was shown by a 
good correlation between FVIII and MaxVel in moderate and mild HA. TF initiation 
of the reaction improved the tracing record but variability increased dramatically, 
particularly in the severe HA group. This may, in part, be related to the overall 
contribution of other components of blood, including red cells, platelets and white 
cells to clot fonnation or the ability of ROTEM® to identify the influence of the 
changes in factor VIII levels at < 1.0 IU/dL on the coagulation system. 
In the CWB category, CT, aO , and tMaxVel differentiated between severe and 
moderate HA in (p = 0.0019, 0.0401, and 0.002 respectively). However, there were 
number of crossover results which the ROTEM@ results were not in agreement with 
the current classification of severe, moderate, and mild haemophilia based on the 
coagulation factor level activity. This shows that the global assays i.e. 
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thromboelastometry, may be influenced by other components of blood and may not 
strongly correlate with the current definition of severity ofhaemophilia. 
The tMax Vel could also differentiate between the moderate and mild HA (p = 
0.0101). The MaxVel parameter could differentiate between moderate and mild HA (p 
= 0.0082). However, the sensitivity and specificity of the tMax Vel parameter was the 
highest amongst all six parameters in all categories (100% sensitivity and 95% 
specificity). The tMaxVel correlated with the FVIII level in CWB test category (r = -
0.625, p = 0.003) and the data suggest that tMaxVel in the CWB category is the most 
useful parameter of ROTEM~ for predicting the severity of haemophilia. The 
significant correlation between APTT and tMaxVel (r = 0.726 P < 0.000l) suggests 
that this parameter may reflect the contact activation in the CWB category therefore 
may not truly represent in vivo haemostasis. 
In CWB+ TF category, only tMax Vel differentiated between the moderate and mild 
HA (p = 0.0 I 0 I). The correlation between the FVIII level and the ROTEM(B) 
parameters in this category was not significant. The sensitivity and specificity of the 
various parameters in this test category were also inferior to the parameters of other 
test categories, as discussed in section 3.6.2.5. 
In CWB+CTI+ TF category, CFT differentiated between severe and moderate HA (p = 
0.0211), and was the most sensitive and specific parameter amongst the three 
conventional parameters. The MaxVel parameter could differentiate between 
moderate and mild HA in this category (p = 0.0192). The sensitivity and specificity of 
the MaxVel were also high (85% sensitivity, 95% specificity) with a significant 
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correlation to the FVIII levels (r = 0.805, p < 0.0001). The MaxVel seems to be the 
most useful parameter of ROTEM E in the CWB+CTI+TF category in predicting the 
severity of haemophilia. 
This study was the first (at the beginning of the study) to conduct ROTEMI)\J analysis 
on haemophilia patients, using CTI and TF to closely mimic in vivo haemostasis in 
whole blood. One of the major variations in the perfonnance and interpretation of 
ROTEM~ measurement is the contribution of preanalytical variables. These variables 
include techniques used for specimen collection, transport, and storage, all which may 
introduce changes due to activation of the coagulation system and not related to the 
underlying disorder in the ROTEM:E traces, affecting the precision and accuracy of 
the test. Coagulation activation of blood by the contact pathway can be abolished by 
inhibiting contact activation through the use of CTI. Therefore, the coagulation 
initiation will only be dependent on the trigger used, which in this instance was a 
minute amount of TF added to the ROTEM® cup. The use of CTI in ROTEM® 
improved the sensitivity of parameters. 
3.8. Conclusion 
In conclusion, ROTEM~ analysis of citrated whole blood under two test categories of 
CWB and CWB+CTI+ TF was most useful for identifying the heterogeneity of the 
patient's global coagulation profile. The MaxVel in CWB+CTI+TF test category 
differentiated the severity of haemophilia between populations, i.e. severe, moderate, 
and mild; and had strong correlation with the FVIII level of individuals. Where TF is 
used to trigger coagulation, in order to mimic in vivo clot formation, this study 
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showed that the use of CTI is essential to improve the sensitivity and specificity of the 
test. 
The tMaxVel in CWB category can also reliably distinguish individuals with HA with 
100% sensitivity from normal population, however, its advantage over conventional 
assays such as APTT remains controversial as the initiation of clot fonnation, similar 
to APTT, is through the contact pathway. 
Although the results showed a significant difference between severe, moderate and 
mild groups, the number of crossovers cannot be ignored. This may prove that not all 
severe, moderate, or mild haemophilia patients have the same coagulation potential 
and modifying elements may playa role in altering the phenotypic expression. 
Therefore, a modified ROTEM(R; analysis usmg CTI and TF, mimicking in vivo 
haemostasis may give additional information over conventional coagulation assays 
and contribute to the management of haemophilia patients including the prediction of 
the clinical phenotype. 
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Chapter 4 Thrombin generation test 
4.1. Introduction 
Thrombin is one of the central enzymes in blood coagulation and both the rate of 
thrombin formation and the total amount of thrombin formed can be considered to be 
a reflection of the potential coagulation activity in plasma (Hemker et al., 2002). 
Activation of the coagulation cascade in vivo is thought to occur through complex 
formation of circulating FVIIa and vessel wall exposed TF, whereas a second pathway, 
the so-called "contact activation" route, can be stimulated in vitro (Biggs et al., 1953). 
The classical laboratory methods to determine coagulation defects in both pathways, 
e.g. the PT for the TF/FVIIa route and the APTT for contact activation, are limited in 
their ability to simulate the dynamics of clot formation because the tests measure only 
the initial thrombin formation required for fibrin formation (95% thrombin is 
generated after initial clot formation) (Mann et al., 2003a). Therefore, the 
coagulability of blood is better quantified by its thrombin generation capacity than by 
measuring the clotting times (Aledort, 2003). 
The TGT was first introduced by Macfarlane and Biggs in 1953 and its use in 
individuals with haemophilia was one of the first clinical applications of the assay. In 
their experiment, in brief, prothrombin was removed from blood samples with 
AI(OH3), then from the prothrombin-free samples, fibrinogen was separated into 
another sample collection tube to make a fibrinogen solution. Blood samples for 
testing were then sub-sampled into the fibrinogen solution and the time taken for 
fibrinogen to clot was measured. The concentration of thrombin in the whole blood at 
each time of sampling was then obtained from the thrombin-dilution curve. 
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Hemker et al. introduced substantial modifications, which made the test easier and 
more precise to perform (Hemker et aI., 2003). The quantity of thrombin generated is 
plotted against time to obtain a curve from which four parameters can be determined: 
1) area under the curve (AUe) or endogenous thrombin potential (ETP); 2) lag time, 
which represents the initiation of coagulation by generation of a small amount of 
thrombin « 5%) (Hemker & Beguin, 1995); 3) Peak thrombin generation (peak 
height), represent the maximum amount of thrombin generated; 4) time to peak height 
of thrombin generation. 
4.2. Aims 
In haemophilia patients, a correlation is usually observed between the clinical 
expression of the disease and the plasma FVIIVFIX activity. However, there are some 
patients with haemophilia where the bleeding tendency is not proportional to their 
plasma FVIWFIX concentration. It is known from clinical experience that 
approximately 10-15% of severe haemophilia patients, despite FVIIVFIX plasma 
levels < 1.0 IU/dL, can exhibit a milder bleeding phenotype and do not have 
haemophilic arthropathy (Bolton-Maggs & Pasi, 2003). From a clinical perspective, it 
would be extremely useful to have a laboratory test that can accurately predict an 
individual's coagulation potential and thus their bleeding tendency. However, there is 
still no validated laboratory test available to predict the overall coagulation status of 
an individual. The aim of the study in this chapter was to critically evaluate the use of 
thrombin generation in evaluation of overall coagulation potential in haemophilia. 
This chapter describes TGT performed on haemophilia A and B individuals, and 
compares the assay in four different test categories: 
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• 
• 
PPP: platelet poor plasma to analyse coagulation factors . 
PRP: platelet rich plasma, in which the platelet count was adjusted by PPP to 
give a platelet count of 150 x 109 IL, to analyse the effect of platelets on 
thrombin generation. 
• PPP+CTI: where samples were collected into tubes with added CTI to 
eliminate the contact activation contribution to thrombin generation. 
• PRP+CTI. 
For each test category statistical analysis was performed using the GraphPad Prism 
version 5.00 for Windows (GraphPad Software, San Diego California USA). Mann-
Whitney U test was performed to compare parameters within and between patients 
group and the control group. Wilcoxon rank test was performed to compare paired 
parameters in the three test categories for each patient group, and KruskaJ-WaJJis 
nonparametric ANaYA test was performed to analyse the variance between three test 
categories. The correlation coefficient was determined using the Spearman rank 
method. The ROC was performed to evaluate the sensitivity and specificity of the 
TGT. In all statistical analysis, a p value of < 0.05 was considered significant (All 
severe haemophilia samples included in the statistical analysis had FYIIIIFIX activity 
level of < 1.0 IU/dL, as measured by the one stage clotting assay). 
TGT in-house assay was also compared to the Calibrated Automated ThrombogramiFi 
(CAT) assay (section 4.4.2, Table 4.4) to investigate the correlation of in-house assay 
and one of the commercially available methods. The comparison was made only in 
the PPP+CTI test category, as the CAT was not available in our laboratory at the 
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beginning of this study, therefore, PRP samples which had to be tested as soon as 
prepared could not be tested by the CAT method. 
4.3. Study subjects 
Ninety seven patients were consented for the study, and in-house TGT data for further 
analysis was available for 73 patients. This included 36 severe HA, eight moderate 
HA, 15 mild HA, seven severe HB, three moderate HB, and four mild haemophiJia B. 
The age range was between 18 and 90 years (mean 43, median 41 years). The control 
group comprised 22 healthy male individuals aged between 22 and 62 (mean 40, 
median 39 years). All severe haemophilia samples included in the statistical analysis 
had FVIII or FIX activity level of < 1.0 IU/dL, as measured by the one stage clotting 
assay. The study was approved by the ethics committee of the Royal Free Hospital, 
and informed consent was obtained from patients and healthy individuals. 
4.4. Results 
The in-house TGT results were expressed by relative fluorescence unit (RFU). The 
RFU was calculated as a percentage of the normal value to enable comparison within 
and between different TG assays. In-house TGT parameters comprised peak height 
(PH) (the maximum amount of thrombin generated), the area under the curve (AVC), 
and the time to the peak height (TP) for the controls and the haemophilia patients. The 
lag time could not be measured in in-house method (the in-house TGT parameters, by 
definition, are same as the parameters which were described by Hemker et al., 
however, to distinguish between the in-house and CAT method, different abbreviation 
was used). The results showed a nonparametric distribution for the majority of the 
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parameters, therefore median and the range (based on 5th_ 95 th percentiles) was 
calculated for each parameter (Table 4.1). 
T bl 41 Th a e . rombin I!:eneration test (in-house) parameters 
Test Normal Severe Moderate Mild Severe Moderate Mild 
TGT HA HA UA HO UO UO Category n ="'" n = 36 n=8 n = 15 n = 7 n = 3- 11 ~ 4-
~1allan f\1oolan Mahan MedIan Median 
(~'I-- q~" pe!"i,:l!'llult'l 
Mt.'lh<l1\ Ml'than 
I ~. q~.' pt'1'"cc:"ntllel I "". 4~'" percentll!!') (~"'- l)~" p('fccnillcl 15" - Q5"'pt."n:cnlllt.'1 tli" - (1~'1' retl'l'l1l1lt» 1'i"·I)'i"'pt'flTrllllcl 
PPP+CTI 95 16 28.5 32.3 23 27 26.5 (66-152) (6.4-31.5) (16-50) (17.8-60.5) (14-31) (12-37) ( 19-50) 
PPP 97 19.6 44.4 42.1 IH 14.4 3H PH (64-159) (6.7-39.5) (18.2-47.9) (16.6-84.1 ) (11.9-29.4 ) (13.9-29.1 ) (31.2-50.5 ) 
% PRP+CTI 97 28.8 30.8 41.6 34 41.4 55.2 (67-133) (9.3-57.6) (15.2-70) (29.4-65.2) (22.9-34.5) (30.8-51.9) (44-60.7) 
PRP 104 31.7 36.3 53.5 26 26 37 (65-134) (9.5-56.9) (24.9-65.4 ) (33.1-69.7) (19-30) (24.5-27.5 ) (35.6-3!U) 
PPP+CTI 90.5 34.4 40 53.3 41 43 38 (78-133) ( 12.1-56.7) (32-70) (27.1-90.8) (33-69) (36-53) (29-48) 
PPP 100 38.8 66.5 55.5 36.7 31.4 44.3 AVe (72-124) (14.6-61.5) (66.1-66.8) (27.9-104.3) (27.1-68.1 ) (26.2-366) (34.9-50.7) 
% PRP+CTI 103 37.2 39.7 49.4 31.6 40.7 50 (71-115) (10.0-71.4 ) (21.3-64.4 ) (28.6-83.8) (26.8-45.4) ( 15.1-43) (19.9-703) 
PRP 93 39.7 54.7 76.9 34 463 55.2 (86-114) (9.0-77.3) (35.0-89.2) (52.0-93.7) (22.9-34.5 ) (35-57.5) (44-66.4) 
PPP+CTI 12 20.5 18.3 17.5 24 18.5 14.3 (9-15) (14.4-52.6) ( 11.5-28) ( 13-22) (15.5-27) (15-37) ( 13.5-15) 
PPP 12 20 12.R 15 
22 22 13.5 
TP (9-15.5) ( 13.5-54.5) (11.5-14) (13-20) (15-25) ( 18.5-25.5) (12.5-15) 
min PRP+CTI 29 50.8 47.5 38.5 
59 36.5 35 
(20.5-49) (37-61 ) (23.5-58) (32.5-56) (55-59) (22.5-58) (32.5-375) 
PRP 22 50 41 32.5 
58 46.3 34.3 
(15-41) (34.5-60) (25-47.5) (24.5-41 ) (58-60) (35-57.5) (32.5-36) 
In 1 .. The medIan and the range (5 - 95 percentiles) for tn-house TGT were calculated In control group and Haemophlha 
patients in four categories. TGT = thrombin generation, PH = peak height, AUC = area under the thrombin generation 
curve, TP = time to peak thrombin generation, PPP = platelet poor plasma, PRP = platelet rich plasma, eTI = corn 
trypsin inhibitor, HA = haemophilia A, HB = haemophilia B. 
-where the number of samples was not statistically significant. minimum and maximum values were reported 
The reference range was established using a control group comprised of 22 male 
healthy volunteers. Within and between assay precision were performed by using two 
normal individuals who had the nearest thrombin generation values to the mean of the 
reference range. Intra- and inter-assay coefficient of variation was calculated by 
performing 10 duplicate assays on each sample in one run and 10 duplicate assays on 
the samples from the same normal individual on different days during a period of 6 
months to take into account the possibility of fluctuations of coagulation potential in 
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the arne donor. The mean of the SD of 10 replicate RFV re ults was divided by the 
mean of 10 replicate . The normal individual with the lowest ev (AVe = 11 %, PH = 
7%, TP = 12%) then kindly olunteered to donate blood amples throughout the tudy. 
Thi ample wa u ed in each a ay a a control and to normali e the raw data in each 
run. 
4.4.1. In-hou e thrombin generation test (TGT) 
4.4.1.1. Peak height 
The median and the range (5 th - 95 lh percentiles) of peak height (PH) were calculated 
for the patient group and normal controls in each te t category (Table 4 .1). PH in the 
patient in each te t cat gory when compared to the control group, howed a 
significant decrea e in all patient groups. 
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Figure 4.1 Thrombin generation curve 
Peak Height in-hou e thrombin generation curve showing a typical relative fluore cence unit 
(RFU/min) over time (Min) in evere, moderate, mjld haemophilia A, and normal samples. 
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Using the Mann-Whitn y U tati tical te t a ignificant differ nee (p < 0.000]) wa 
found between of th control and patient group in the 4 eategorie (Figure 4.2, 4.3 
4.4, and 4.5). 
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Figure 4.2 Peak height thrombin generation (PPP TI) 
Peak height TGT PPP+ TI (expres ed a a percentage of the control sample) in severe, moderate and 
mild HA and HB compared to normal group. Median (middle line) with inter-quartile range (error bars) 
illu trated in each group. (the p value are for the indicated paired population) 
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Figure 4.3 Peak height thrombin generation (PPP) 
Peak height TGT PPP (expre sed a a percentage of the control ample) in evere, moderate and mild 
HA compared to normal group. Median (middle line) wilh inler-quartile range (error bar) illustrated in 
each group. (the p value are for the indicated paired populations) 
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Mann Whitney statistical analysis was perfonned to compare median difference of PH 
between mild, moderate, and severe HA. Significant differences were found between 
PH of severe and moderate HA patients in PPP and PPP+CTI test categories. (p = 
0.0017 and 0.0001 respectively). However, no significant difference was found 
between PH of mild and moderate groups (p = 0.412 and 0.S36 respectively). The 
median FVIII activity levels, which were measured by one-stage clotting factor assay 
(Appendix 1), were 3.0 IU/dL (Sth_ 9S th percentile I-S.0 IU/dL) and 13.0 IU/dL (sth_ 
9Sth percentile 8-48.0 IU/dL) for moderate and mild HA respectively. These results 
showed that the mild HA group have negative skewed results (skewed toward left), 
which may partly explain the lack of significant difference between the two groups. 
On the other hand, this may show insensitivity of the TGT in differentiating between 
the two groups. However, the fundamental question remains as to whether the TGT 
should be correlated to the clinical phenotype or to a single coagulation factor activity, 
if it is to be of diagnostic value. The aim of employing such global assays i.e. 
ROTEM~ or TGT, is to take into account other modifiers of coagulation potential, 
and to prove or disprove whether such an effect exists. Perhaps one should expect a 
lesser degree of correlation with measured FVIII/FIX, or a new classification of 
severity based on global assays, if such tests proved useful. In PRP and PRP+CTI 
categories, no significant differences were found between severe and moderate, or 
mild and moderate groups (Figures 4.4, and 4.5). 
Using Wilcoxon paired test, no significant difference was found between the PH 
parameter of PPP and PPP+CTI (p = 0.139), and PRP and PRP+CTI (p = 0.726) test 
categories (paired data on all patient groups). However, a significant difference was 
lIS 
found between the PH parameter of PPP and PRP (p = 0.0004), and PPP+CTI and 
PRP+CTI (p = 0.0221) te t categorie . 
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Figure 4.4 Peak height thrombin generation (PRP+ TI) 
Peak height TGT PRP+ TI (expre ed a a percentage of the control ample) in evere, moderate and 
mild HA compared to normal group. Median (middle line) with inter-quartile range (error bars) 
illu trated in each group. (the p value are for the indicated paired populations) 
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Figure 4.5 Peak height thrombin generation (PRP) 
Normal 
Peak height TGT PRP (expre ed a a percentage of the control sample) in evere, moderate and mild 
HA compared to normal group. Median (middle line) with inter-quartile range (error bar) illustrated in 
each group. (the p value are for the indicated paired populations) 
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Speannan statistical test was perfonned to analyse the correlation of PH in all HA and 
HB patients between different test categories. A significant correlation was found 
between the PH in PPP and PPP+CTI test categories (r = 0.873, p < 0.0001) (Table 
4.2). However, there were no strong correlations between PH of PPP and PRP (r = 
0.424, p = 0.005), PPP+CTI and PRP+CTI (r = 0.409, p = 0.00 I). 
Table 4.2 Thrombin generation correlation of test categories 
Spearman PPP PPP+CTI PRP PRP+CTI Correlation 
r = 0.873 r = 0.424 r = 0.294 
PPP 
P < 0.0001 p = 0.005 P = 0.045 
r = 0.873 r = 0.452 r = 0.409 
PPP+CTI 
p < 0.0001 P = 0.0007 P = 0.0009 
r = 0.424 r = 0.452 r = 0.862 
PRP 
P = 0.005 p = 0.0007 p < 0.0001 
r = 0.294 r = 0.409 r= 0.862 
PRP+CTI 
p = 0.045 P = 0.0009 p < 0.0001 
The correlatIon of PH In-house TGT of all patients between dIfferent categones In showed no strong 
correlation between PPP and PRP. TGT = thrombin generation, PH = peak height, PPP = platelet poor 
plasma, PRP = platelet rich plasma. CTI = com trypsin inhibitor. 
4.4.1.2. Area under curve 
The median and the range (51h - 95th percentiles) of AUC were calculated for the 
patient groups and nonnal controls in each test category (Table 4.1). The AUC 
parameter of patient groups in each test category was compared to the control group, 
which showed significant decrease compared to nonnal in all patient groups. Using 
the Mann-Whitney U statistical test a significant difference (p = 0.003) was found 
between the median of control and patient groups in all different categories (Figures 
4.6,4.7,4.8, and 4.9). 
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Mann Whitney tati tical analy i wa perfonned to compare the median difference of 
AUC between mild , moderate, and evere HA. ignificant difference wa found 
between the AUC of e ere and moderate HA patient in PPP+CTJ (p = 0.0237) and 
PPP (p = 0.045) te t categori . However no ignificant difference was found 
between the AU of mild and mod rate group (p = 0.536, 0.412 re pectively). In 
PRP and PRP+CTI categorie , no ignificant difference were found between evere 
and moderate, or mild and mod rat group (Figure 4.8 , and 4.9). In HE groups, a 
ignificant differenc wa found b twe n A C of moderate and mild HB in PRP te t 
category (p = 0.049). 
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Figure 4.6 Area under the curve thrombin generation in PPP+CTI 
The AUe (expre ed a a percentage of the control ample) of TGT in PPP+ TI of evere, moderate. 
mild HA and HB compared to the normal control group. Median (middle line) with inter-quartile range 
(error bar ) illu !rated in each group. (the p alue are for the indicated paired population) 
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Figure 4.7 rea under the cun'e thrombin generation in PPP 
The AU (expre ed a a percentage of the control ample) ofTGT in PPP of evere, moderate, mild 
HA and HB compared to the normal control group. Median (middle line) with inter-quartile range 
(error bar) illu trated in each group. (the p value are for the indicated paired populations) 
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Figure 4.8 rea under the curve thrombin generation in PRP+CTI 
The A UC (expre ed a a percentage of the control ample) of TGT in PRP+CTI of severe, moderate, 
mild HA and HB compared to the normal control group. Median (middle line) with inter-quartile range 
(error bar) illu trated in each group. (the p alue are for the indicated paired populations) 
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Figure 4.9 rea under the curve thrombin generation in PRP 
The A C (e pre ed a a percentage of the control ample) of TGT in PRP of evere, moderate, mild 
HA and HB compared to the normal control group. Median (middle line) with inter-quartile range 
(error bar) illu trated in each group. (the p alue are for the indicated paired populations) 
4.4.1.3. Time to peak 
The median and range (5 lh - 95 th percentile) of TP wa calculated for the patient 
group and normal control in each te t category (Table 4.1). TP parameter of patient 
groups in each te t category wa compared to the control group, which showed a 
significant increa e in all patient group . U ing the Mann-Whitney U tatistical te t a 
ignificant differ nc (the highe t p = 0.042) was found between the median of 
control and patient group in all different te t categories (Figure 4.] 0, 4.1], 4.12, and 
4.13). 
Mann Whitn Y stati tical ana]y i wa performed to compare the median difference of 
TP between mild, mod rate, and severe HA. Significant difference wa found 
between the TP of evere and moderate HA patient in PPP (p = 0.0395) but not in 
PPP+CTI (p = 0.1] 25) te t categorie. 0 significant difference wa found between 
the TP of mild and moderate group . In PRP and PRP+CTI categorie , no significant 
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difference wa found between evere and moderate, or mild and moderate group 
(Figures 4.12 , and 4.13). In HB group no ignificant difference wa found between 
severe and moderate, or moderate and mild HB ubgroup. 
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Figure 4.10 Time to peak t hrombin generation in PPP+CTI 
Time to peak thrombin generation in PPP+CTl of evere, moderate, mild HA and HB compared to 
normal control . Median (middle line) with inter-quartile range (error bar) illustrated in each group. 
(the p value are for the indicated paired populations) 
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Figure 4.11 Time to peak thrombin generation in PPP 
Time to peak thrombin generation in PPP of evere, moderate, mild HA and HB compared to normal 
controls. Median (middle line) with inter-quartile range (error bars) illu trated in each group. (the p 
value are for the indicated paired population ) 
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Figure 4.12 Time to peak thrombin generation in PRP+CTJ 
Time to peak thrombin generation in PRP+CTI of severe, moderate, mild HA and HB compared to 
normal control . Median (middle line) with inter-quartile range (error bar) illustrated in each group. 
(the p value are for the indicat d paired population) 
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Figure 4.13 Time to peak thrombin generation in PRP 
Time to peak thrombin generation in PRP of evere, moderate, mi ld HA and HB compared to normal 
control . Median (middle line) with inter-quarti le range (error bar) illu trated in each group. (the p 
value are for the indicated paired population) 
122 
4.4.2. Calibrated automated thrombogram@ 
Calibrated automated thrombogram;jl (CAT) assay was performed on the PPP+CTI 
test category only and was compared to the in-house TGT. The CAT parameters were 
included ETP, Peak thrombin generation, and time to peak (ttPeak). Table 4.3 
summarises the results for nonnal controls and patient groups. The results were 
converted to percentage of normal in order to compare to the in-house TGT results. 
Table 4.3 Calibrated automated thrombogram~ (CAT) parameters 
Test Normal Severe Moderate Mild Severe Moderate Mild CAT Category HA HA HA UB UB UB 
PPP+CTI 
n = ..,., n ~ 36 n~8 n ~ 16 n ~ 7 n ~ 3* n ~ 3" 
\1edl3n MeOlan Median Mcdt.m Mcdum M ... 'dHm M",'dlall 
(~'". 4~" rnn:nll!cl 15'"· ~5'" rer~nllllc) (5'''- 'l,"'. pt'fceniliel (;'''- ~5'" J'It.'fcenllle) 1.'\"'· 45"'[lf."fCCnlllc) 1:""·'1<;'·'!K"fu'fltIIL') (~". I)'i"'pl'rn'nllid 
ETP nM.min 1472 512 614 602 437 539 47R ( 1151-1956) (299-689) (520-844) (473-1136) (366-526) (517-SRO) (277-772) 
% 95.6 30.5 39.5 39 22.5 28.3 28 
(61.3-156) (21-43) (33-54) (31-73) ( 17.5-28) (24-37) (20-35) 
nM.min' 175.5 20 34.6 36.9 24.3 26 27 
Peak (115-132) ( 13.5-54.5) (30-48.9) (27-90) (17-32) (25-28) ( 16-48) 
% 97 15.5 17.5 19 10 11.3 14 
(49-164) (9-22) ( 15-25) (14-47) (6-16) (10-14) (8-19) 
ttPeak 9.8 16 14.3 15.3 14.9 20 IS.R min (6.8-13.3) (14.6-18.8) (12-17) (11-18) (12-19) ( 18.5-22) ( 12-20) 
,h th .. The medIan and the range (5 - 95 percentiles) CAT parameters were calculated 10 control group and Haemophlha patients 10 
PPP+CTI category. C AT ~ calibrated automated thrombogram. ETP = endogenous thrombin potential. Peak ~ maximum peak height thrombin 
generation. ttPeak ~ time to maximum peak height thrombin generation. PPP ~ platelet poor plasma. eTi = com trypsin inhibitor. HA 
haemophilia A, HB ~ haemophilia B. 
*where the number of samples was not statistically significant. minimum and maximum values were reported 
Mann-Whitney statistical analysis showed no significant difference between the Peak 
(p = 0.0928), ETP (p = 0.720), or ttPeak (p = 0.817) of moderate and mild HA 
individuals. There were also no significant differences between the Peak (p = 0.066) 
or ttPeak (p = 0.318) of moderate and severe HA. However there was significant 
difference between the medians ofETP in the severe and moderate HA (p = 0.0405). 
Using the Spearman statistical test, in-house TGT parameters of all HA an HB 
patients (n = 73) in the PPP+CTI test category were compared to CAT parameters 
(Table 4.4) (r value of > 0.5 and p value of < 0.05 considered to be strong and 
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significant correlation). A relatively strong correlation was observed between PH and 
Peak thrombin generation (r = 0.635, P < 0.0001). In contrast, AVC had a lesser 
correlation with ETP (r = 0.538, P = 0.001) and TP had a weak correlation but 
significant with the ttPeak (r = 0.254, p = 0.005). 
Table 4.4 Comparison of in-house TGT and CAT 
~ AUC% PH% TP CAT 
r = 0.538 r = 0.595 r = -0.282 
ETP% 
P = 0.001 P < 0.0001 P = 0.01 
r = 0.577 r = 0.635 r = -0.334 
Peak% 
p =0.001 P < 0.0001 P =0.201 
r = -0.099 r = -0.135 r= 0.254 
ttPeak 
p = 0.520 P = 0.006 P = 0.005 
A strong and slgmficant correlatIOn was observed between PH and Peak when TGT parameters were 
compared to eAT parameters. AUe and ETP had a less significant correlation in comparison with PH 
and Peak, whilst TP and ttPeak a weak but significant correlation (n = 73). eAT = calibrated automated 
thrombogram, ETP = endogenous thrombin potential, Peak = maximum peak height thrombin 
generation, ttPeak = time to maximum peak height thrombin generation, TGT = in-house thrombin 
generation test, AUe = area under the thrombin generation curve, PH = peak height thrombin 
generation, TP = time to peak height thrombin generation. 
ROCs were calculated for all parameters in each test category in mild HA only (Table 
4.5). The PH was the most sensitive parameter ofTGT in PRP+CTI test category with 
sensitivity of 100% and specificity of 94% followed by PPP+CTI (sensitivity = 94%, 
specificity = 94%) to distinguish between hypocoagulability and normal states. The 
sensitivity and the specificity analysis in this section was meant to be used for 
evaluation of diagnostic power of TGT. The ROC was used demonstrate if parameters 
of the TGT or CAT have a potential to discriminate between two groups of normal 
and abnormal in terms of their thrombin generation capacity. The results showed that 
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the use of cn would improve the sensitivity and the specificity of the test. The Peak 
was the most sensitive parameter of the CAT but less sensitive (92%) and specific 
(90%) than the PH in TGT. The sensitivity and specificity of AUC was relatively low 
when compared to the PH parameter. The sensitivity and specificity ofTP was lowest 
among other parameters of TGT. 
T bl 'fl' . a e 4.5 Thrombin 2eneratlon sensitIvIty and specl C!ty ID al test categorIes 
ROC 
TGT Test Mild HAjJatients Category Sensitivity Specificity Likelihood 
% % Ratio 
PPP 80 94 13.6 
PH PPP+CTI 94 94 16.9 
% PRP 83 94 15.0 
PRP+CTI 100 94 1B.0 
PPP BO 94 13.6 
AUC PPP+CTI 88 94 15.B 
% PRP 50 94 9.0 
PRP+CTI 79 94 14.0 
PPP 40 94 6.8 
TP PPP+CTI 75 94 13.5 
min PRP 60 94 10.8 
PRP+CTI 56 94 10.0 
ETP PPP+CTI 
% 
69 95 13.9 
Peak 
% 
PPP+CTI 92 90 9.2 
ttPeak 
min 
PPP+CTI 62 95 12.3 
SenSItiVIty and specIficIty of TGT and CAT for each test category were 
analysed. PH in PRP+CTI was the most sensitive parameter of in,-house 
TGT, ROC = receiver operating characteristic curve, CAT = cahbrated 
automated thrombogram, ETP = endogenous thrombin potential, Peak = 
maximum peak height thrombin generation, ttPeak = time :0 maxim~m 
peak height thrombin generation, TGT = in-house thro~bm generatIOn 
test AUC = area under the thrombin generation curve m TGT, PH = 
peak height thrombin generation in TGT, TP = time to peak height 
thrombin generation in TGT, PPP = platelet poor plasma, PRP = platelet 
rich plasma, CTI = com trypsin inhibitor. 
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The sensitivity and specificity was also calculated for the most sensitive parameters of 
in-house TGT and CAT for all patients (n = 73) (Table 4.6). The in-house PH in 
PRP+CTI category showed the highest sensitivity and specificity (l00%, and 94% 
respectively). 
Table 4.6 Sensitivity and specificity for all patients 
Sensitivity Specificity Likelihood ratio 
~/O % 
PH PRP+CTI 100 94.4 18.0 
PH PPP+CTI 99.0 94.4 17.8 
Peak PPP+CTI 97.7 90.0 9.8 
... SenSItIvIty and specIficIty of TGT for peak heIght of TGT and CAT were analysed. PH 10 PRP+CTI 
was the most sensitive parameter of in-house TGT. TGT = thrombin generation test, PH = TGT, PH = 
peak height thrombin generation in TGT, Peak = peak height in calibrated automated thrombogram", 
PPP = platelet poor plasma, PRP = platelet rich plasma, eTI = com trypsin inhibitor. 
4.5. Discussion 
Since the modification and simplification of TGT by Hemker et a/. its clinical 
application has been increased in recent years. Although the utility and reliability of 
TGT in various clinical scenarios is yet to be proven, there is growing interest in 
finding a test which can measure the generation of thrombin, the central player of 
haemostasis and thrombosis. Several studies support the value of thrombin generation 
in detecting hyper- and hypocoagulable states (Beltran-Miranda et aI., 2005; Dargaud 
et al., 2005; Dargaud et aI., 2007; Dargaud et al., 2010; Hemker et aI., 2006; Lewis et 
al., 2007; van Veen et al., 2009). 
In this study, thrombin generation in a cohort of haemophilia A and B patients was 
evaluated under four different test categories. The use of CTI, to inhibit the contact 
pathway, was also investigated by comparing samples with and without CTI in PPP 
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and PRP. Under each condition, the PH, TP and the AUC parameters of thrombin 
generation were measured and compared to the group of healthy individuals. 
The results showed a decrease in PH and AUC, and a prolongation ofTP in all patient 
groups and all test categories when compared to the normal group (P < 0.000 I). In the 
severe HA group the PH ranged 6.6-31.3% in the PPP+CTI category with an SO of 
7%, and in PPP category the PH ranged 6.7-39.5% with an SO of8.1%. This suggests 
that the use of CTI reduced the variability confinning findings by other researchers 
(Luddington & Baglin, 2004) that some of the variations are the result of sample 
activation prior to or during sample preparation in the PPP or PRP categories when no 
CTI was used. 
The AUC results showed a high within-group variation in the severe HA group with a 
range of 12.4-56.1% (SO = 12.41%) in PPP+CTI and 14.9-61.2% (SO = 11.99%) in 
PPP categories. These wide ranges and high SD confirm the earlier reports of 
heterogeneity of thrombin generation in haemophilia patients (Lewis et aI., 2007; van 
Veen et aI., 2009) suggesting that some of these variations with similar levels of 
FVIII may be related to other coagulation factors and all variations cannot be 
attributed to cellular components. 
The heterogeneity of thrombin generation in severe HA group was greater in 
PRP+CTI (PH ranged 9.3-57.6%) and PRP (PH ranged 9.5-56.9%) when compared to 
PPP+CTI (PH ranged 6.4-31.5%) and PPP (PH ranged 6.7-39.5%) test categories. 
This higher variation may be partly related to the source of phospholipids, which in 
PRP is the individual's own platelets, unlike synthetic phospholipids used in PPP 
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TGT. The heterogeneity of platelets has been alluded to by various experts as a 
potential basis for the heterogeneity of the clinical phenotype (Dargaud, 2006; Yee, 
2006). Indeed very early coagulation studies relied on patients own platelets as a 
source of phospholipids causing marked inter-individual variability (Buckwalter el aI., 
1949). To improve reproducibility and decrease variability, exogenous phospholipid 
has been used for the last few decades with improvement in the reproducibility for the 
various coagulation tests (Monroe et al., 2002). 
The low concentration of TF (0.5 pM) in PRP may also increase the variability of the 
results. Lewis et al. (2007) reported a wide variability of thrombin generation of 
severe HA patients in PRP+CTI samples. They could only report the initial rate of 
thrombin generation due to a too low TF concentration (0.3 pM) for initiation of the 
coagulation. As a result, the ETP and Peak thrombin generation could not be 
calculated in their study. In this study the final concentration of TF for PRP TGT was 
0.5 pM, which enabled us to obtain the AVC results within the running time of the 
test. 
The median PH for generated thrombin in PRP+CTI and PRP was higher than the 
median PH in PPP+CTI (p = 0.0001) and PPP (p = 0.0164) in the severe HA group, 
despite a low concentration of TF. The effect of VWF cannot be ignored as some 
individuals had high levels of VWF. A recent study has shown that VWF in addition 
to its function in platelet adhesion and as the carrier of FVIII, is also required for 
thrombin generation in PRP via a mechanism in which fibrin and platelet receptor 
GP 1 b are involved (Faber el al., 2003). Therefore, thrombin generation in PRP is 
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dependent upon platelet function (Dargaud et at., 2006a), VWF level, and the 
concentration of FVIIUFIX in haemophilia AlB. 
Significant difference was found between the median PH of severe and moderate HA 
patients in PPP and PPP+CTI test categories (p = 0.0017, and 0.0001 respectively). 
The results suggest that thrombin generation is dependent upon the level of FYIII 
between severe (FVIII < 1.0 IU/dL) and moderate (FVIII = 1-5.0 IU/dL). However, 
no significant difference was found between the PH of moderate and mild groups (p = 
0.412, 0.536 respectively), although the sample size in these groups was not 
statistically significant (n = 8 and 15, respectively). 
The analysis of the sensitivity and specificity of the TGT parameters showed the TGT 
can be used to distinguish between nonnal and abnonnal in tenns of their thrombin 
generation potential. The likelihood ratio was significantly higher in the PH parameter 
of in-house TGT in PPP+CTI (likelihood ratio = 17.8) when compared to the Peak 
parameter of the CAT in the same test category (likelihood ratio = 9.8). 
In PPP+CTI test category, there was a relatively strong correlation between PH of in-
house TGT and Peak height of CAT (r = 0.635, p = <0.0001), and to lesser extent 
between AVC and ETP (r = 0.538,p = 0.001). However, there was a weak correlation 
between the TP of in-house TGT and ttPeak of CAT (r = 0.254, p = 0.005). Although 
the methods are similar in principle such discrepancies are not uncommon. In recent 
multicentre studies the use of different TF and PL sources was shown to produce a 
large variability in thrombin generation testing (Dargaud et at., 2010; Gerotziafas el 
aI., 2005). In our study the TF source and the dilution factor was similar to the CAT 
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starting reagent, but the CAT reagent was supplied in a Iyophilised fonn in which the 
phospholipids are also incorporated into the reagent. In contrast, in the in-house 
method, the tissue factor was freshly made. diluted and just prior to the testing. freshly 
made phospholipids were added to the plasma sample. This may explain the precision 
and accuracy of the in-house TGT which is revealed in the ROC analysis in which the 
in-house TGT results were more sensitive and specific to distinguish between nonnal 
and abnormal thrombin generation potential, when compared to the CAT analyser. 
4.6. Conclusion 
TGT appears to be a reliable test to exclude individuals with lower than normal 
coagulation FVIII or FIX levels. In particular the likelihood ratio of PH makes this 
parameter ideal for investigation of hypo coagulability. The use ofCn to eliminate the 
interference of the contact system was also shown to play an important part in 
improving the accuracy and precision of thrombin generation. Although crossovers of 
results were observed between populations of severe, moderate, and mild groups in 
different parameters of TGT, but in general, statistically the differences were 
significant. For those who did not fall into the relevant severity group, however, this 
may indicate that the severity classification of haemophilia by TGT may not 
necessarily follow the same severity classification with clotting factor assay. The 
global assays may reflect the effect of other modifying elements which may have 
positive or negative 
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The heterogeneity of thrombin generation, in particular in severe HA and HB, was 
also demonstrated in this study, suggesting that the rate and amount of thrombin 
generation are not entirely dependent on the small amounts of FVlII or IX in this 
group of patients. 
Other modifiers of thrombin generation are discussed in the following chapters. 
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Chapter 5 Clot waveform analysis 
5.1. Introduction 
The accurate assay of clotting factor levels is critical in the diagnosis and management 
of patients with clotting factor deficiencies. Measurement of FVIII or FIX activity is 
generally perfonned by one stage clotting based assays, or by amidolytic assays using 
chromogenic substrates. The lower assay limit is often affected by the quality of the 
deficient plasma, activating reagent, type of standard, and other analytical variables. 
As a result, the lower detection limit of conventional assays, such as one-stage APTT 
based clotting assay for detennination of FVIII or FIX levels, is generally 1.0-2.0 
IU/dL (Hardisty & Macpherson, 1962). Therefore, it is difficult to diagnose the true 
severity of haemophilia A or B by conventional assays when the level of FVIII or FIX 
is measured as 1.0 IU/dL or less (Shima et aI., 2008). 
During the perfonnance of routine clotting assays such as APTT and PT, it is possible 
to obtain a continuous measurement of changes in light transmittance that occur as the 
test plasma sample clots. The resultant photo-optical data profiles obtained by 
continuous monitoring are called clot wavefonns. The wavefonn is mathematically 
processed by a software algorithm to derive several parameters such as coagulation 
velocity and acceleration (Downey et al., 1997). 
Using this approach, Shima et al. (2002) observed that the APTT clot waveform 
analysis on a number of patients with severe HA was different from patient to patient 
despite the fact that all had FVIII:C level of < 1.0 IU/dL. In their experiment, samples 
of FVIII deficient plasma were prepared to which serially diluted recombinant FVIlI 
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was added to provide an array of contrived FVIII deficient plasma samples ranging 
from zero to 1.0 IU/dL (0, 0.1, 0.2, 0.3, 0.5, 0.75, and 1.0 IU/dL final concentration 
FVIII). One-stage clotting assay and clot waveform analysis were performed on the 
diluted samples. FVIII level in theses series was closely correlated with the minimum 
value of the second derivative (Min2) of the APTT waveform. Min2 is the measure of 
the acceleration of change in optical transmission at the initiation of coagulation. 
This data suggests that the APTT is variably affected by other plasma factors (Shima 
et aJ., 2008). Other studies have also indicated that clot waveform analysis and 
especially Min2 values may have greater discriminatory power in assessing low 
clotting factor activity and may provide additional information in these patients 
(Shima et al., 2002). Thus clot waveform analysis may be useful for the investigation 
of the clinical phenotype of individual patients and their response to therapy. 
This chapter describes the clot waveform analysis on haemophilia A and B 
individuals who participated in this study. The APTT test was performed on the 
MDA ® coagulometer (Organon Teknika, Cambridge, UK) in the Haemostasis 
laboratory, Addenbrooke's Hospital, Cambridge, UK with kind permission of Dr 
Roger Luddington. The waveform was mathematically processed by a software 
algorithm, provided with the MDA ®, to derive two relevant parameters, Min I 
(maximum coagulation velocity, %T/s) and Min2 (maximum coagulation 
acceleration, % T/s2). 
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5.2. Study subjects 
Ninety seven patients were consented for the study, and clot waveform analysis were 
performed on 73 individuals with haemophilia who were included in the study. These 
comprised 36 severe, eight moderate. 15 mild HA, and seven severe, three moderate, 
and four mild HB, aged between 18 and 90 years (mean 43, median 41 years). The 
control group comprised 22 healthy male individuals aged between 22 and 62 (mean 
40, median 39 years). Patients on prophylaxis or on demand treatment were asked to 
omit treatment for a minimum of 72 h to allow the FVIII or FIX level to return to 
baseline level (All severe haemophilia individuals samples included in the statistical 
analysis had FVIII:C or FIX:C levels < 1.0 rU/dL, after wash-out period (sections 
2.1.1 and 2.1.2) as measured by the one stage clotting assay). Those who required 
treatment were excluded from study. The study was approved by the ethics committee 
of the Royal Free Hospital, and informed consent was obtained from patients and 
healthy individuals. 
5.3. Results 
The APTT, Min I (velocity) and Min2 (acceleration) parameters (section 1.5) of clot 
waveform analysis were extracted from software on the MDA g!) coagulometer. One-
stage clotting factor assay was performed on all patients and control groups. The 
results showed nonparametric distributions, therefore median and the ranges (based on 
sth_ 95 th percentiles) for MinI and Min2 were calculated for the patient and normal 
control groups (Table 5.1). The results were also normalised and expressed in 
percentage of mean normal ( control group). The results showed a significant decrease 
of MinI and Min2 in all patient groups. The CV for MinI, Min2 and APTT in severe 
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HA group were 42%, 52%, and 23% respectively. In severe HB group the CV for the 
same parameters were 37%, 50%, and 24% respectively. Using the Mann-Whitney U 
statistical test a significant difference (p < 0.000 I) was found between the median of 
control and patient groups in all different categories (Figures 5.1, 5.2). 
Tb a Ie 5.1 Clot waveform anah'sis on haemo )hilia A and B, and control2rouP. 
Clot Normal Severe Moderate Mild Severe Moderate UA UA UA UB UB 
Wave 
form 
n = .,., 
n = 36 n=8 n = 15 n ~ 7 n ~ 3* 
Mahan ~edlan Median Median Medllln Med,d!! (~Lf _ ~5'" perccnllle) (5"· \)5" percc:nlJlel \5'"- '15" pen.:entllc) (5'"_ q."i,n rercentlie) (5'~ - 4.~'" pet"l'l'nllk') (""'. 9~'" pt.'1\"c,°IIIIll') 
MinI 6.616 1.500 2.519 3.542 1.737 3.126 
%T/s (5.415-8.668) (0.564-3.14) ( 1.392-4.275) (2.154-5.571 ) ( 1.22-3.035) (2.441-4.737) 
MinI 98.0 22.0 37.4 53.0 26.0 47.0 
% (80-129) (8-47) (21-63) (32-83 ) ( 18-46) (37-72) 
Min2 0.584 0.113 0.25 0.373 0.136 0.328 
%T/s2 (0.508-0.757) (0.028-0.287) (0.12-0.45) (0.185-0.593) (0.09-0.318 ) (0.258-0.508) 
Min2 97 19 41 62 23 56 
% (84-125) (5-48) (20-74 ) (31-98) (15-54 ) (44-87) 
APTT 29.0 70.2 53.1 42.2 5tU 50.0 
s (24-36) (55.5-11 \.6) (45-66.1 ) (35.8-75.9) (47-92.7) (43.5-58.3 ) 
FVIIII 100 3 11 2 
FIX (50-150) < 1 (1-5) (5-48) <I (2-4) 
IU.dl 
Mild 
UB 
11 C" 4* 
Ml'd).l11 
('i'" C,,,'i' pC'rIcl1tlkl 
3.525 
(3.077-4.522) 
53.0 
(47-68) 
0.357 
(0.295-0.484) 
61 
(51-X3) 
48.5 
(34.4-59.6 ) 
5 
(5-13 ) 
1lI 1lI The medIan and the range (5 - 95 percentiles) Clot waveform parameters, APTT, and FVllIIFIX levels were 
calculated in patient and control groups. MinI = minimum value offisrt derivative (coagulation velocity, % change in 
transmitance (T)/second) Min2 = minimum value of second derivative (coagulation acceleration, % change in 
transmitance (T)lsecond2 ) 
.where the number of samples was not statistically significant, minimum and maximum values were reported 
Mann Whitney statistical analysis was performed to compare the median difference of 
MinI and Min2 between mild, moderate, and severe HA. Significant difference was 
found between the MinI of severe and moderate HA patients (p = 0.003), and the 
Min2 of severe and moderate HA (p = 0.001). No significant difference was found 
between the MinI or Min2 of mild and moderate HA groups (p = 0.057, P = 0.084 
respectively). In the HB group, a significant difference was found between severe and 
moderate HB for MinI (p = 0.017) and Min2 (p = 0.017) however, no significant 
difference was found between moderate and mild HB for neither Min I (p = 0.857) nor 
Min2 (p = 0.990). 
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Figure 5. 1 lot waveform ana ly i (M ini ) 
ignificant difference were found between evere and moderate HA (p = 0.003), but not between 
moderate and mild HA (p = 0.057). In HB, a ignificant difference was found between evere and 
moderate HB (p = 0.017), but no ignificant difference betwe n moderate and mild HB (p = 0.857). 
Median (middle line) with inter-quartile range (error bar) illustrated in each group. (the p values are 
for the indicated paired populations) 
Clot Waveform 
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Figure 5.2 Jot waveform analysi (Min2) 
Significant difference were found between evere and moderate HA (p = 0.00 J) , but not between 
moderate and mild HA (p = 0.0 4) . In HB, a ignificant difference was found between evere and 
moderate HB (p = 0.017), but no ignificant difTerence between moderate and mild HB (p = 0.990). 
136 
Median (middle line) with inter-quartile range (error bars) illustrated in each group. (the p values arc 
for the indicated paired populations) 
Statistical analysis by Speannan correlation was performed to compare the clot 
wavefonn parameters, FVIII level and APTT of moderate and mild HA (combined) 
(Table 5.2). Significant correlation was found between Min I and FVIII level (r = 
0.786,p < 0.0001), however, the correlation between MinI and APTT (r = -0.611, p < 
0.000 I) was not as strong as the correlation with FVIII level. Min2 correlation with 
FVIII level was also significantly strong (r = 0.759, P < 0.0001) and to lesser extent 
with APTT (r = -0.658, P < 0.0001). The correlation between FVIII level and the 
APTT was moderately strong (r = -0.513, p = 0.001). 
Table 5 2 Clot waveform correlation with FVIII and APTT 
Clot waveform MinI Min2 APTT FVIII 
analysis 
MinI r = 0.985 r = -0.611 r = 0.786 
n=23 p < 0.0001 P < 0.0001 P < 0.0001 
Min2 r = 0.985 r = -0.658 r = 0.759 
n =23 p < 0.0001 P < 0.0001 P < 0.000] 
APTT r = -0.611 r = -0.658 r = -0.513 
n=23 p < 0.0001 p < 0.000] p = 0.001 
FVIII r = 0.786 r = 0.759 r=-0.513 
n = 23 P < 0.0001 P < 0.0001 P = 0.00] 
Spearman correlatIOn was performed to analyse the relatIOn between clot waveform parameter, FVIII, 
and APTT of combined moderate and mild HA (n = 23). Mini = minimum value of fisrt derivative 
(coagulation velocity), Min2 = minimum value of second derivative (coagulation acceleration). 
To illustrate a better picture of correlation between the clot waveform parameters, 
APTT, and the FVIII level, linear regression analysis was performed between 
combined moderate and mild HA group MinllMin2 and FVIII (Figures 5.3 and 5.4) 
and APTT (Figures 5.5 and 5.6). 
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Figure 5.3 Clot waveform linear regression curve (Min] vs FVIII) 
Linear regression curve of Min I clot wave form on moderate and mild HA (r2 = 0.624) (the outlier 
FVJII = 48 IU/dL) 
1.0 
0.8 
Min2 0.6 
%T/s2 
0.4 
0.2 
0.0 
0 
Linear regression curve 
Min2 vs FVIII 
combined moderate and mild HA 
20 40 
Moderate and Mild HA 
FVlIIlU/dL 
60 
Figure 5.4 Clot waveform linear regression in combined moderate and mild (Min2 vs FVIIJ) 
Linear regression curve of Min2 clot wave form on combined moderate and mild HA (r2 = 0.568) (the 
outlier FVIlI = 48 JU/dL) . 
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Figure 5.5 Clot waveform linear regression in combined moderate and mild HA (Min I vs APTT) 
Linear regression curve of APTT clot wave form on moderate and mild HA (r2 = 0.374). 
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Figure 5.6 Clot waveform linear regression in combined moderate and mild HA (Min2 vs APTT) 
Linear regression curve of APTT clot wave form on moderate and mild HA (r2 = 0.229). 
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In the severe HA group, because FVIIJ < 1.0 IU/dL correlation could not be 
performed, however, linear regression analysis was performed between Min I/Min2 
and APTT of severe HA group (Figures 5.7 and 5.8). The r2 was 0.274 and 0.332 for 
MinI and Min2 respectively. 
Linear regression curve 
MinI vs APTT 
severe HA 
60 
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. '. Min] ••• 
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Figure 5.7 Clot waveform linear regression in severe HA (Min] vs APTT) 
Linear regression curve of APTT clot wave form on severe HA patients (.-2 = 0.274). 
140 
Min2 
%Tli 
60 
40 
20 
o 
o 
Linear regression curve 
Min] vs APTT 
all HA 
• 
: ... 
. '. 
••• .... 
~: , 
50 
." 
.I. 
I 
APTT (s) 
• • • 
• 
• • 
100 150 
Figure 5.8 Clot waveform linear regression in severe HA (Min2 vs APTT) 
Linear regression curve of APTT clot wave foml on severe HA patients (r2 = 0.332). 
The sensitivity, specificity and the likelihood ratio of Min 1 and Min2 parameters for 
all patients (Table 5.3) and mild HA (Table 5.4) were calculated. The sensitivity and 
specificity showed if the parameters were capable of distinguishing between normal 
and abnormal coagulation velocity and acceleration. 
T bl 53 a e Sensitivity and specificity of clot waveform parameters for all patients 
Clot waveform Sensitivity Specificity Likelihood Ratio 
analysis % % 
MinI 99 96 22.7 
Min2 97 96 22.2 
... 
The sensItIvIty, specIficIty, and Itkellhood ratIo were calculated for Clot wavefonn parameters of all 
patients. Min I = minimum value of first derivative (coagulation velocity)Min2 = minimum va lue of 
second derivative (coagulation acceleration). 
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T bl 5 a e .4 Sensitivity and specificity of clot waveform parameters mild HA patients 
Clot wavefonn Sensitivity Specificity Likelihood Ratio 
analysis % % 
MinI 93 96 21.5 
Min2 80 96 18.4 
... 
The sensItIvIty, specIficIty, and lIkelIhood ratio were calculated for Clot waveform parameters of MIld 
HA patients. Mini = minimum value offisrt derivative (coagulation velocity), Min2 = minimum value 
of second derivative (coagulation acceleration). 
5.4. Discussion 
The clinical significance of detecting levels of FVIII/FIX activities of < 1.0 IU/dL is 
very high as the individuals with such levels are at greatest risk of bleeding. However, 
not all individuals with severe haemophilia experience the same clinical phenotype. It 
is known from clinical experience that approximately 10-15% of severe haemophilia 
patients, despite similar FVIIIIFIX plasma levels of < 1.0 IU/dL, can exhibit a milder 
bleeding phenotype (Bolton-Maggs & Pasi, 2003). 
The clot wavefonn analysis performed in this study showed that such heterogeneity 
exists among the severe HA and HB individuals, and it was more pronounced in Min 1 
and Min2 parameters when compared to the APTT. The broad range of Mini (5 th -
95th percentile = 8-47%) and Min2 (5 th - 95th percentile = 5-48%) in severe HA and 
HB individuals (18-46%, and 15-54% respectively) demonstrate that categorising all 
severe haemophilia individuals under the same "< 1.0 IU/dL" activity level of their 
relevant factor may not reflect their clinical phenotype manifestation. 
142 
The APTT, as well as the one-stage clotting assay, measures the endpoint, which is 
the clotting time of a citrated plasma sample. This is the point at which coagulation is 
initiated and the first visible fibrin strands appear. In contrast, Min I represents the 
velocity of the reaction in the process of clot formation and Min2 is a measurement of 
acceleration of change in light transmission, whereas the APTT or one-stage clotting 
assay is the time at which the fibrin is formed. The data in this chapter confirms 
previous experiment by Shima et at. (2002), that the correlation of MinI and Min2 
with the level of the FVIII is more significant than the correlation of APTT and the 
FVIII. 
The coefficient of determination (i') for Mini and FVIII was 0.624, which shows that 
more than 62% of variance in Min I axis can be explained by variance of FVIII 
activity level axis. The i' for Min2 was 0.568 which also shows that 57% of the 
variance in the Min2 axis can be explained by variance of FVIII activity levels axis. 
Therefore, the APTT was shown to be a weak predictor to explain the variance of 
FVIII with r of 0.229. This may indicate that the time to clot formation may be 
affected by other modifing or interfering factors, whereas such influence on the rate 
and the accelaration of clot formation may be less effectual than the deficient factor. 
The sensitivity and specificity of clot waveform analysis showed that the Min 1 and 
Min2 could be used as discriminatory parameters in assessing the severity of HA and 
HB and for monitoring haemophilia patients. 
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5.5. Conclusion 
The result of this study demonstrates that patients generally assigned to having 
FVIIIIFIX levels of < 1.0 IU/dL may have variable concentrations below that level 
which cannot be reliably measured by conventional methods. The clot waveform 
parameters, Min 1 and Min2, appear to be reliable predictors of FVIIIIIX levels, based 
on their coefficient of determination, and can be used in cases where the level of < 1.0 
lU/dL is interested such as gene therapy monitoring, or monitoring treatment, on 
known HA or HB patients and in an emergency situation i.e. out of hours, where the 
technical support is limited. Although these parameters are sensitive in distinguishing 
abnormal results from normal, they are not specific to a particular disorder. These 
parameters are simple to extract from the raw data, fast to obtain, and cost effective. 
The future studies could include haemophilia C as it has even greater phenotype 
heterogeneity compared to FXI activity level. 
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Chapter 6 Variation of clinical phenotype in haemophilia 
6.1. Introduction 
The variability of clinical phenotype among severe haemophilia patients has been 
documented in several studies (Aledort et aI., 1994; Aznar et al., 2000; layandharan 
& Srivastava, 2008; van Dijk et aI., 2005a). The clinical phenotype of severe 
haemophilia consists of spontaneous joint and muscle bleeds. These frequent joint 
bleeds will lead to irreversible arthropathy (Bolton-Maggs & Pasi, 2003; layandharan 
& Srivastava, 2008). About 10-15% of patients with FVIII levels of < 1.0 IU/dL have 
clinically mild disease in terms of frequency of bleeds, extent of arthropathy and 
lower requirement for factor infusion (Janco et al., 1996). The age at which the 
individuals with haemophilia experience their first joint bleeds also varies 
considerably. Most individuals with severe haemophilia experience their first bleed by 
age 3-5 years, however, it has been reported that some individuals can bleed before 
the age of one year (Fischer et al., 2002). It is also known that patients from the same 
family, carrying the same gene defect, may not have an identical bleeding tendency 
(Barnes et al., 2007). 
The mechanism of this phenotypic heterogeneity is not clearly understood (Dargaud et 
al., 2004). Many environmental and genetic differences between patients could 
account for this phenotypic heterogeneity. Recent studies have suggested that the 
presence of FV Leiden (FVL) G I 69 I A can modify the clinical phenotype in haemophilia 
(Franchini & Lippi, 2009; van Dijk et aI., 2004). Resistance to the anticoagulant effect 
of activated protein C (APC) is the most frequent inherited risk factor for venous 
thromboembolism (VTE) (Dahlback, 1994). The Leiden mutation in exon 10 of the 
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factor V gene is responsible for the majority of cases that have prevalence of 2-7% 
among Caucasian populations. Heterozygous carriers of FVL have approximately 5-
fold increased risk of VTE, whereas homozygous carriers have a 20-80-fold increased 
risk (Lee et aI., 2000). 
The prothrombin G20210A mutation IS another inherited risk factor for VTE. 
Prothrombin is the circulating precursor of thrombin, which plays a central role in 
haemostasis, in particular, the formation of fibrin. A mutation in the 3' -untranslated 
region of the prothrombin (PT3') has been associated with elevated plasma 
prothrombin levels which may increase the risk ofVTE (Tizzano et aI., 2002b). 
AT, PC, and PS deficiencies are well established risk factors of VTE and the 
coexistence of any or combined deficiencies of these proteins has been reviewed or 
studied by many investigators (Escuriola Ettingshausen et ai., 2001; Nowak-Gottl et 
al., 2003). Increased levels of other procoagulant factors such as FVIII, FIX, and 
VWF (van Dijk et aI., 2004), or decreased levels of FXII (Johnson et ai., 2010) have 
also been shown to confer an increased risk of thrombosis and are also candidate 
modifiers of the haemophilia phenotype. 
The underlying mutation in F8 or F9 may also play a role in clinical phenotype 
expressions. The type of gene mutation is responsible for the residual FVIII or FIX 
levels in the plasma, therefore, the molecular defects that totally prevents the 
synthesis of the protein (null mutation) are usually associated with undetectable factor 
activity and antigen, whereas non-null mutations account for variable factor levels. 
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6.2. Aims 
In this chapter, the aims of the study were: 
• To identify the presence of concurrent pro-thrombotic or anti-thrombotic 
factors that may contribute to the heterogeneity of thrombin generation in 
haemophilia patients. 
• To investigate the influence of the factor VIII gene defect among the severe 
HA individual on the clinical phenotype. 
• To investigate the possibility of certain clinical features to predict the severity 
of the disease. The markers chosen for correlation included: 
o age of first bleed, 
o The number of joint bleeds per year, 
o The amount of treatment (factor concentrate) consumption per year 
may indicate the severity. 
6.3. Study subjects 
Ninety seven haemophilia patients were enrolled in the study, of which 73 included 
after excluding those who had residual FVIII/FIX (see section 2.1.2). These 
comprised 36 severe, eight moderate, 15 mild haemophilia A, and seven severe, three 
moderate, and four mild haemophilia 8, aged between 18 and 90 years (mean 43, 
median 41 years). Patients on prophylaxis or on demand treatment were asked to omit 
treatment for a minimum of 72 h to allow the FVIII or FIX level to return to baseline 
level. Those who required treatment were excluded from study. The study was 
approved by the ethics committee of the Royal Free Hospital, and informed consent 
was obtained from patients and healthy individuals. The normal reference ranges 
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(Table 6. I) were taken from the Katharine Dormandy Haemophilia Centre and 
Thrombosis Unit (KDHCTU) Laboratory. 
6.4. Results 
6.4.1. Prothrombotic risk factors 
Pro-thrombotic risk factors including FVL, PT3', PC, PS, and AT were investigated 
by perfonning the assays as described in section 2.4. Table 6.1 summarises the results. 
Table 61 P th b f . k f . h ro rom 0 IC r1S actors ID \. aemoph Ita 
FVL PT3' AT PC Free PS VWF:Ag 
(Ab,ent) (Absent) (~I-115IUldL) (58-137IU/dL) (67·127 IU/dL) (45-171 IU/dL) 
Severe HA 2 I None I 
n = 36 Heterozygous Heterozygous I 5 
Moderate HA None None 2 I 2 3 
n=8 
Mild HA None I I I None 3 
n = 15 Heterozygous 
Severe DB None None 
n=7 None None None 2 
Moderate HB None None I None None None 
n=3 
Mild DB None None I I None I 
n=4 
Prothrombollc fisk factors (reference range IU/dL m brackets) investigated m all pattent groups. The number 
of effected individuals for each risk factor has been illustrated in this table. HA = haemophilia A, HB = 
haemophilia B, FVL = factor V Leiden, PT3' = prothrombin 3' untransiated region mutation, AT = 
antithrombin, PC = protein C, Free PS = free protein S, VWF:Ag = von WiJlebrand factor antigen. 
Abnonnal AT, PC, and free PS levels for all patient groups ranged 65-78 IU/dL, 40-
68 IU/dL, and 44-65 IU/dL respectively. These abnormalities were thought to be due 
to the chronic liver disease as a result of hepatitis C. Liver function tests including 
alanine aminotransferase (ALT), aspartate aminotransferase (AST) and y-glutamyl 
transferase (y-GT) were perfonned on all samples to exclude those with hepatic 
failure from the study as outlined in the exclusion criteria (section 2.1.2). However, it 
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was assumed that some individuals with normal liver function tests may still exhibit 
some degree of hepatic abnormalities through their abnormal AT, PC, and free PS. 
After discussion with the Haemophilia Consultant Haematologist, the abnormalities of 
AT, PC, and free PS were not considered as sufficiently clinically significant to affect 
the thrombin generation results. 
VWF:Ag levels were increased in 14 individuals (range 172-300 IU/dL, reference 
range 45-171 IU/dL). The increased VWF:Ag was also believed to be related to the 
liver abnormalities and/or HIV infection as result of the inflammatory response (as 
discussed with the Haemophilia Consultant Haematologist). However, increased 
VWF:Ag levels are known to be a thrombotic risk factor which may influence the 
bleeding phenotype of individuals. The severe HA group was divided into two 
subgroups of normal VWF:Ag and increased VWF:Ag levels. The Mann-Whitney U 
statistical test showed no significant difference between PH+CTI or AUC+CTI of two 
subgroups (p = 0.157, and 0.314 respectively). 
6.4.2. Procoagulant factors 
Other coagulation factor levels were also analysed to investigate any co-existent 
deficiency of procoagulant factors, including FII, FV, FVII, FX, and FXI (section 2.4). 
Table 6.2 illustrates the number of individuals with decreased procoagulant factors. 
The majority of individuals with decreased FXI activity levels (n = II, FXI activity 
levels between 55-69 IU/dL) were reviewed by the Haemophilia Consultant 
Haematologist and the abnormality were considered not to be clinically significant, 
and not to cause any adverse effect on their bleeding phenotype. One individual, 
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however, was considered to have a clinically significant low level of FXI (FXI = 36 
IV/dL) and further genetic analysis was requested to confirm if genetic mutation 
existed within the FXI gene (result of mutational analysis was not available at timc of 
presentation of this thesis). 
The Mann-Whitney U statistical test showed no significant difference betwecn 
PH+CTI or AUC+CTI parameters of TGT in severe HA with decreased FXI levels 
and those with normal FXI (p = 0.350, and 0.306 respectively). 
T bl 62 P a e . f rocoagu ant actors 
FII FV FVII FX FXI 
(72·12R [U/dL) (50-127IU/dL) (61-150 IU/dL) (64-125 lU/dL) (70-145IU/dL) 
Severe HA I I None 1 12 n = 36 
Moderate HA None None None None 4 n=8 
Mild HA None None None None 2 n = 15 
Severe HB None None I None 2 n=7 
Moderate HB None None None None None n=3 
MildHB None None 1 None None n=4 
Co-exIstence of other procoagulant factors Investtgated In all pattent groups (r~ference ra,nge I,n 
brackets). The number of affected individuals for each risk factor has been Illustrated tn thIS 
table. HA = haemophilia A, HB = haemophilia B. 
The number of individuals with FVL or PT3' mutation, low natural inhibitors or 
prothrombotic factors was not statistically significant to perform any comparative 
statistical analysis. Descriptive statistical analysis was performed to compare the most 
sensitive parameters of ROTEM®, TGT, CAT, and clot waveform analysis. 
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One severe HA individual with heterozygous FVL had increased PH (35%) in 
PRP+CTI category of the in-house TGT and shorter ttPeak (13.5 min) of the CAT 
when compared to the relevant median (29% and 16 min respectively), whereas 
another individual with the same mutation did not show the same trend. There was 
one severe HA individual with the PT3' mutation and borderline PS level of 63 IU/dL 
(reference range 67-127 IU/dL) who had higher Peak (18%) and ETP (50%) than the 
median Peak (16%) and ETP (31%) in severe HA group. One severe HA individual, 
with FXI level of 36 JU/dL, had reduced Peak (5%) and ETP (I 5%), and longer TP 
(38 min) than the relevant median (16%, 31 %, and 20.5 min respectively). 
6.4.3. Mutational analysis 
The mutational data was obtained from the Genetic Laboratory of KDHC&TU. Of 36 
severe HA subjects, 32 mutational analyses were available to date. Nineteen 
individuals had intron 22 inversion (59%), of which 12 were distal (63%) and 7 were 
proximal (37%). There were 7 missense mutations (23%), three large deletions (> 
200bp deletion) (9%), two insertion (6%), and one small deletion « 200bp deletion) 
(3%). The mutational analysis of the severe HA group was divided into two 
subgroups: null mutations and non-null mutations. The null mutations consisted of 
inversions (n = 19) and large deletions (n = 3); and non-null mutations consisted of 
missense mutations (n = 7), small deletion (n = 1), and insertions (n = 2). FVIII 
antigen analysis was perfonned on all samples and individuals with FVIII antigen 
above 1.0 IU/dL were excluded from the null mutation subgroup. 
151 
The two groups were compared by TGT, CAT, ROTEM@, and clot waveform analysis 
parameters. The Mann-Whitney U test showed significant differenccs betwecn 
individuals with null mutations and non-null mutations subgroups by PPP+CTI 
AUC% (p = 0.0014) (Figure 6.1), PPP+CTI PH% (p = 0.0076) (Figure 6.2) 
parameters of the TOT; PPP+CTI ETP% (p = 0.0084) (Figure 6.3), PPP+CTI Peak% 
(p = 0.0096) (Figure 6.4) parameters of the CAT; and CWB+CTI+TF tMaxVel (p = 
0.0455) parameter of the ROTEM@. However, considering the sensitivity and 
specificity of these parameters in hypocoagulability, the PH in PPP+CTI test category 
with both sensitivity and specificity of 94% would be the best test in differentiating 
between the two subgroups of null and non-null mutation severe HA. 
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Figure 6.1 TGT Mutational comparison (AVC) . 
The AUC% compared between null Mutations and non-null MutatIons subgroups of severe HA. 
Significant differences were found between PPP+CTI AUC% parameter ofTGT (p = 0.0014). 
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Figure 6.2 TGT Mutational comparison (PH) 
The PH% compared between null Mutations and non-null Mutations subgroups of severe HA. 
Significant differences were found between PPP+CTI PH% parameter ofTGT (p = 0.0076). 
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Figure 6.3 CAT mutational comparison (ETP) 
The ETP% compared between null Mutations and non-null Mutations subgroups of evere HA. 
Significant differences were found between PPP+CTI ETP% parameter of the CAT (p = 0.0084). 
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Figure 6.4 CAT mutational comparison (Peak) 
T~e . Peak% compared between null mutations and non-null mutations subgroups of severe HA. 
Slgmficant differences were found between PPP+CTI Peak% parameter of the CAT (p = 0.0096). 
In the severe HB group there were seven individuals with FIX levels of < 1 JU/dL, of 
which five individuals had missense mutations and two had deletions in their F9. 
Because of the small number, statistical analysis could not be performed. 
6.4.4. Clinical phenotype 
There is no consensus in the current literature on how best to define clinical 
phenotype (Lee et al., 2005; Schulman et aI., 2008), furthermore most of the patients 
in the haemophilia centre were on prophylaxis. The patients on demand treatment 
have been offered prophylaxis in the past and have refused, and therefore is a self 
selected group of non severe phenotype. A clinical discussion forum was set up with 
two medical consultants (Dr Pratima Chowdary, Consultant Haematologist, and Dr 
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Thyn Thyn Yee Associate Specialist) who knew the patients' history in view of long 
tenn contact and three specialist nurses (Patricia Lilley, Barbara Subel, and Debra 
Pollard) who knew the patients for more than 10 years. Following active discussion 
and debate, it was agreed that the following data be extracted from the medical notes 
and be correlated independently to the global coagulation measures: 
• The age of first joint bleed. 
• The average usage of treatment during the last five years (factor replacement 
concentrate per kg of the individual's body weight, per year). This relates to 
the use of prophylaxis, and in patients on an on-demand treatment regimen it 
relates to the number of bleeds. 
• The number of joint bleeds per year (the average of the last five years). 
• Treatment regimen - regular prophylaxis versus on demand treatment. All 
severe patients have been offered prophylaxis, and most patients who have a 
significant bleeding tendency tend to continue prophylaxis. Patients with not 
so severe bleeding tendency tend to either be on prophylaxis or switch to on-
demand treatment based on their personal circumstances and choice. 
• Clinical impression of bleeding tendency - there is a very slow turnover of 
patients and staff in the centre, and it was felt that a clinical impression might 
provide a valuable clue on the bleeding tendency. A list of participants was 
given to two consultants and three senior nurses who had been involved in 
treating and caring for the participants throughout their registration with the 
KDHCTU. 
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The Speannan correlation statistical analysis was perfonned to investigate if there was 
any correlation between the laboratory test parameters and clinical phenotype 
parameters. 
The age at the first joint bleed correlated significantly with all three parameters in-
house TGT in PRP+CTI category (Table 6.3). The ETP parameter of the CAT and 
time to peak (TP) of PPP+CTI category of the in-house TGT were also found to 
correlate with the age at the first joint bleed (r = 0.426, P = 0.043; and r = -0.432, p = 
0.028, respectively). 
Table 6.3 Clinical phenotype correlation with TGT, age at the 
fi t·· b rs Jomt leed. 
Age at the first bleed r p 
(n = 23) 
PRP+CTI AUC% 0.693 0.003 
PRP+CTI PH% 0.718 0.002 
PRP+CTI TP -0.703 0.002 
ETP 0.426 0.043 
PPP+CTI TP -0.432 0.028 
PRP TGT appeared to be strongly correlatmg wIth the age at 
the first joint bleed. The ETP and TP in PPP+CTI test 
category also weakly correlated with age at the first joint 
bleed. TGT = thrombin generation test, PRP = platelet rich 
plasma, PPP = platelet poor plasma, eTI = com trypsin 
inhibitor, AVC = area under the thrombin generation curve 
in in-house TGT, PH = peak height thrombin generation in 
in-house TGT, TP = time to peak thrombin generation in in-
house TGT, ETP = endogenous thrombin potential in the 
calibrated automated thrombogram~. 
The number of joint bleeds per year was significantly correlated with the ETP 
parameter of the CAT (r = -0.601, P = 0.014). The factor concentrate consumption 
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(IU/Kglyear) correlated significantly with the MinI (r = 0.647, p = 0.001) and Min2 
(r = 0.526, p = 0.036) of the clot wavefonn analysis. 
The Mann-Whitney U test showed significant difference between the PH PPP+CTI 
category of the TGT of those individuals who were on prophylaxis and those who 
were on demand treatment regimens (p = 0.0047). The median PH in the on 
prophylaxis group (n = 21) was 14% (inter-quartile range: ]2-20%) whereas the 
median PH in the on demand group (n = 14) was 20% (inter-quartile range: 16-29%). 
This result showed that the on-demand group of severe HA patients may have less 
severe bleeding phenotype than those on prophylactic regimen. 
6.S. Discussion 
A large heterogeneity in thrombin generation was noticed in patients with severe HA 
and HB using different global assays, as described in previous chapters. In this 
chapter, the aim was to investigate the existence of modifying factors that may 
contribute to this heterogeneity between individuals with severe HA or HB. 
Prothrombotic, and procoagulant factors were analysed and their effects were 
investigated on thrombin generation, ROTEM®, and clot waveform analysis. 
There were two individuals that were heterozygous for FVL in the severe HA group, 
accounting for 5.7% of the total severe HA group, which is consistent with the 
prevalence ofFVL in Europe (Gray et al., 2006). The PH+CTI parameter of the TGT 
was increased and the time to peak parameter of the CAT was shorter in one subject. 
There was also one severe HA patient who was heterozygous for PT3' and whose 
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thrombin generation showed an increase in PH+CTI and ETP levels, compared to the 
median the same group. The number of affected individuals was not enough to 
perform statistical analysis, and prove or disprove whether presence of a 
prothrombotic risk factor may have influenced the PH and ETP. However, the results 
were in agreement with an earlier report that no association was found in the cohort 
patients to confinn or reject the modulation of bleeding phenotype in the presence of a 
prothrombotic risk factor (Beltran-Miranda et al., 2005). 
The co-existence of other mild inherited bleeding disorders was also investigated and 
one individual with low (clinically significant) FXI level was identified. Peak height 
TGT was reduced and time to peak was increased in this individual, reflecting a 
possible adverse effect of low FXI level on thrombin generation. Clinically, the 
individual is one of the severe bleeders. His first bleed was at the age of one month, 
and started prophylaxis regimen at the very early age. He had one major joint surgery. 
The type of mutation was significantly related to an individual's thrombin generation 
capacity. The null mutation subgroup showed a significantly reduced thrombin 
generation when compared to the non-Null mutation subgroup. This was shown by 
AVe (p = 0.0014), PH (p = 0.0076), ETP (p = 0.0084), and Peak (p = 0.0096) 
thrombin generation methods in PPP+CTI test category, and also time to maximum 
velocity (p = 0.0455) of ROTEM® in CWB+CTI+ TF test category. A recent study 
also showed that ETP was significantly higher in individuals with less severe types of 
F8 mutations among severe HA patients (Santagostino et al., 2010). 
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The most common predictors of the clinical phenotype of severe HA patients included 
age at first joint bleed, bleeding frequency, factor consumption and orthopaedic scores 
(Aledort et aI., 1994). However, since the introduction of primary prophylaxis to 
prevent bleeding episodes, the natural history of the severe haemophilia has changed 
dramatically, and the clinical phenotype is more difficult to define (Santagostino el aI., 
2010). In the mUltidisciplinary discussion held in the Haemophilia Centre, attended by 
two consultant haematologists and three specialist nurses, there was agreement that 
amongst adult patients, an on demand regimen was generally preferred by patients 
who have a less severe bleeding tendency. Patients on prophylaxis, as a group may 
either have a known previous severe bleeding tendency, severe joint damage or are 
disciplined to receive regular prophylaxis. 
The total factor consumption was felt to be a reasonable surrogate marker of the 
bleeding tendency, as was demonstrated by Schulman et aI., (2008). Factor 
consumption per year was documented for 5 years, and the average IU/kg/year was 
calculated for correlation. As the patients enrolled in the study included patients on 
primary and secondary prophylaxis, it was felt that the joint scores may not truly 
represent the underlying bleeding tendency for correlation. 
The study described in this thesis showed that the PH parameter of the in-house TGT 
was significantly higher in the severe HA on-demand group than those who were on a 
prophylaxis regimen. However, other parameters of thrombin generation, ROTEM J<" 
or clot waveform analysis did not show a significant difference between the two 
groups. Several studies have confirmed that age of first joint bleed is variable in 
patients with severe haemophilia (Bolton-Maggs & Pasi, 2003; Jayandharan & 
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Srivastava, 2008; van Dijk et al., 2005a). In a recent study, Santagostino el al. (20 I 0) 
reported an association between the severity of clinical phenotype of severe 
haemophilia and ETP measured in PRP. The authors reported that no correlation was 
found between the severity of clinical phenotype and thrombin generation in PPP, for 
which they referred to the role of platelets in thrombin generation. Similarly in the 
study described in this thesis, AVC, PH, and TP parameters of in-house thrombin 
generation measured in PRP+CTI strongly correlated with the age at first joint bleed. 
In addition, the ETP parameter of the CAT, and the TP parameter of in-house TGT 
measured in PPP+CTI were also correlated, to a lesser extent, with the age at the first 
joint bleed. 
The involvement of platelets in thrombin generation reflects in vivo conditions as the 
activation of platelets is crucial for initiation and propagation phases of thrombin 
fonnation. In a short report Dargaud et al. (2006) compared ETPs of two severe HA 
patients with five healthy controls to examine the function of platelets. They observed 
that when contact factor activation was eliminated, the thrombin-platelet feedback 
loop was a major detenninant of thrombin generating capacity and platelets had a 
greater role in regulating the propagation of thrombin generation than its initiation. In 
the study described in this thesis, eTI was used to eliminate the contact activation, 
which may have enhanced the sensitivity of the assay compared to study by 
Santagostino et al. (2010). 
Interestingly, only parameters of clot wavefonn analysis correlated significantly with 
the factor concentrate consumption (MinI, r = 0.647, P = 0.001 and Min2, r = 0.526, 
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p = 0.036). No correlation was found between factor consumption and TGT or 
ROTEM® parameters. 
6.6. Conclusion 
Although the results suggest that clinical phenotype can be predicted by some 
parameters of thrombin generation and thromboelastometry, the prophylaxis regimen 
does alter the bleeding tendency and indeed more than 50% of the individuals in this 
study were on a prophylactic regimen. However, among the clinical phenotype 
predictors, age at first bleed is an important marker as prophylaxis is yet to start. The 
TOT in platelet rich plasma, with contact factor inhibition, was shown to be the most 
sensitive parameter for predicting the clinical phenotype of individual patients. 
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Chapter 7 General discussion and conclusion 
7.1. General discussion 
The ability to predict severe bleeding or thrombotic tendency is an important goal for 
patients and their treating clinicians for individualised management enabling cost 
effective treatment. This goal has remained largely elusive because individual 
molecular markers of coagulation do not provide an overall picture of an individual's 
haemostatic balance. In the study of haemostasis, and the investigation of patients for 
bleeding or thrombotic conditions, there is a renewed interest in assays that evaluate 
net clotting potential, or the generation of key enzymes in the coagulation system (c.g., 
thrombin), which provide a comprehensive fingerprint of a patient's haemostatic state. 
In this study, the use of three different global assays was evaluated and the potential 
for use in regular clinical practice in patients with haemophilia was investigated. 
All the three global assays, ROTEM®, TGT, and clot waveform analysis, were shown 
to be reliable diagnostic tests to identify individuals with lower than normal 
coagulation FVIII or FIX levels. The heterogeneity of thrombin generation, in 
particular in severe haemophilia A and B, was also demonstrated by all three global 
assays. This indicates that the rate and amount of thrombin generation are not 
exclusively dependent on the amount of FVIII or IX level in the samples. 
The use of eTI to eliminate the interference of the contact system was also shown to 
play an important role in improving the accuracy and precision of thrombin 
generation. The PH in PPP+CTI, and PH and TP in PRP+CTI in-house TGT were the 
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most sensitive and specific parameters to distinguish bctwccn thrombin generation 
potential of normal and haemophilia patients. This confirms earlicr reports by other 
groups that the use of CTI at low TF concentration (1.0 pM) for initiation of thrombin 
generation improves assay variations (Dargaud el aI., 2005; Luddington & Baglin, 
2004; van Veen et al., 2008) 
The correlation between the results of in-house TGT and CAT mcthod was not 
strongly significant despite the fact that the methods are similar in principlc. Such 
discrepancies are not uncommon, as shown in recent multicentre studics whcre thc usc 
of different tissue factor and phospholipid sources was shown to produce a large 
variability in thrombin generation results (Dargaud et al., 2009; Gcrotziafas el aI., 
2005). In the study in this thesis, the tissue factor source and the dilution factor for the 
in-house method was similar to the CAT starting reagent, but the CAT reagent was 
supplied in a lyophilised form in which the phospholipids are incorporated in to the 
reagent. For the in-house method the tissue factor was freshly made and diluted just 
prior to testing, followed by addition of freshly made phospholipids to the plasma 
sample. This may explain the precision and accuracy of the in-house TGT 
demonstrated by ROC analysis in which the in-house TGT produced morc scnsitive 
and specific results than the CAT assay. A large heterogeneity in sevcrc HA and HB 
groups was demonstrated by the three global assays which were employed in this 
study. This could be explained, in part, by the fact, that the clearance of FVIII/FIX 
prophylaxis treatment is different between individuals. The effort made to ensurc no 
residual factor concentrate remained after appropriate hours off treatmcnt, by the 
exclusion of 13 HA patients who had FVIII activity levels of> 1.0 IU/dL, cxplains 
the heterogeneity in clearance of residual treatment. In a study by ven Dijk el al. 
163 
(2005), it was shown that severe HA, treated prophylactically with factor concentrates, 
those with a shorter FVIII half-life required slightly more clotting factor to prevent 
joint bleeds and subsequent arthropathy than similar patients with a longer FVIJI half-
life. Therefore it would be more appropriate to conduct such studies before the start of 
prophylactic regimen i.e. newly diagnosed children or adults. On the other hand, 
however, this study showed that the type of mutation in severe HA is significant in 
thrombin generation potential. It has been speculated that patients with "severe 
molecular defects" (inversions, large deletions and nonsense mutations) produce no 
FVIII, whereas those with "less severe molecular defects" may produce a small 
amount of circulating FVIII (i.e. FVIII antigen), but their FVIII clotting activity is 
remain less than 1.0 IU/dL as measured by one-stage clotting factor assay (Oldenburg, 
2001; Schwaab et al., 1995). 
Clot waveform analysis was carried out in this study, and showed that heterogeneity 
exists among the severe haemophilia A and B individuals, and was more pronounced 
in MinI and Min2 parameters when compared to the APTT. MinI and Min2 appear to 
be sensitive, simple, fast and cost effective in diagnosing hypocoaguJability and may 
be useful in the monitoring of haemophilia patients. 
The coeffiecient of determination (r) for MinI and FVIII was 0.624 (Figure 5.3 
chapter 5), suggesting that more than 62% of variance in Min I axis can be explained 
by variance of FVIII axis. The r for Min2 was 0.568 which also shows that 57% of 
the variance in the Min2 axis can be explained by variance of FVIII activity levels 
axis. However, the APTT was shown to be a weak predictor to explain the variance of 
FVIII with r of 0.229. This may indicate that the time to clot formation may be 
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affected by other modifing or interfering factors, whereas such influence on the rate 
and the accelaration of clot formation may be less effectual than the deficient factor. 
The analysis of clinical phenotype has proven to be difficult and other investigators 
have also experienced similar problems. There are conflicting observations by 
different groups on correlation of global assays with the clinical phenotype of 
haemophWa patients. While some have found parameters of thrombin generation to 
correlate with the clinical phenotype (Dargaud et aI., 2005; Santagostino el a/., 2010), 
others have not found such a correlation (Beltran-Miranda et aI., 2005). However, this 
study identified that thrombin generation in platelet rich plasma correlated more 
significantly than platelet poor plasma or the whole blood, with age of first joint bleed, 
a clinical marker most often used in scores for defining the clinical phenotype. 
It has been well established that platelets playa central and crucial role in generation 
of thrombin both in the primary and the secondary phases of haemostasis. Several 
studies have shown the inter-individual differences in platelet function and concluded 
that this phenomenon may playa part in modifying the clinical phenotype of severe 
haemophilia (Dargaud et al., 2005; Monroe et al., 2002b; Santagostino et aI., 2010; 
Siegemund et al., 2003; Vee, 2006). In the study described in this thesis, significant 
correlation was found between the age at first joint bleed of the severe HA group and 
PH, AVC, and TP parameters of the in-house TGT in PRP+CTI category. The age of 
first joint bleed is thought to be one of the most reliable indicators to differentiating 
between the severe patients and non severe patients. (Escuriola Ettingshausen el al., 
200 I; Van den Berg et af., 2007). Although, it should be acknowledged that due to 
limitations, we could not obtain clinical data for all participants in this study and only 
23 individuals were entered in this analysis, therefore the significance level was 
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reduced to p < 0.0 I to reject the null hypothesis. However, the levcl of significance 
(P) for this correlation was 0.002, 0.003, and 0.002 for PH, AVe, and TP respectively. 
which indicates that correlation is not just by coincidence. 
It is well established from clinical practice that those individuals who arc on an on-
demand treatment regimen have less bleeding frequency than those who are on 
regular prophylaxis. Subgroups of 9-10% of patients with severe HA, showing only 
little radiological joint damage while treated on-demand have been described both by 
Aledort et al. (1994) and Molho et al. (2000). Therefore, theoretically, the thrombin 
generation potential of the former group should be higher than the latter group. This 
study showed that the PH parameter of in-house TOT (PPP+CTI) was significantly 
higher (p = 0.0047) in the severe HA on-demand group than those who werc in the on 
prophylactic regimen group. However, other parameters of TOT or other assays did 
not show a similar trend. 
The type of F81F9 mutation is also known to predict the clinical phenotype. Severc 
defects such as intron 22 of F8 in severe HA patients are always associated with a 
severe clinical phenotype, whereas missense mutations are known to cause a less 
severe clinical phenotype (Jayandharan et al., 2005). However, in this study the 
heterogeneity of results were noted in all parameters of global assays. Despite this 
heterogeneity, the result of in-house TOT, CAT, and to a lesser extent ROTEM 
<)« 
showed a significant difference between the null and non-null mutations subgroups. 
The global assays evaluated in this study assessed coagulation, but the fibrinolytic 
pathways were not addressed, which are clinically relevant. It was not in the scope of 
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this study to investigate the fibrinolysis pathway of hacmostasis in our group of 
individuals, as most current assays for assessing fibrinolysis arc not global assays, and 
are most helpful in identifying defects of the fibrinolytic pathway, but arc unlikely to 
assess the impact of low thrombin generation on the overall fibrinolysis. There arc 
assays which assess thrombin activatable fibrinolysis inhibitor (TAFI) activity, 
however, to date, only one study has suggested an association of the fibrinolytic 
activity and the bleeding phenotype in haemophilia A and B individuals (Grunewald 
et at., 2002). In their study, Grunewald et at. showed that the median tissue-type 
plasminogen activator (t-PA) was significantly elevated in patients with a more severe 
phenotype. They hypothesised, that the higher frequency and/or intensity of bleeding 
events in the severe bleeder group (compared to a less severe bleeder group) of their 
study induced the generation of more fibrin through repeated or prolonged stimulation 
of procoagulant mechanisms. Increased availability of fibrin in tum facilitated the 
activation of the fibrinolytic system. 
Inter-individual variations in the pharmacokinetics of FVIII may also playa part in 
the bleeding phenotype. Thus variability of FVIII/FIX clearance may havc an impact 
on clinical phenotype in patients on regular prophylaxis, as suggested previously 
(Escuriola Ettingshausen et aI., 2001; van Dijk et aI., 2005b). Taking into account the 
limitations of one-stage clotting assay at FVIIUFIX level of < 1.0 JU/dL, it is difficult 
to exclude the presence of residual treatment material, which could have an impact on 
the global assays, thus undennining some of the negative correlations in this study. 
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7.2. Limitations of the study 
In this study although 49 severe HA and 14 severe HB were consented. Due to slow 
clearance of FVIII/FIX, detectable levels were found in the plasma of 13 severe HA 
and seven severe HB, and consequently excluded from further data analysis. In 
particular in severe HB patients, 5 days washout period proved to be inadequate for 
clearance of the residual FIX. This caused a limitation in interpretation of global 
assays in the severe HB group. The small number of participants in moderate and mild 
HB groups also limited the interpretation ofresu\ts, primarily because of the closeness 
of their median FIX activity levels (median FIX in moderate HB = 2.0 IU/dL, mild 
HB = 5.0 IU/dL). This may have caused a bias in differentiation power of TGT, 
ROTEM®, and clot waveform parameters to distinguish between moderate and mild 
HB groups. Therefore, it is suggested that for future studies for identification of the 
baseline levels, due consideration is given to the individual pharmacokinetic profile 
before recommending the washout period. 
7.3. Conclusion 
The use of global assays in demonstrating the coagulation potential of haemophilia 
patients proved to be useful, sensitive and specific compared to conventional methods, 
which assess individual factor levels. However, the complex nature of global assays, 
make them difficult to interpret on their own. Therefore, these assays should be used 
in parallel with the conventional tests in order to be more useful. The lack of 
standardisation for these assay does limit their use in routine clinical practise as 
reproducibility of laboratory assays is one of the main principles of their validity, 
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which should be comparable not only within the laboratory but also between 
laboratories at local, national and international level. 
For correlation with clinical phenotype, careful attention to the preanalytical variables 
is important and efforts should be made to eliminate as many confounding factors as 
possible in order to obtain a bias free outcome. The use of CTI proved to make TGT 
and ROTEM® parameters more sensitive. Although, in correlating clinical phenotype 
with parameters of global assays, some of the confounding factors cannot be reversed 
such as the effect of prophylaxis on clinical phenotype. 
7.4. The use of global assays in local routine practice 
The outcome of this study has generated a huge interest among the KDHCTU 
clinicians, scientists, and nurses. Particularly, those who were involved in the care and 
recruitment of individuals participated in the study. The KDHCTU treats and cares for 
a number of haemophilia patients who have developed an inhibitor toward FVIII/FIX, 
and also a number of acquired haemophiliacs who are registered at the KDHCTU. 
Monitoring these patients with conventional assays is not optimal and the usc of 
global assays has already been proved useful by other investigators (lngerslev et aI., 
2000; S0rensen & Ingerslev, 2004a). However, the use of eTI to minimise the 
preanalytical variables in ROTEM® analysis was novel in this study, and since the 
outcome, the practice has been changed. The use of clot waveform analysis has also 
being considered in a group of HB patients who have undergone gene therapy in the 
KDHCTU, and once analysed, it will be published. 
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The publication of outcome wi1l be the next step, as the interest in this field. 
particularly the use of three different global assays, is growing. Although two posters 
have already been presented in two international events on thrombosis and 
haemostasis, detailed publications in form of scientific paper are necessary to inform 
the interested researchers in this field about the outcomes of this study. 
7.5. Future studies 
Global assays are undergoing a revival smce it is increasingly recognised that 
conventional single factor assays do not always predict the clinical phenotype either 
in patients with inherited bleeding disorders or in patients with thrombotic conditions. 
Furthennore these assays, to varying extents, represent the complex interactions 
between the various coagulation factors and cellular components. In clinical 
laboratories there is a great need for such tools to be able to characterise patients with 
increased risk of thrombosis or bleeding, and for optimisation of anti-thrombotic or 
anti-bleeding therapy. 
For global assays to be clinically relevant validation of the tests is required by 
correlation with clinical outcomes. Indeed the TGT, CAT, and some ROTEM(Rl 
parameters have shown a significant correlation to the clinical markers. Unfortunately 
due to the limitations eluded to earlier, the clinical correlation has been less than 
satisfactory. Therefore, further studies are required with more robust clinical 
endpoints to better define the role of these assays In the routine clinical care of 
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patients. This is particularly relevant as these assays which identify the heterogeneity 
of coagulation in these disorders are ideally suited for individualised treatment of 
patients once appropriate thresholds for clinical outcomes are defined. 
Due consideration needs to be given to the role of preanalytical variables including 
the type of anticoagulant used. A recent study has shown that the calcium chelation 
may affect dynamics of TF initiated thrombin generation as well as the whole blood 
thromboelastometry (Mann et al., 2007). Moreover, it has been documented that 
citrate and calcium chelation interferes with the metabolic processes in platclets 
(Schneider et al., 1997). Therefore eTI as an alternative anticoagulant may be 
employed in a future study to reflect more accurately the in vivo scenario. 
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Chapter 8 Reflection 
"Tell me and J jorget, show me and I remember, involve me and / understand" 
(Can/iIeius ahout 450 B. C) 
The purpose of this chapter is to reflect upon my experience during the completion of 
the Professional Doctorate in the Biomedical Science (DBMS). By expressing my 
feelings about the events, I could understand my weaknesses and find ways for 
improvement. (Brookfield, 1986) suggests that educational programs should be 
interactive, include reflective components, and be related to experience. By including 
these components, learners are given more autonomy and are encouraged to take 
charge of their own learning. My aim is to provide an insight into how to use the 
"self-reflection" (Schon, 1983) and "writing" (Greenwood, 1991) processes as two 
important means of personal and professional growth. 
8.1. The need for continuous professional development 
Despite having an MSc degree in the field of haematology, I felt that I needed to 
develop my professional expertise in this field to an advanced level with high quality 
academic knowledge to support my practice. On the other hand, the Institute of 
Biomedical Science (IBMS) continuous professional development (CPD) programme 
to maintain, improve and broaden the professional knowledge and skills was another 
motivating factor to search for a way to continue my personal development in a 
structured approach. 
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Having read about the DBMS course at the University of Portsmouth, I felt that this 
was the right course to embark on in order to fulfil my learning needs. I started the 
DBMS in October 2003 to accomplish my learning needs. 
The first part (Stage 2, Part 1) of the course was interesting, challenging and 
motivating. The importance of reflective practice, as part of the learning process, was 
emphasised. I learnt that it is impossible to memorise every event and experiment in 
my mind for a later date and to return and learn from them or try to remember what 
happened and learn from it. Then the reflective writing was introduced and I learnt to 
write the events down so that I can pull them together into a coherent body of 
knowledge and come to recognise the totality of what J know. There is something in 
writing that enables us to recapture the experience and reflect on it and learn from it. 
Thus, in reflective practice the purpose of reflective writing is learning (Jasper, 2005). 
The Advanced Research Techniques Unit was very specific to the needs of the 
individual to understand the process of conducting a research project. The preparation 
of a resource pack for a new diagnostic test before its introduction into the laboratory 
was a unique experience. By writing the resource pack, I Jearnt how to apply the research 
into practice, and what steps needed to be taken to facilitate this. The unit helped me to 
design the research project and follow the steps to: 
• identify the appropriate research question 
• select the appropriate study design 
• prepare a research protocol 
• obtain an ethics committee approval 
• sample the research population in accordance with accepted criteria 
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• 
• 
• 
conduct the study in a planned, structured approach 
analyse and interpret the findings using the appropriate statistical tests 
report and disseminate findings 
The critical appraisal of literature was a valuable experience and I gained a good deal 
of confidence from it. It gave me skills that allowed me to make sense of research 
evidence, to assess the quality of the research, and to determine the best evidence for 
practice. It was a great help to me in the second part of the course, "the Prolessional 
Research and Development Project ", in order to appraise, evaluate and compare 
different methodologies and studies in preparation of the Professional Research and 
Development Proposal. As Sackett (1996) indicated, evidence-based medicine is the 
conscientious, explicit and judicious use of current best evidence in making decisions 
about the care of individual patients. Boud et al. (1985) also state that to maximise 
learning through critical reflection we need to locate ourselves within the experience 
and explore the available theory and knowledge to understand the experience in 
different ways. 
The peer review process, as a quality control for draft articles, involved the critical 
appraisal of a draft article for publication in a chosen journal with reference to the 
instruction to authors of that particular publisher. In this process I learned how to 
examine the benefits and shortcomings of a research study, and to recommend 
improvements or request reanalysis of data before publication. The peer review 
process allows the reader to make some judgment about the relative quality and merit 
of the research. It stops a lot of substandard and poor science from reaching 
publication. 
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However, the process of peer review is not perfect. The manuscript may be judged on 
the reputation of the author instead of quality. An excellent paper written by a new 
scientist can be rejected, whilst a poorer but uncontroversial paper by an established 
researcher can sail through the peer review process. The reviewers or referees may 
vary markedly in their opinions. Reviewers may use their anonymity as justification 
for being unnecessarily critical or harsh when commenting on the author's work. 
The Publication and Dissemination Unit gave me the opportunity to search for the 
theory of the publication process from different sources and put the obtained 
knowledge into practice. At the end of Part I of the course I felt confident to start the 
Professional Research and Development Project. I believe the first part of the course 
was very well planned and structured in a way that the researcher could start his/her 
journey armed with relevant skills needed to combat any challenge. That was how my 
journey started. 
8.2. The professional research and development project 
As a systematic process, the general purpose of research is to contribute to the body of 
knowledge that shapes and guides clinical practice settings (Tarling & Crofts, 2002). 
To be evidence-based and clinically useful, clinical practice must balance the 
strengths and limitations of all relevant research evidence with the practical realities of 
the healthcare and clinical settings. To classify a research report as strong or weak 
evidence in practice, it is necessary to evaluate the quality of the research as well as 
the reported outcome. It may not be appropriate simply to accept the conclusion 
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reported by the researchers as additional factors need to be considered such as 
methodologies, instrumentations and interventions. 
To find out about the accuracy of a diagnostic test, we need to perform a proper cross 
sectional study of patients with the relevant disorder. The ambitious aim of evidence 
based medicine and evidence based pathology in particular, is to advance clinical 
diagnosis of disease through research, and dissemination of new knowledge that meet 
high standards of critical review. If the current methodologies are not fit for purpose, 
improvement and employment of new techniques and advances should be constantly 
studied. Once a new technique becomes available, through research and innovation, 
then this should be thorougbly investigated for its suitability in clinical practice 
(Figure 8.1). 
Implement ing the new 
The need for change 
advance into practice 
in current practice 
Identify 
The problem in 
current practice 
Literature review of 
Evaluate and compare the 
advances to the current or 
current knowledge and 
recent advances 
gold standard methods 
Figure 8.1. Renection cycle adapted to clinical research ." 
Identification of a problem in current practice and the cycle reviewing, evaluatmg and Implementmg 
new changed to improve the outcome. 
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Research questions within the context of evidence-based health care usually start in 
practice and can concern any aspect of the clinical encounter. The KDHCTU, where I 
work as a senior biomedical scientist, is one of the largest haemophilia treatment 
centres in Europe. Therefore the chosen topic of the research had to be in line with the 
objectives of the KDHCTU as a comprehensive care centre for patients with inherited 
and acquired bleeding disorders, including diagnosis and management. The topic of 
my thesis was to evaluate global assays in a group of patients with an inherited 
bleeding disorder, haemophilia; and the research hypothesis was that the 'global 
assays can predict the severity and clinical phenotype of patients with haemophilia 
better than the current conventional methods'. 
Although the topic was broad and challenging, I was ready to embark on it to advance 
my expertise in this field. A comprehensive review of literature and a full 
understanding of the history, mechanism, and prognosis of the topic were needed 
before conducting the research. This created a great opportunity for me to refresh my 
memory, read and learn more and more about the whole process of haemostasis, and 
critically review the literature on the topic. The critical appraisal of literature was a 
valuable experience that I gained during the Publication and Dissemination Unit of 
the course, and more was added when I learned to reflect upon it and understand what 
happened, what went right and what went wrong, and why things turned out the way 
they did. 
Although the goal of this study was to put literature into practice, it was always in my 
mind to bring novelty into the project to make it more fulfilling and rewarding. 
Therefore, I obliged myself to search even deeper in order to obtain the appropriate 
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knowledge to interpret and appraise the literature. This was not without challenges in 
an ever evolving field of science with a number of dedicated researchers around the 
world, working hard to find a better way of diagnosing, managing and, ultimately, 
caring for patients with haemophilia. This required keeping up-to-date with all 
publications on the topic, around the world and to find out what has been added to the 
current knowledge, any agreement or disagreement from previous understandings, and 
how my work could contribute to the current knowledge, at least at local level. This 
was particularly hard for a part-time student with ajob and family commitments. 
Once the research question was outlined, I started to work on the research proposal. 
With the kind help of my supervisors the proposal was written and an application for a 
research grant was sent to the Katharine Donnandy Trust. The ethical approval is a 
vital component of the research process. The process was long and the quantity of 
paperwork required was huge. Writing the patient's infonnation sheet as a part the 
application process was interesting and thoughtful. 
The optimisation and some modifications of methodology for the TGT and ROTEM@ 
was next in the study protocol. At the time of the study there were only a few 
publications on the application of TGT and ROTEM® in diagnosis of individuals with 
haemophilia. The use of fluorogenic substrate was also limited to a few other studies. 
The use of a contact pathway inhibitor, the cn, was just found to be useful in TGT in 
2005, and the use of cn in the ROTEM® analysis was evaluated for the first time in 
the study reported here and it was a great opportunity to publish the outcome. Another 
improvement in this study was a further spinning of the plasma samples in order to 
minimise the effect of micro particles and platelet remnant in the TGT. This was found 
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when I tested the double spun plasma samples for the presence of phospholipids in the 
samples by kaolin clotting time (KCT) test. The KCT is essentially an APTT test 
without added phospholipids. The double spun plasma samples had significantly 
shorter KCT than the triple spun plasma samples, therefore, the third spin, which was 
at 6000g for 2 minutes, was added to the study protocol. 
At the beginning of the study, CAT was not yet in the market. Therefore, I performed 
the tests manually, in which the phospholipid vesicles had to be prepared by adding 
the precise amount of three different types of synthetic phospholipids in order to 
prepare a near physiologic substrate resembling platelet's surface. The tissue factor 
was readily available, but its concentration had to be optimised for the purpose of 
TGT. 
Reflecting on the process of making these reagents, it gives me a sense of fulfilment 
in which I obtained experience in every stage of the TGT, from making and 
optimising the reagents to applying the test and make it work in a way which would 
compete with the CAT. Although, I did not invent any of these different processes, 
looking at different publications for different parts and gathering them all together to 
produce a protocol and then witnessing the outcome was a great experience. 
By the end this experimental analysis, a test protocol for TGT and ROTEM® was 
produced which was unique at the time for three reasons: 
• The use of CTI to inhibit the contact activation and mimic in vivo 
haemostasis as close as possible. 
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• 
• 
The use of third spin to eliminate the interference of phospholipids in 
platelet poor plasma TGT. 
The use of freshly made reagents rather than commercially lyophilised 
reagents. 
However, patient recruitment and sample collection was a long and time consuming 
process. The amount of work involved in this huge project, and the delay in the 
clinical data collections made it impossible to publish any paper in time before other 
publications in the same subject. We did, however, manage to present two posters at 
the International Society on Thrombosis and Haemostasis (lSTH) in 2007 and 2009, 
this was a huge privilege. 
Patient recruitment was planned with the help of Dr Pratima Chowdary, the 
KDHC&TU Consultant Haematologist and Ms Patricia Lilly, Research Nurse. Due to 
the time restriction and long process of sample preparation, particularly for plasma 
rich platelet (PRP) samples, only two to three patients could be recruited each week. 
The TGT on PRP and ROTEM® analysis had to be performed on the same day and 
the rest was frozen for batch analysis. 
Once the recruitment was completed and enough samples were collected, a plan for 
analysis was drawn up with the help of my laboratory supervisor, Miss Anne Riddell. 
It was a huge task to analyse all the samples for a large number of tests. Over 15,000 
items of data were inserted into Excel spreadsheet for 97 patients and 22 normal 
individuals. Statistical analysis was a huge task and I had to learn to be able to 
perform statistical analysis. With the help of the KDHCTU data manager and 
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statistician Mrs Anja Griffioen, I learnt to perform statistical analysis on the data. This 
was a great experience and another learning outcome for me arising from the project. 
The next task was to obtain clinical information from patients' notes or from the 
individuals themselves. The process of going through medical notes and obtaining the 
clinical phenotype of patients was the most time consuming part of this research 
project. First of all, I could not perfonn the task myself because a clinician was 
needed to investigate the medical notes. Secondly, this part of the study was blinded 
therefore I could not go through the clinical notes, and thirdly, as a result of change of 
consultant haematologist, inevitably, the task was postponed until the new consultant 
took the responsibility for this aspect of the study. Reflecting on this part of the study, 
there was a period of time when I almost lost my inspiration. I struggled to find the 
motivation to continue when I thought that the research would fall through because of 
lack of support from the clinical team. However, the new consultant, Dr Pratima 
Chowdary, took responsibility and up until the submission of this thesis helped me to 
complete the task. 
During the process of writing I have had to revise my thesis outline, and adjusted my 
statements of problem and research questions. This, no doubt came as a result of 
communication with my supervisors at work and the University, analysing data, and 
preparing several drafts of my thesis chapters. Once I finished writing the thesis, I 
found it necessary to consider the final shape of the document for submission. The 
University has detailed a policy and procedures for the presentation of a professional 
doctorate thesis which needs to be carefully studied and applied. 
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Some of the challenges I faced were compounded by factors related to the fact that I 
am a full-time employee and a part-time student. There were times when I felt 
overwhelmed by the amount of work I was faced with and struggled to see what was 
relevant. I experienced a rollercoaster ride of emotions, which cannot have been easy 
for those around me either, both at work and at home. 
Supervision was an invaluable source of support and affinnation. When I struggled to 
understand, my supervisors, whether in the workplace or at the University, helped me 
to work things out; when I was frustrated with the speed at which things were moving, 
they allowed me to vent my frustrations; when I became fed up with looking at my 
research, they told me I was nonnal. I would advise anyone who plans to embark on a 
research project to have clear questions in mind and good support and supervision. 
These are invaluable. 
The research journey was accompanied by a parallel journey of my own. It has been a 
satisfying, difficult, tedious, demanding, emotionally turbulent, intellectually 
stimulating, and ultimately transfonnative journey. I will never be the same again. 
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Appendices 
Appendix 1 
APTT and FYIII/FIX activity levels as measured by one-stage factor assay. 
Mild HA APTT FJJ/J Moderate APTT FV/II Mild HB 
.~ IlIdL HA s 11idL 
MiHA I 44.0 27 MoHA I 56.6 2 MiHBI 
MiHA2 46.5 R MoHA2 50.R 5 MiHB2 
.\1iHA .1 39.0 15 MoHAJ 46.4 5 MiHB3 
MiHA 4 42.2 10 MoHA4 48.0 4 MiHB4 
MIliA 5 4!U R MoHA5 53.5 2 
MiliA 6 415 17 MoHA6 50.1 3 
MiliA 7 46.3 10 MoHA 7 66.1 
MiHA 8 412 14 MoHAR 52.7 5 
MiHA I} 75.9 II MoHAI} 46.0 5 
MIHA 10 40.9 II MoHA 10 45.0 3 
MiliA II 40.1 14 MoHA II 54.R 2 
MiliA 12 44.0 10 
MiliA 13 46.7 14 
MiliA 14 35.R 4R 
MiHA 15 4!U 6 
MIliA 16 38.0 J3 
MiHA = mild haemophilia A, MoHA = moderate haemophilia A, 
MiHB = mild haemophilia B. MoHB = moderate haemophilia 8. 
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APTT FIX Moderate 
s fL'/dL HB 
49.6 6 MoHB I 
41.6 7 MoHB2 
45.3 6 MoHB3 
39.4 13 
APTT FIX 
.,. IUdl. 
50.0 4 
53.5 2 
58.3 2 
